Author: "Qian, Jm" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Qian, Jm"' showing total 224 results

Start Over Author "Qian, Jm"

224 results on '"Qian, Jm"'

1. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

Author: Yao JC, Oh DY, Qian JM, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia LQ, Komoto I, Sriuranpong V, and Shimada Y
Subjects: mTOR inhibitors, East Asian population, neuroendocrine tumors, everolimus, RADIANT-4, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282
Abstract: James C Yao,1 Do-Youn Oh,2 Jiaming Qian,3 Young Suk Park,4 Fabian Herbst,5 Antonia Ridolfi,6 Miguel Izquierdo,5 Tetsuhide Ito,7 Liqun Jia,8 Izumi Komoto,9 Virote Sriuranpong,10 Yasuhiro Shimada11 1Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Medical Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; 3Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China; 4Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea; 5Novartis Oncology, Novartis Pharma AG, Basel, Switzerland; 6Novartis Oncology, Novartis Pharma S.A.S, Rueil-Malmaison, Paris, France; 7Department of Gastroenterology, Kyushu University Hospital, Fukuoka, Japan; 8Department of Medical Oncology, China-Japan Friendship Hospital, Beijing, China; 9Department of Surgery, Kansai Electric Power Hospital, Osaka, Japan; 10Department of Medical Oncology, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 11Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan Background: In RADIANT-4, everolimus showed an improvement of 7.1 months in median progression-free survival (PFS) vs placebo among patients with advanced, well-differentiated, nonfunctional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin. The present analysis focuses on the effect of everolimus on the East Asian-subgroup population of the RADIANT-4 study. Methods: Patients were randomized to receive everolimus 10 mg/day or matching placebo. The primary end point was PFS (central review). Secondary end points were overall response rate, safety, and tolerability. Results: Among 302 patients enrolled in RADIANT-4, 46 were included in the East Asian subgroup (everolimus, n=28; placebo, n=18) analysis. Everolimus was associated with an 82% reduction in the relative risk of disease progression or death (HR 0.18, 95% CI 0.09–0.38). The median PFS (central review) in this subgroup was 11.2 months with everolimus vs 3.1 months with placebo. Adverse events (AEs) occurred in all 28 patients treated with everolimus and ten patients receiving placebo. The majority of these AEs were grade 1 or 2. Most commonly reported (≥30% of incidence) drug-related AEs of any grade included stomatitis (75%, n=21) and rash (43%, n=12) in the everolimus arm. Conclusion: Everolimus demonstrated a clinically meaningful PFS benefit in the East Asian population. The safety findings were consistent with the known safety profile of everolimus. These results support the use of everolimus in the East Asian population with advanced, nonfunctional NETs of GI or lung origin. Keywords: mTOR inhibitors, everolimus, RADIANT-4, neuroendocrine tumors, East Asian population
Published: 2019

2. PP4R1 accelerates cell growth and proliferation in HepG2 hepatocellular carcinoma

Author: Wu G, Ma ZY, Qian JM, and Liu B
Subjects: lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282
Abstract: Gang Wu, Zhenyu Ma, Jianmin Qian, Bin LiuDepartment of General Surgery, Huashan Hospital, Fudan University, Shanghai, People’s Republic of ChinaAbstract: Hepatocellular carcinoma (HCC), as the fifth most common cancer worldwide, has become the third leading cause of cancer-related deaths. It is reported that protein phosphatase 4 (PP4) is an essential protein for nucleation, growth, and stabilization of microtubules in centrosomes/spindle bodies during cell division. Besides, previous studies have identified protein phosphatase 4 regulatory subunit 1 (PP4R1) as a constitutive interaction partner of PP4 catalytic subunit PP4C. The PP4C-PP4R1 PP4 complex plays a role in dephosphorylation, regulation of histone acetylation, and NF-κB activation. However, little is known about the pathological functions of PP4R1 in human cancers. Thus, in order to investigate how PP4R1 functions in human HCC, two common hepatocarcinogenesis HCC cell lines HepG2 and SMMC-7721 were employed, transduced with recombinant lentivirus expressing PP4R1 short hairpin RNA. Compared with the controls, the cells treated with Lv-shPP4R1 showed a significant decrease in cell proliferation and colony formation. The results of flow cytometry showed that the knockdown of PP4R1 caused HepG2 cells arrest at G2/M phase in the cell cycle. Furthermore, the transduction of Lv-shPP4R1 into HepG2 cells led to the inactivation of two major mitogen-activated protein kinase signaling cascades: p38 and c-Jun N-terminal kinase (JNK), indicating that PP4R1 could promote cell proliferation, which might be regulated by p38 and c-Jun N-terminal kinase pathways. In a word, this study highlights the crucial role of PP4R1 in promoting HCC cell growth, which might elucidate the pathological mechanism of HCC.Keywords: hepatocellular carcinoma, PP4R1, shRNA, proliferation, apoptosis
Published: 2015

3. SEARCH FOR ANOMALOUS Z-]GAMMA-GAMMA-GAMMA EVENTS AT LEP

Author: Acciarri, M, Adam, A, Adriani, O, Aguilarbenitez, M, Ahlen, S, Alcaraz, J, Aloisio, A, Alverson, G, Alviggi, Mg, Ambrosi, G, An, Q, Anderhub, H, Anderson, Al, Andreev, Vp, Angelescu, T, Antonov, L, Antreasyan, D, Alkhazov, G, Arce, P, Arefiev, A, Azemoon, T, Aziz, T, Baba, Pvks, Bagnaia, Paolo, Bakken, Ja, Baksay, L, Ball, Rc, Banerjee, S, Banicz, K, Barillere, R, Barone, Luciano Maria, Baschirotto, A, Basile, M, Battiston, R, Bay, A, Becattini, F, Becker, U, Behner, F, Bencze, Gl, Berdugo, J, Berges, P, Bertucci, B, Betev, Bl, Biasini, M, Biland, A, Bilei, Gm, Bizzarri, R, Blaising, Jj, Bobbink, Gl, Bock, R, Bohm, A, Borgia, B, Boucham, A, Bourilkov, D, Bourquin, M, Boutigny, D, Bouwens, B, Brambilla, E, Branson, Jg, Brigljevic, V, Brock, Ic, Brooks, M, Bujak, A, Burger, Jd, Burger, Wj, Burgos, C, Busenitz, J, Buytenhuijs, A, Bykov, A, Cai, Xd, Capell, M, Romeo, Gc, Caria, M, Carlino, G, Cartacci, Am, Casaus, J, Castello, R, Cavallo, N, Cerrada, M, Cesaroni, F, Chamizo, M, Chang, Yh, Chaturvedi, Uk, Chemarin, M, Chen, A, Chen, C, Chen, G, Chen, Gm, Chen, Hf, Chen, Hs, Chen, M, Chiefari, G, Chien, Cy, Choi, Mt, Chung, S, Cifarelli, L, Cindolo, F, Civinini, C, Clare, I, Clare, R, Coan, Te, Cohn, Ho, Coignet, G, Colino, N, Commichau, V, Costantini, S, Cotorobai, F, Delacruz, B, Cui, Xt, Cui, Xy, Dai, Ts, Dalessandro, R, Deasmundis, R, Degre, A, Deiters, K, Denes, E, Denes, P, Denotaristefani, F, Dibitonto, D, Diemoz, M, Dimitrov, Hr, Dionisi, C, Dittmar, M, Dorne, I, Dova, Mt, Drago, E, Duchesneau, D, Duhem, F, Duinker, P, Duran, I, Dutta, S, Easo, S, Elmamouni, H, Engler, A, Eppling, Fj, Erne, Fc, Extermann, P, Fabbretti, R, Fabre, M, Falciano, S, Favara, A, Fay, J, Felcini, M, Ferguson, T, Fernandez, D, Fernandez, G, Ferroni, Fernando, Fesefeldt, H, Fiandrini, E, Field, Jh, Filthaut, F, Fisher, Ph, Forconi, G, Fredj, L, Freudenreich, K, Gailloud, M, Galaktionov, Y, Gallo, E, Ganguli, Sn, Garciaabia, P, Gau, Ss, Gentile, Simonetta, Gerald, J, Gheordanescu, N, Giagu, Stefano, Goldfarb, S, Goldstein, J, Gong, Zf, Gonzalez, E, Gougas, A, Goujon, D, Gratta, G, Gruenewald, Mw, Gu, C, Guanziroli, M, Gupta, Vk, Gurtu, A, Gustafson, Hr, Gutay, Lj, Hartmann, B, Hasan, A, Hauschildt, D, He, Jt, Hebbeker, T, Herbert, M, Herve, A, Hilgers, K, Hofer, H, Hoorani, H, Hou, Sr, Hu, G, Ille, B, Ilyas, Mm, Innocente, V, Janssen, H, Jin, Bn, Jones, Lw, Dejong, P, Josamutuberria, I, Kasser, A, Khan, Ra, Kamyshkov, Y, Kapinos, P, Kapustinsky, Js, Karyotakis, Y, Kaur, M, Khokhar, S, Kienzlefocacci, Mn, Kim, D, Kim, Jk, Kim, Sc, Kim, Yg, Kinnison, Ww, Kirkby, A, Kirkby, D, Kirkby, J, Kirsch, S, Kittel, W, Klimentov, A, Konig, Ac, Koffeman, E, Kornadt, O, Koutsenko, V, Koulbardis, A, Kraemer, Rw, Kramer, T, Krastev, Vr, Krenz, W, Kuijten, H, Kunin, A, Deguevara, Pl, Landi, G, Lanzano, S, Laurikainen, P, Lebedev, A, Lebrun, P, Lecomte, P, Lecoq, P, Lecoultre, P, Lee, Dm, Lee, Js, Lee, Ky, Leedom, I, Leggett, C, Legoff, Jm, Leiste, R, Lenti, M, Leonardi, E, Levtchenko, P, Li, C, Lieb, E, Lin, Wt, Linde, Fl, Lindemann, B, Lista, L, Liu, Y, Lohmann, W, Longo, E, Lu, W, Lu, Ys, Lubbers, Jm, Lubelsmeyer, K, Luci, Claudio, Luckey, D, Ludovici, L, Luminari, L, Lustermann, W, Ma, Wg, Macdermott, M, Maity, M, Malgeri, L, Malik, R, Malinin, A, Mana, C, Mangla, S, Maolinbay, M, Marchesini, P, Marin, A, Martin, Jp, Marzano, F, Massaro, Ggg, Mazumdar, K, Mcmahon, T, Mcnally, D, Mele, S, Merk, M, Merola, L, Meschini, M, Metzger, Wj, Mi, Y, Mihul, A, Mills, Gb, Mir, Y, Mirabelli, G, Mnich, J, Moller, M, Monaco, V, Monteleoni, B, Morand, R, Morganti, S, Moulai, Ne, Mount, R, Muller, S, Nagy, E, Napolitano, M, Nessitedaldi, F, Newman, H, Niaz, Ma, Nippe, A, Nowak, H, Organtini, Giovanni, Ostonen, R, Pandoulas, D, Paoletti, S, Paolucci, P, Pascale, G, Passaleva, G, Patricelli, S, Paul, T, Pauluzzi, M, Paus, C, Pauss, F, Pei, Yj, Pensotti, S, Perretgallix, D, Pevsner, A, Piccolo, D, Pieri, M, Pinto, Jc, Piroue, Pa, Pistolesi, E, Plasil, F, Plyaskin, V, Pohl, M, Pojidaev, V, Postema, H, Produit, N, Qian, Jm, Qureshi, Kn, Raghavan, R, Rahalcallot, G, Rancoita, Pg, Rattaggi, M, Raven, G, Razis, P, Read, K, Redaelli, M, Ren, D, Ren, Z, Rescigno, M, Reucroft, S, Ricker, A, Riemann, S, Riemers, Bc, Riles, K, Rind, O, Rizvi, Ha, Ro, S, Robohm, A, Rodriguez, Fj, Roe, Bp, Rohner, M, Rohner, S, Romero, L, Rosierlees, S, Rosmalen, R, Rosselet, P, Vanrossum, W, Roth, S, Rubbia, A, Rubio, Ja, Rykaczewski, H, Salicio, J, Salicio, Jm, Sanchez, E, Sanders, Gs, Santocchia, A, Sarakinos, Me, Sarkar, S, Sartorelli, G, Sassowsky, M, Sauvage, G, Schafer, C, Schegelsky, V, Schmitz, D, Schmitz, P, Schneegans, M, Scholz, N, Schopper, H, Schotanus, Dj, Shotkin, S, Schreiber, Hj, Shukla, J, Schulte, R, Schultze, K, Schwenke, J, Schwering, G, Sciacca, C, Sehgal, R, Seiler, Pg, Sens, Jc, Servoli, L, Sheer, I, Shevchenko, S, Shi, Xr, Shumilov, E, Shoutko, V, Son, D, Sopczak, A, Soulimov, V, Spartiotis, C, Spickermann, T, Spillantini, P, Steuer, M, Stickland, Dp, Sticozzi, F, Stone, H, Strauch, K, Sudhakar, K, Sultanov, G, Sun, Lz, Susinno, Gf, Suter, H, Swain, Jd, Syed, Aa, Tang, Xw, Taylor, L, Timellini, R, Ting, Scc, Ting, Sm, Toker, O, Tonutti, M, Tonwar, Sc, Toth, J, Trowitzsch, G, Tsaregorodtsev, A, Tsipolitis, G, Tully, C, Ulbricht, J, Urban, L, Uwer, U, Valente, E, Vandewalle, Rt, Vetlitsky, I, Viertel, G, Vikas, P, Vikas, U, Vivargent, M, Vogel, H, Vogt, H, Vorobiev, I, Vorobyov, Aa, Vuilleumier, L, Wadhwa, M, Wallraff, W, Wang, Jc, Wang, Xl, Wang, Yf, Wang, Zm, Weber, A, Weill, R, Willmott, C, Wittgenstein, F, Wright, D, Wu, Sx, Wynhoff, S, Zu, Zz, Yang, Bz, Yang, Cg, Yang, G, Yao, Xy, Ye, Ch, Ye, Jb, Ye, Q, Yeh, Sc, You, Jm, Yanus, N, Yzerman, M, Zaccardelli, C, Zemp, P, Zeng, M, Zeng, Y, Zhang, Dh, Zhang, Zp, Zhou, B, Zhou, Gj, Zhou, Jf, Zhu, Ry, Zichichi, A, Vanderzwaan, Bcc, Acciarri, M., Adam, A., Adriani, O., Aguilarbenitez, M., Ahlen, S., Alcaraz, J., Aloisio, Alberto, Alverson, G., Alviggi, Mariagrazia, Ambrosi, G., An, Q., Anderhub, H., Anderson, A. L., Andreev, V. P., Angelescu, T., Antonov, L., Antreasyan, D., Alkhazov, G., Arce, P., Arefiev, A., Azemoon, T., Aziz, T., P. V. K., Bagnaia, P., Bakken, J. A., Baksay, L., Ball, R. C., Banerjee, S., Banicz, K., Barillere, R., Barone, L., Baschirotto, A., Basile, M., Battiston, R., Bay, A., Becattini, F., Becker, U., Behner, F., Bencze, G. L., Berdugo, J., Berges, P., Bertucci, B., Betev, B. L., Biasini, M., Biland, A., Bilei, G. M., Bizzarri, R., Blaising, J. J., Bobbink, G. L., Bock, R., Bohm, A., Borgia, B., Boucham, A., Bourilkov, D., Bourquin, M., Boutigny, D., Bouwens, B., Brambilla, E., Branson, J. G., Brigljevic, V., Brock, I. C., Brooks, M., Bujak, A., Burger, J. D., Burger, W. J., Burgos, C., Busenitz, J., Buytenhuijs, A., Bykov, A., Cai, X. D., Capell, M., Romeo, G. C., Caria, M., Carlino, G., Cartacci, A. M., Casaus, J., Castello, R., Cavallo, N., Cerrada, M., Cesaroni, F., Chamizo, M., Chang, Y. H., Chaturvedi, U. K., Chemarin, M., Chen, A., Chen, C., Chen, G., Chen, G. M., Chen, H. F., Chen, H. S., Chen, M., Chiefari, Giovanni, Chien, C. Y., Choi, M. T., Chung, S., Cifarelli, L., Cindolo, F., Civinini, C., Clare, I., Clare, R., Coan, T. E., Cohn, H. O., Coignet, G., Colino, N., Commichau, V., Costantini, S., Cotorobai, F., Delacruz, B., Cui, X. T., Cui, X. Y., Dai, T. S., Dalessandro, R., Deasmundis, R., Degre, A., Deiters, K., Denes, E., Denes, P., Denotaristefani, F., Dibitonto, D., Diemoz, M., Dimitrov, H. R., Dionisi, C., Dittmar, M., Dorne, I., Dova, M. T., Drago, E., Duchesneau, D., Duhem, F., Duinker, P., Duran, I., Dutta, S., Easo, S., Elmamouni, H., Engler, A., Eppling, F. J., Erne, F. C., Extermann, P., Fabbretti, R., Fabre, M., Falciano, S., Favara, A., Fay, J., Felcini, M., Ferguson, T., Fernandez, D., Fernandez, G., Ferroni, F., Fesefeldt, H., Fiandrini, E., Field, J. H., Filthaut, F., Fisher, P. H., Forconi, G., Fredj, L., Freudenreich, K., Gailloud, M., Galaktionov, Y., Gallo, E., Ganguli, S. N., Garciaabia, P., Gau, S. S., Gentile, S., Gerald, J., Gheordanescu, N., Giagu, S., Goldfarb, S., Goldstein, J., Gong, Z. F., Gonzalez, E., Gougas, A., Goujon, D., Gratta, G., Gruenewald, M. W., Gu, C., Guanziroli, M., Gupta, V. K., Gurtu, A., Gustafson, H. R., Gutay, L. J., Hartmann, B., Hasan, A., Hauschildt, D., J. T., He, Hebbeker, T., Herbert, M., Herve, A., Hilgers, K., Hofer, H., Hoorani, H., Hou, S. R., Hu, G., Ille, B., Ilyas, M. M., Innocente, V., Janssen, H., Jin, B. N., Jones, L. W., Dejong, P., Josamutuberria, I., Kasser, A., Khan, R. A., Kamyshkov, Y., Kapinos, P., Kapustinsky, J. S., Karyotakis, Y., Kaur, M., Khokhar, S., Kienzlefocacci, M. N., Kim, D., Kim, J. K., Kim, S. C., Kim, Y. G., Kinnison, W. W., Kirkby, A., Kirkby, D., Kirkby, J., Kirsch, S., Kittel, W., Klimentov, A., Konig, A. C., Koffeman, E., Kornadt, O., Koutsenko, V., Koulbardis, A., Kraemer, R. W., Kramer, T., Krastev, V. R., Krenz, W., Kuijten, H., Kunin, A., Deguevara, P. L., Landi, G., Lanzano, S., Laurikainen, P., Lebedev, A., Lebrun, P., Lecomte, P., Lecoq, P., Lecoultre, P., Lee, D. M., Lee, J. S., Lee, K. Y., Leedom, I., Leggett, C., Legoff, J. M., Leiste, R., Lenti, M., Leonardi, E., Levtchenko, P., Li, C., Lieb, E., Lin, W. T., Linde, F. L., Lindemann, B., Lista, L., Liu, Y., Lohmann, W., Longo, E., Lu, W., Y. S., Lu, Lubbers, J. M., Lubelsmeyer, K., Luci, C., Luckey, D., Ludovici, L., Luminari, L., Lustermann, W., W. G., Ma, Macdermott, M., Maity, M., Malgeri, L., Malik, R., Malinin, A., Mana, C., Mangla, S., Maolinbay, M., Marchesini, P., Marin, A., Martin, J. P., Marzano, F., G. G. G., Mazumdar, K., Mcmahon, T., Mcnally, D., Mele, S., Merk, M., Merola, Leonardo, Meschini, M., Metzger, W. J., Mi, Y., Mihul, A., Mills, G. B., Mir, Y., Mirabelli, G., Mnich, J., Moller, M., Monaco, V., Monteleoni, B., Morand, R., Morganti, S., Moulai, N. E., Mount, R., Muller, S., Nagy, E., Napolitano, Marco, Nessitedaldi, F., Newman, H., Niaz, M. A., Nippe, A., Nowak, H., Organtini, G., Ostonen, R., Pandoulas, D., Paoletti, S., Paolucci, P., Pascale, G., Passaleva, G., Patricelli, Sergio, Paul, T., Pauluzzi, M., Paus, C., Pauss, F., Pei, Y. J., Pensotti, S., Perretgallix, D., Pevsner, A., Piccolo, D., Pieri, M., Pinto, J. C., Piroue, P. A., Pistolesi, E., Plasil, F., Plyaskin, V., Pohl, M., Pojidaev, V., Postema, H., Produit, N., Qian, J. M., Qureshi, K. N., Raghavan, R., Rahalcallot, G., Rancoita, P. G., Rattaggi, M., Raven, G., Razis, P., Read, K., Redaelli, M., Ren, D., Ren, Z., Rescigno, M., Reucroft, S., Ricker, A., Riemann, S., Riemers, B. C., Riles, K., Rind, O., Rizvi, H. A., Ro, S., Robohm, A., Rodriguez, F. J., Roe, B. P., Rohner, M., Rohner, S., Romero, L., Rosierlees, S., Rosmalen, R., Rosselet, P., Vanrossum, W., Roth, S., Rubbia, A., Rubio, J. A., Rykaczewski, H., Salicio, J., Salicio, J. M., Sanchez, E., Sanders, G. S., Santocchia, A., Sarakinos, M. E., Sarkar, S., Sartorelli, G., Sassowsky, M., Sauvage, G., Schafer, C., Schegelsky, V., Schmitz, D., Schmitz, P., Schneegans, M., Scholz, N., Schopper, H., Schotanus, D. J., Shotkin, S., Schreiber, H. J., Shukla, J., Schulte, R., Schultze, K., Schwenke, J., Schwering, G., Sciacca, Crisostomo, Sehgal, R., Seiler, P. G., Sens, J. C., Servoli, L., Sheer, I., Shevchenko, S., Shi, X. R., Shumilov, E., Shoutko, V., Son, D., Sopczak, A., Soulimov, V., Spartiotis, C., Spickermann, T., Spillantini, P., Steuer, M., Stickland, D. P., Sticozzi, F., Stone, H., Strauch, K., Sudhakar, K., Sultanov, G., Sun, L. Z., Susinno, G. F., Suter, H., Swain, J. D., Syed, A. A., Tang, X. W., Taylor, L., Timellini, R., S. C. C., Ting, S. M., Toker, O., Tonutti, M., Tonwar, S. C., Toth, J., Trowitzsch, G., Tsaregorodtsev, A., Tsipolitis, G., Tully, C., Ulbricht, J., Urban, L., Uwer, U., Valente, E., Vandewalle, R. T., Vetlitsky, I., Viertel, G., Vikas, P., Vikas, U., Vivargent, M., Vogel, H., Vogt, H., Vorobiev, I., Vorobyov, A. A., Vuilleumier, L., Wadhwa, M., Wallraff, W., Wang, J. C., Wang, X. L., Wang, Y. F., Wang, Z. M., Weber, A., Weill, R., Willmott, C., Wittgenstein, F., Wright, D., S. X., Wu, Wynhoff, S., Z. Z., Zu, Yang, B. Z., Yang, C. G., Yang, G., Yao, X. Y., C. H., Ye, J. B., Ye, Ye, Q., Yeh, S. C., You, J. M., Yanus, N., Yzerman, M., Zaccardelli, C., Zemp, P., Zeng, M., Zeng, Y., Zhang, D. H., Zhang, Z. P., Zhou, B., Zhou, G. J., Zhou, J. F., Zhu, R. Y., Zichichi, A., and B. C. C.
Subjects: ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, PHOTONS, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Particle Physics - Experiment, L3 EXPERIMENT
Abstract: We have searched for anomalous Z --> gamma gamma gamma events with the L3 detector at LEP. No significant deviations from the expected QED e(+)e(-)-->gamma gamma gamma events are observed. The branching ratio upper limit for a composite Z decaying directly into three photons is found to be 1.0 x 10(-1) at 95% C.L. The branching ratio upper limits for the process Z-->gamma X,X-->gamma gamma are in the range of 0.4 to 1.3 x 10(-5), depending on the mass and width of the scalar particle X. In the context of a model with magnetic monopoles coupling to the Z, we find BR(Z-->gamma gamma gamma) < 0.8 x 10(-5) at 95% C.L; this results in a lower mass limit of 510 GeV for a magnetic monopole.
Published: 1995

4. Energy and Particle Flow in 3-Jet and Radiative 2-Jet Events from Hadronic Z-Decays

Author: Acciarri, M, Adam, A, Adriani, O, Aguilarbenitez, M, Ahlen, S, Alcaraz, J, Aloisio, A, Alverson, G, Alviggi, Mg, Ambrosi, G, An, Q, Anderhub, H, Anderson, Al, Andreev, Vp, Angelescu, T, Antonov, L, Antreasyan, D, Alkhazov, G, Arce, P, Arefiev, A, Azemoon, T, Aziz, T, Baba, Pvks, Bagnaia, Paolo, Bakken, Ja, Baksay, L, Ball, Rc, Banerjee, S, Banicz, K, Barillere, R, Barone, Luciano Maria, Baschirotto, A, Basile, M, Battiston, R, Bay, A, Becattini, F, Becker, U, Behner, F, Bencze, Gl, Berdugo, J, Berges, P, Bertucci, B, Betev, Bl, Biasini, M, Biland, A, Bilei, Gm, Bizzarri, R, Blaising, Jj, Bobbink, Gj, Bock, R, Bohm, A, Borgia, B, Boucham, A, Bourilkov, D, Bourquin, M, Boutigny, D, Bouwens, B, Brambilla, E, Branson, Jg, Brigljevic, V, Brock, Ic, Brooks, M, Bujak, A, Burger, Jd, Burger, Wj, Burgos, C, Busenitz, J, Buytenhuijs, A, Bykov, A, Cai, Xd, Capell, M, Romeo, Gc, Caria, M, Carlino, G, Cartacci, Am, Casaus, J, Castello, R, Cavallo, N, Cerrada, M, Cesaroni, F, Chamizo, M, Chang, Yh, Chaturvedi, Uk, Chemarin, M, Chen, A, Chen, C, Chen, G, Chen, Gm, Chen, Hf, Chen, Hs, Chen, M, Chiefari, G, Chien, Cy, Choi, Mt, Chung, S, Cifarelli, L, Cindolo, F, Civinini, C, Clare, I, Clare, R, Coan, Te, Cohn, Ho, Coignet, G, Colino, N, Costantini, S, Cotorobai, F, Delacruz, B, Cui, Xt, Cui, Xy, Dai, Ts, Dalessandro, R, Deasmundis, R, Degre, A, Deiters, K, Denes, E, Denes, P, Denotaristefani, F, Dibitonto, D, Diemoz, M, Dimitrov, Hr, Dionisi, C, Dittmar, M, Djambazov, L, Dorne, I, Dova, Mt, Drago, E, Duchesneau, D, Duhem, F, Duinker, P, Duran, I, Dutta, S, Easo, S, Elmamouni, H, Engler, A, Eppling, Fj, Erne, Fc, Extermann, P, Fabbretti, R, Fabre, M, Falciano, S, Favara, A, Fay, J, Felcini, M, Ferguson, T, Fernandez, D, Fernandez, G, Ferroni, Fernando, Fesefeldt, H, Fiandrini, E, Field, Jh, Filthaut, F, Fisher, Ph, Forconi, G, Fredj, L, Freudenreich, K, Gailloud, M, Galaktionov, Y, Gallo, E, Ganguli, Sn, Garciaabia, P, Gentile, Simonetta, Gerald, J, Gheordanescu, N, Giagu, Stefano, Goldfarb, S, Goldstein, J, Gong, Zf, Gonzalez, E, Gougas, A, Goujon, D, Gratta, G, Gruenewald, Mw, Guanziroli, Cgm, Gupta, Vk, Gurtu, A, Gustafson, Hr, Gutay, Lj, Hasan, A, Hauschildt, D, He, Jt, Hebbeker, T, Hebert, M, Herve, A, Hilgers, K, Hofer, H, Hoorani, H, Hou, Sr, Hu, G, Ille, B, Ilyas, Mm, Innocente, V, Janssen, H, Jin, Bn, Jones, Lw, Dejong, P, Josamutuberria, I, Kasser, A, Khan, Ra, Kamyshkov, Y, Kapinos, P, Kapustinsky, Js, Karyotakis, Y, Kaur, M, Khokhar, S, Kienzlefocacci, Mn, Kim, D, Kim, Jk, Kim, Sc, Kim, Yg, Kinnison, Ww, Kirkby, A, Kirkby, D, Kirkby, J, Kirsch, S, Kittel, W, Klimentov, A, Konig, Ac, Koffeman, E, Kornadt, O, Koutsenko, V, Koulbardis, A, Kraemer, Rw, Kramer, T, Krastev, Vr, Krenz, W, Kuijten, H, Kumar, Ks, Kunin, A, Deguevara, Pl, Landi, G, Lanske, D, Lanzano, S, Laurikainen, P, Lebedev, A, Lebrun, P, Lecomte, P, Lecoq, P, Lecoultre, P, Lee, Dm, Lee, Js, Lee, Ky, Leedom, I, Leggett, C, Legoff, Jm, Leiste, R, Lenti, M, Leonardi, E, Levtchenko, P, Li, C, Lieb, E, Lin, Wt, Linde, Fl, Lindemann, B, Lista, L, Liu, Y, Lohmann, W, Longo, E, Lu, W, Lu, Ys, Lubbers, Jm, Lubelsmeyer, K, Luci, Claudio, Luckey, D, Ludovici, L, Luminari, L, Lustermann, W, Ma, Wg, Macdermott, M, Maity, M, Malgeri, L, Malik, R, Malinin, A, Mana, C, Mangla, S, Maolinbay, M, Marchesini, P, Marin, A, Martin, Jp, Marzano, F, Massaro, Ggg, Mazumdar, K, Mcbride, P, Mcmahon, T, Mcnally, D, Mele, S, Merk, M, Merola, L, Meschini, M, Metzger, Wj, Mi, Y, Mihul, A, Mills, Gb, Mir, Y, Mirabelli, G, Mnich, J, Moller, M, Monaco, V, Monteleoni, B, Morand, R, Morganti, S, Moulai, Ne, Mount, R, Muller, S, Nagy, E, Napolitano, M, Nessitedaldi, F, Newman, H, Niaz, Ma, Nippe, A, Nowak, H, Organtini, Giovanni, Ostonen, R, Pandoulas, D, Paoletti, S, Paolucci, P, Pascale, G, Passaleva, G, Patricelli, S, Paul, T, Pauluzzi, M, Paus, C, Pauss, F, Pei, Yj, Pensotti, S, Perretgallix, D, Pevsner, A, Piccolo, D, Pieri, M, Pinto, Jc, Piroue, Pa, Pistolesi, E, Plasil, F, Plyaskin, V, Pohl, M, Pojidaev, V, Postema, H, Produit, N, Qian, Jm, Qureshi, Kn, Raghavan, R, Rahalcallot, G, Rancoita, Pg, Rattaggi, M, Raven, G, Razis, P, Read, K, Redaelli, M, Ren, D, Ren, Z, Rescigno, M, Reucroft, S, Ricker, A, Riemann, S, Riemers, Bc, Riles, K, Rind, O, Rizvi, Ha, Ro, S, Robohm, A, Rodriguez, Fj, Roe, Bp, Rohner, M, Rohner, S, Romero, L, Rosierlees, S, Rosmalen, R, Rosselet, P, Vanrossum, W, Roth, S, Rubbia, A, Rubio, Ja, Rykaczewski, H, Salicio, J, Salicio, Jm, Sanchez, E, Sanders, Gs, Santocchia, A, Sarakinos, Me, Sarkar, S, Sartorelli, G, Sassowsky, M, Sauvage, G, Schafer, C, Schegelsky, V, Schmitz, D, Schmitz, P, Schneegans, M, Scholz, N, Schopper, H, Schotanus, Dj, Shotkin, S, Schreiber, Hj, Shukla, J, Schulte, R, Schultze, K, Schwenke, J, Schwering, G, Sciacca, C, Scott, I, Sehgal, R, Seiler, Pg, Sens, Jc, Servoli, L, Sheer, I, Shevchenko, S, Shi, Xr, Shumilov, E, Shoutko, V, Son, D, Sopczak, A, Soulimov, V, Spartiotis, C, Spickermann, T, Spillantini, P, Steuer, M, Stickland, Dp, Sticozzi, F, Stone, H, Strauch, K, Sudhakar, K, Sultanov, G, Sun, Lz, Susinno, Gf, Suter, H, Swain, Jd, Syed, Aa, Tang, Xw, Taylor, L, Timellini, R, Ting, Scc, Ting, Sm, Toker, O, Tonutti, M, Tonwar, Sc, Toth, J, Trowitzsch, G, Tsaregorodtsev, A, Tsipolitis, G, Tully, C, Ulbricht, J, Urban, L, Uwer, U, Valente, E, Vandewalle, Rt, Vetlitsky, I, Viertel, G, Vikas, P, Vikas, U, Vivargent, M, Vogel, H, Vogt, H, Vorobiev, I, Vorobyov, Aa, Vuilleumier, L, Wadhwa, M, Wallraff, W, Wang, Jc, Wang, Xl, Wang, Yf, Wang, Zm, Weber, A, Weber, J, Weill, R, Willmott, C, Wittgenstein, F, Wright, D, Wu, Sx, Wynhoff, S, Xu, Zz, Yang, Bz, Yang, Cg, Yang, G, Yao, Xy, Ye, Ch, Ye, Jb, Ye, Q, Yeh, Sc, You, Jm, Yunus, N, Yzerman, M, Zaccardelli, C, Zemp, P, Zeng, M, Zeng, Y, Zhang, Dh, Zhang, Zp, Zhou, B, Zhou, Gj, Zhou, Jf, Zhu, Ry, Zichichi, A, Vanderzwaan, Bcc, Acciarri, M., Adam, A., Adriani, O., Aguilarbenitez, M., Ahlen, S., Alcaraz, J., Aloisio, Alberto, Alverson, G., Alviggi, Mariagrazia, Ambrosi, G., An, Q., Anderhub, H., Anderson, A. L., Andreev, V. P., Angelescu, T., Antonov, L., Antreasyan, D., Alkhazov, G., Arce, P., Arefiev, A., Azemoon, T., Aziz, T., P. V. K., Bagnaia, P., Bakken, J. A., Baksay, L., Ball, R. C., Banerjee, S., Banicz, K., Barillere, R., Barone, L., Baschirotto, A., Basile, M., Battiston, R., Bay, A., Becattini, F., Becker, U., Behner, F., Bencze, G. L., Berdugo, J., Berges, P., Bertucci, B., Betev, B. L., Biasini, M., Biland, A., Bilei, G. M., Bizzarri, R., Blaising, J. J., Bobbink, G. J., Bock, R., Bohm, A., Borgia, B., Boucham, A., Bourilkov, D., Bourquin, M., Boutigny, D., Bouwens, B., Brambilla, E., Branson, J. G., Brigljevic, V., Brock, I. C., Brooks, M., Bujak, A., Burger, J. D., Burger, W. J., Burgos, C., Busenitz, J., Buytenhuijs, A., Bykov, A., Cai, X. D., Capell, M., Romeo, G. C., Caria, M., Carlino, G., Cartacci, A. M., Casaus, J., Castello, R., Cavallo, N., Cerrada, M., Cesaroni, F., Chamizo, M., Chang, Y. H., Chaturvedi, U. K., Chemarin, M., Chen, A., Chen, C., Chen, G., Chen, G. M., Chen, H. F., Chen, H. S., Chen, M., Chiefari, Giovanni, Chien, C. Y., Choi, M. T., Chung, S., Cifarelli, L., Cindolo, F., Civinini, C., Clare, I., Clare, R., Coan, T. E., Cohn, H. O., Coignet, G., Colino, N., Costantini, S., Cotorobai, F., Delacruz, B., Cui, X. T., Cui, X. Y., Dai, T. S., Dalessandro, R., Deasmundis, R., Degre, A., Deiters, K., Denes, E., Denes, P., Denotaristefani, F., Dibitonto, D., Diemoz, M., Dimitrov, H. R., Dionisi, C., Dittmar, M., Djambazov, L., Dorne, I., Dova, M. T., Drago, E., Duchesneau, D., Duhem, F., Duinker, P., Duran, I., Dutta, S., Easo, S., Elmamouni, H., Engler, A., Eppling, F. J., Erne, F. C., Extermann, P., Fabbretti, R., Fabre, M., Falciano, S., Favara, A., Fay, J., Felcini, M., Ferguson, T., Fernandez, D., Fernandez, G., Ferroni, F., Fesefeldt, H., Fiandrini, E., Field, J. H., Filthaut, F., Fisher, P. H., Forconi, G., Fredj, L., Freudenreich, K., Gailloud, M., Galaktionov, Y., Gallo, E., Ganguli, S. N., Garciaabia, P., Gentile, S., Gerald, J., Gheordanescu, N., Giagu, S., Goldfarb, S., Goldstein, J., Gong, Z. F., Gonzalez, E., Gougas, A., Goujon, D., Gratta, G., Gruenewald, M. W., C. G. M., Gupta, V. K., Gurtu, A., Gustafson, H. R., Gutay, L. J., Hasan, A., Hauschildt, D., J. T., He, Hebbeker, T., Hebert, M., Herve, A., Hilgers, K., Hofer, H., Hoorani, H., Hou, S. R., Hu, G., Ille, B., Ilyas, M. M., Innocente, V., Janssen, H., Jin, B. N., Jones, L. W., Dejong, P., Josamutuberria, I., Kasser, A., Khan, R. A., Kamyshkov, Y., Kapinos, P., Kapustinsky, J. S., Karyotakis, Y., Kaur, M., Khokhar, S., Kienzlefocacci, M. N., Kim, D., Kim, J. K., Kim, S. C., Kim, Y. G., Kinnison, W. W., Kirkby, A., Kirkby, D., Kirkby, J., Kirsch, S., Kittel, W., Klimentov, A., Konig, A. C., Koffeman, E., Kornadt, O., Koutsenko, V., Koulbardis, A., Kraemer, R. W., Kramer, T., Krastev, V. R., Krenz, W., Kuijten, H., Kumar, K. S., Kunin, A., Deguevara, P. L., Landi, G., Lanske, D., Lanzano, S., Laurikainen, P., Lebedev, A., Lebrun, P., Lecomte, P., Lecoq, P., Lecoultre, P., Lee, D. M., Lee, J. S., Lee, K. Y., Leedom, I., Leggett, C., Legoff, J. M., Leiste, R., Lenti, M., Leonardi, E., Levtchenko, P., Li, C., Lieb, E., Lin, W. T., Linde, F. L., Lindemann, B., Lista, L., Liu, Y., Lohmann, W., Longo, E., Lu, W., Y. S., Lu, Lubbers, J. M., Lubelsmeyer, K., Luci, C., Luckey, D., Ludovici, L., Luminari, L., Lustermann, W., W. G., Ma, Macdermott, M., Maity, M., Malgeri, L., Malik, R., Malinin, A., Mana, C., Mangla, S., Maolinbay, M., Marchesini, P., Marin, A., Martin, J. P., Marzano, F., G. G. G., Mazumdar, K., Mcbride, P., Mcmahon, T., Mcnally, D., Mele, S., Merk, M., Merola, Leonardo, Meschini, M., Metzger, W. J., Mi, Y., Mihul, A., Mills, G. B., Mir, Y., Mirabelli, G., Mnich, J., Moller, M., Monaco, V., Monteleoni, B., Morand, R., Morganti, S., Moulai, N. E., Mount, R., Muller, S., Nagy, E., Napolitano, Marco, Nessitedaldi, F., Newman, H., Niaz, M. A., Nippe, A., Nowak, H., Organtini, G., Ostonen, R., Pandoulas, D., Paoletti, S., Paolucci, P., Pascale, G., Passaleva, G., Patricelli, Sergio, Paul, T., Pauluzzi, M., Paus, C., Pauss, F., Pei, Y. J., Pensotti, S., Perretgallix, D., Pevsner, A., Piccolo, D., Pieri, M., Pinto, J. C., Piroue, P. A., Pistolesi, E., Plasil, F., Plyaskin, V., Pohl, M., Pojidaev, V., Postema, H., Produit, N., Qian, J. M., Qureshi, K. N., Raghavan, R., Rahalcallot, G., Rancoita, P. G., Rattaggi, M., Raven, G., Razis, P., Read, K., Redaelli, M., Ren, D., Ren, Z., Rescigno, M., Reucroft, S., Ricker, A., Riemann, S., Riemers, B. C., Riles, K., Rind, O., Rizvi, H. A., Ro, S., Robohm, A., Rodriguez, F. J., Roe, B. P., Rohner, M., Rohner, S., Romero, L., Rosierlees, S., Rosmalen, R., Rosselet, P., Vanrossum, W., Roth, S., Rubbia, A., Rubio, J. A., Rykaczewski, H., Salicio, J., Salicio, J. M., Sanchez, E., Sanders, G. S., Santocchia, A., Sarakinos, M. E., Sarkar, S., Sartorelli, G., Sassowsky, M., Sauvage, G., Schafer, C., Schegelsky, V., Schmitz, D., Schmitz, P., Schneegans, M., Scholz, N., Schopper, H., Schotanus, D. J., Shotkin, S., Schreiber, H. J., Shukla, J., Schulte, R., Schultze, K., Schwenke, J., Schwering, G., Sciacca, Crisostomo, Scott, I., Sehgal, R., Seiler, P. G., Sens, J. C., Servoli, L., Sheer, I., Shevchenko, S., Shi, X. R., Shumilov, E., Shoutko, V., Son, D., Sopczak, A., Soulimov, V., Spartiotis, C., Spickermann, T., Spillantini, P., Steuer, M., Stickland, D. P., Sticozzi, F., Stone, H., Strauch, K., Sudhakar, K., Sultanov, G., Sun, L. Z., Susinno, G. F., Suter, H., Swain, J. D., Syed, A. A., Tang, X. W., Taylor, L., Timellini, R., S. C. C., Ting, S. M., Toker, O., Tonutti, M., Tonwar, S. C., Toth, J., Trowitzsch, G., Tsaregorodtsev, A., Tsipolitis, G., Tully, C., Ulbricht, J., Urban, L., Uwer, U., Valente, E., Vandewalle, R. T., Vetlitsky, I., Viertel, G., Vikas, P., Vikas, U., Vivargent, M., Vogel, H., Vogt, H., Vorobiev, I., Vorobyov, A. A., Vuilleumier, L., Wadhwa, M., Wallraff, W., Wang, J. C., Wang, X. L., Wang, Y. F., Wang, Z. M., Weber, A., Weber, J., Weill, R., Willmott, C., Wittgenstein, F., Wright, D., S. X., Wu, Wynhoff, S., Z. Z., Xu, Yang, B. Z., Yang, C. G., Yang, G., Yao, X. Y., C. H., Ye, J. B., Ye, Ye, Q., Yeh, S. C., You, J. M., Yunus, N., Yzerman, M., Zaccardelli, C., Zemp, P., Zeng, M., Zeng, Y., Zhang, D. H., Zhang, Z. P., Zhou, B., Zhou, G. J., Zhou, J. F., Zhu, R. Y., Zichichi, A., and B. C. C.
Subjects: PHYSICS, E+E ANNIHILATION, LUND MONTE-CARLO, High Energy Physics::Phenomenology, QUARK, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, 3-JET EVENTS, High Energy Physics::Experiment, FRAGMENTATION MODELS, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), QCD, GLUON JETS, PARTON
Abstract: We report on a detailed study of the energy and particle flow in the event plane of three-jet events q(q) over barg$ and radiative two-jet events in hadronic Z decays recorded with the L3 detector. We find a significant decrease in particle and energy density in the angular region between quark and antiquark jets for q(q) over barg$ events as compared with events. Several QCD model predictions are compared with the observed effect.
Published: 1995

5. An Improved Measurement of B(0)-(b)bar(0) Mixing In Z(0) Decays

Author: Adeva, B., Adriani, O., Aguilarbenitez, M., Ahlen, S., Akbari, H., Alcaraz, J., Aloisio, A., Alverson, G., Alviggi, Mg, Ambrosi, G., An, Q., Anderhub, H., Anderson, Al, Andreev, Vp, Angelov, T., Antonov, L., Antreasyan, D., Arce, P., Arefiev, A., Atamanchuk, A., Azemoon, T., Aziz, T., Baba, Pvks, Bagnaia, P., Bakken, Ja, Baksay, L., Ball, Rc, Banerjee, S., Bao, J., Barillere, R., Barone, L., Battiston, R., Bay, A., Becattini, F., Becker, U., Behner, F., Behrens, J., Beingessner, S., Bencze, Gl, Berdugo, J., Berges, P., Bertucci, B., Betev, Bl, Biasini, M., Biland, A., Bilei, Gm, Bizzarri, R., Blaising, Jj, Blumenfeld, B., Bobbink, Gj, Bocciolini, M., Bock, R., Bohm, A., Borgia, B., Bourilkov, D., Bourquin, M., Boutigny, D., Bouwens, B., Brambilla, E., Branson, Jg, Brock, Ic, Brooks, M., Buisson, C., Bujak, A., Burger, Jd, Burger, Wj, Burq, Jp, Busenitz, J., Cai, Xd, Capell, M., Caria, M., Carlino, G., Carminati, F., Cartacci, Am, Cerrada, M., Cesaroni, F., Chang, Yh, Chaturvedi, Uk, Chemarin, M., Chen, A., Chen, C., Chen, Gm, Chen, Hf, Chen, Hs, Chen, J., Chen, M., Chen, Ml, Chen, Wy, Chiefari, G., Chien, Cy, Chmeissani, M., Chung, S., Civinini, C., Clare, I., Clare, R., Coan, Te, Cohn, Ho, Coignet, G., Colino, N., Contin, A., Crijns, F., Cui, Xt, Cui, Xy, Dai, Ts, Dalessandro, R., Deasmundis, R., Degre, A., Deiters, K., Denes, E., Denes, P., Denotaristefani, F., Dhina, M., Dibitonto, D., Diemoz, M., Dimitrov, Hr, Dionisi, C., Dova, Mt, Drago, E., Driever, T., Duchesneau, D., Duinker, P., Elmamouni, H., Engler, A., Eppling, Fj, Erne, Fc, Extermann, P., Fabbretti, R., Fabre, M., Falciano, S., Fan, Sj, Fackler, O., Fay, J., Felcini, M., Ferguson, T., Fernandez, D., Fernandez, G., Ferroni, F., Fesefeldt, H., Fiandrini, E., Field, J., Filthaut, F., Finocchiaro, G., Fisher, Ph, Forconi, G., Foreman, T., Freudenreich, K., Friebel, W., Fukushima, M., Gailloud, M., Galaktionov, Y., Gallo, E., Ganguli, Sn, Garciaabia, P., Gau, Ss, Gele, D., Gentile, S., Goldfarb, S., Gong, Zf, Gonzalez, E., Gottlicher, P., Gougas, A., Goujon, D., Gratta, G., Grinnell, C., Gruenewald, M., Gu, C., Guanziroli, M., Guo, Jk, Gupta, Vk, Gurtu, A., Gustafson, Hr, Gutay, Lj, Hangarter, K., Hasan, A., Hauschildt, D., He, Cf, Hebbeker, T., Hebert, M., Herten, G., Herten, U., Herve, A., Hilgers, K., Hofer, H., Hoorani, H., Hu, G., Hu, Gq, Ille, B., Ilyas, Mm, Innocente, V., Janssen, H., Jezequel, S., Jin, Bn, Jones, Lw, Kasser, A., Khan, Ra, Kamyshkov, Y., Kapinos, P., Kapustinsky, Js, Karyotakis, Y., Kaur, M., Khokhar, S., Kienzlefocacci, Mn, Kinnison, Ww, Kirkby, D., Kirsch, S., Kittel, W., Klimentov, A., Konig, Ac, Koffeman, E., Kornadt, O., Koutsenko, V., Koulbardis, A., Kraemer, Rw, Kramer, T., Krastev, Vr, Krenz, W., Krivshich, A., Kumar, Ks, Kunin, A., Landi, G., Lanske, D., Lanzano, S., Lebrun, P., Lecomte, P., Lecoq, P., Lecoultre, P., Lee, Dm, Leedom, I., Legoff, Jm, Leiste, R., Lenti, M., Leonardi, E., Lettry, J., Leytens, X., Li, C., Li, Ht, Li, Pj, Li, Xg, Liao, Jy, Lin, Wt, Lin, Zy, Linde, Fl, Lindemann, B., Linnhofer, D., Lista, L., Liu, Y., Lohmann, W., Longo, E., Lu, Ys, Lubbers, Jm, Lubelsmeyer, K., Luci, C., Luckey, D., Ludovici, L., Luminari, L., Ma, Wg, Macdermott, M., Malhotra, Pk, Malik, R., Malinin, A., Mana, C., Mao, Dn, Mao, Yf, Maolinbay, M., Marchesini, P., Marion, F., Marin, A., Martin, Jp, Martinezlaso, L., Marzano, F., Massaro, Ggg, Matsuda, T., Mazumdar, K., Mcbride, P., Mcmahon, T., Mcnally, D., Meinholz, T., Merk, M., Merola, L., Meschini, M., Metzger, Wj, Mi, Y., Mills, Gb, Mir, Y., Mirabelli, G., Mnich, J., Moller, M., Monteleoni, B., Morand, R., Morganti, S., Moulai, Ne, Mount, R., Muller, S., Nadtochy, A., Nagy, E., Napolitano, M., Newman, H., Neyer, C., Niaz, Ma, Nippe, A., Nowak, H., Organtini, G., Pandoulas, D., Paoletti, S., Paolucci, P., Passaleva, G., Patricelli, S., Paul, T., Pauluzzi, M., Pauss, F., Pei, Yj, Perretgallix, D., Perrier, J., Pevsner, A., Piccolo, D., Pieri, M., Piroue, Pa, Plasil, F., Plyaskin, V., Pohl, M., Pojidaev, V., Produit, N., Qian, Jm, Qureshi, Kn, Raghavan, R., Rahalcallot, G., Raven, G., Razis, P., Read, K., Ren, D., Ren, Z., Rescigno, M., Reucroft, S., Ricker, A., Riemann, S., Rind, O., Rizvi, Ha, Roe, Bp, Rohner, M., Rohner, S., Romero, L., Rose, J., Rosierlees, S., Rosmalen, R., Rosselet, P., Rubbia, A., Rubio, Ja, Rykaczewski, H., Sachwitz, M., Sajan, E., Salicio, J., Salicio, Jm, Sanders, Gs, Santocchia, A., Sarakinos, Ms, Sartorelli, G., Sassowsky, M., Sauvage, G., Schegelsky, V., Schmiemann, K., Schmitz, D., Schmitz, P., Schneegans, M., Schopper, H., Schotanus, Dj, Shotkin, S., Schreiber, Hj, Shukla, J., Schulte, R., Schulte, S., Schultze, K., Schutte, J., Schwenke, J., Schwering, G., Sciacca, C., Scott, I., Sehgal, R., Seiler, Pg, Sens, Jc, Servoli, L., Sheer, I., Shen, Dz, Shevchenko, S., Shi, Xr, Shumilov, E., Shoutko, V., Soderstrom, E., Sopczak, A., Spartiotis, C., Spickermann, T., Spillantini, P., Starosta, R., Steuer, M., Stickland, Dp, Sticozzi, F., Stone, H., Strauch, K., Stringfellow, Bc, Sudhakar, K., Sultanov, G., Sumner, Rl, Sun, Lz, Suter, H., Sutton, Rb, Swain, Jd, Syed, Aa, Tang, Xw, Taylor, L., Timmermans, C., Ting, Scc, Ting, Sm, Tonutti, M., Tonwar, Sc, Toth, J., Tsaregorodtsev, A., Tsipolitis, G., Tully, C., Tung, Kl, Ulbricht, J., Urban, L., Uwer, U., Valente, E., Vandewalle, Rt, Vetlitsky, I., Viertel, G., Vikas, P., Vikas, U., Vivargent, M., Vogel, H., Vogt, H., Vorobiev, I., Vorobyov, Aa, Vuilleumier, L., Wadhwa, M., Wallraff, W., Wang, Cr, Wang, Gh, Wang, Jh, Wang, Qf, Wang, Xl, Wang, Yf, Wang, Zm, Weber, A., Weber, J., Weill, R., Wenaus, Tj, Wenninger, J., White, M., Willmott, C., Wittgenstein, F., Wright, D., Wu, Rj, Wu, Sx, Wu, Yg, Wyslouch, B., Xie, Yy, Xu, Yd, Xu, Zz, Xue, Zl, Yan, Ds, Yan, Xj, Yang, Bz, Yang, Cg, Yang, G., Yang, Ks, Yang, Qy, Yang, Zq, Ye, Ch, Ye, Jb, Ye, Q., Yeh, Sc, Yin, Zw, You, Jm, Yunus, N., Yzerman, M., Zaccardelli, C., Zemp, P., Zeng, M., Zeng, Y., Zhang, Dh, Zhang, Zp, Zhou, B., Zhou, Jf, Zhu, Ry, Zhuang, Hl, Zichichi, A., Vanderzwaan, Bcc, Adeva, B., Adriani, O., Aguilarbenitez, M., Ahlen, S., Akbari, H., Alcaraz, J., Aloisio, Alberto, Alverson, G., Alviggi, Mariagrazia, Ambrosi, G., An, Q., Anderhub, H., Anderson, A. L., Andreev, V. P., Angelov, T., Antonov, L., Antreasyan, D., Arce, P., Arefiev, A., Atamanchuk, A., Azemoon, T., Aziz, T., P. V. K., Bagnaia, P., Bakken, J. A., Baksay, L., Ball, R. C., Banerjee, S., Bao, J., Barillere, R., Barone, L., Battiston, R., Bay, A., Becattini, F., Becker, U., Behner, F., Behrens, J., Beingessner, S., Bencze, G. L., Berdugo, J., Berges, P., Bertucci, B., Betev, B. L., Biasini, M., Biland, A., Bilei, G. M., Bizzarri, R., Blaising, J. J., Blumenfeld, B., Bobbink, G. J., Bocciolini, M., Bock, R., Bohm, A., Borgia, B., Bourilkov, D., Bourquin, M., Boutigny, D., Bouwens, B., Brambilla, E., Branson, J. G., Brock, I. C., Brooks, M., Buisson, C., Bujak, A., Burger, J. D., Burger, W. J., Burq, J. P., Busenitz, J., Cai, X. D., Capell, M., Caria, M., Carlino, G., Carminati, F., Cartacci, A. M., Cerrada, M., Cesaroni, F., Chang, Y. H., Chaturvedi, U. K., Chemarin, M., Chen, A., Chen, C., Chen, G. M., Chen, H. F., Chen, H. S., Chen, J., Chen, M., Chen, M. L., Chen, W. Y., Chiefari, Giovanni, Chien, C. Y., Chmeissani, M., Chung, S., Civinini, C., Clare, I., Clare, R., Coan, T. E., Cohn, H. O., Coignet, G., Colino, N., Contin, A., Crijns, F., Cui, X. T., Cui, X. Y., Dai, T. S., Dalessandro, R., Deasmundis, R., Degre, A., Deiters, K., Denes, E., Denes, P., Denotaristefani, F., Dhina, M., Dibitonto, D., Diemoz, M., Dimitrov, H. R., Dionisi, C., Dova, M. T., Drago, E., Driever, T., Duchesneau, D., Duinker, P., Elmamouni, H., Engler, A., Eppling, F. J., Erne, F. C., Extermann, P., Fabbretti, R., Fabre, M., Falciano, S., Fan, S. J., Fackler, O., Fay, J., Felcini, M., Ferguson, T., Fernandez, D., Fernandez, G., Ferroni, F., Fesefeldt, H., Fiandrini, E., Field, J., Filthaut, F., Finocchiaro, G., Fisher, P. H., Forconi, G., Foreman, T., Freudenreich, K., Friebel, W., Fukushima, M., Gailloud, M., Galaktionov, Y., Gallo, E., Ganguli, S. N., Garciaabia, P., Gau, S. S., Gele, D., Gentile, S., Goldfarb, S., Gong, Z. F., Gonzalez, E., Gottlicher, P., Gougas, A., Goujon, D., Gratta, G., Grinnell, C., Gruenewald, M., Gu, C., Guanziroli, M., Guo, J. K., Gupta, V. K., Gurtu, A., Gustafson, H. R., Gutay, L. J., Hangarter, K., Hasan, A., Hauschildt, D., C. F., He, Hebbeker, T., Hebert, M., Herten, G., Herten, U., Herve, A., Hilgers, K., Hofer, H., Hoorani, H., Hu, G., G. Q., Hu, Ille, B., Ilyas, M. M., Innocente, V., Janssen, H., Jezequel, S., Jin, B. N., Jones, L. W., Kasser, A., Khan, R. A., Kamyshkov, Y., Kapinos, P., Kapustinsky, J. S., Karyotakis, Y., Kaur, M., Khokhar, S., Kienzlefocacci, M. N., Kinnison, W. W., Kirkby, D., Kirsch, S., Kittel, W., Klimentov, A., Konig, A. C., Koffeman, E., Kornadt, O., Koutsenko, V., Koulbardis, A., Kraemer, R. W., Kramer, T., Krastev, V. R., Krenz, W., Krivshich, A., Kumar, K. S., Kunin, A., Landi, G., Lanske, D., Lanzano, S., Lebrun, P., Lecomte, P., Lecoq, P., Lecoultre, P., Lee, D. M., Leedom, I., Legoff, J. M., Leiste, R., Lenti, M., Leonardi, E., Lettry, J., Leytens, X., Li, C., H. T., Li, P. J., Li, X. G., Li, Liao, J. Y., Lin, W. T., Lin, Z. Y., Linde, F. L., Lindemann, B., Linnhofer, D., Lista, L., Liu, Y., Lohmann, W., Longo, E., Y. S., Lu, Lubbers, J. M., Lubelsmeyer, K., Luci, C., Luckey, D., Ludovici, L., Luminari, L., W. G., Ma, Macdermott, M., Malhotra, P. K., Malik, R., Malinin, A., Mana, C., Mao, D. N., Mao, Y. F., Maolinbay, M., Marchesini, P., Marion, F., Marin, A., Martin, J. P., Martinezlaso, L., Marzano, F., G. G. G., Matsuda, T., Mazumdar, K., Mcbride, P., Mcmahon, T., Mcnally, D., Meinholz, T., Merk, M., Merola, Leonardo, Meschini, M., Metzger, W. J., Mi, Y., Mills, G. B., Mir, Y., Mirabelli, G., Mnich, J., Moller, M., Monteleoni, B., Morand, R., Morganti, S., Moulai, N. E., Mount, R., Muller, S., Nadtochy, A., Nagy, E., Napolitano, Marco, Newman, H., Neyer, C., Niaz, M. A., Nippe, A., Nowak, H., Organtini, G., Pandoulas, D., Paoletti, S., Paolucci, P., Passaleva, G., Patricelli, Sergio, Paul, T., Pauluzzi, M., Pauss, F., Pei, Y. J., Perretgallix, D., Perrier, J., Pevsner, A., Piccolo, D., Pieri, M., Piroue, P. A., Plasil, F., Plyaskin, V., Pohl, M., Pojidaev, V., Produit, N., Qian, J. M., Qureshi, K. N., Raghavan, R., Rahalcallot, G., Raven, G., Razis, P., Read, K., Ren, D., Ren, Z., Rescigno, M., Reucroft, S., Ricker, A., Riemann, S., Rind, O., Rizvi, H. A., Roe, B. P., Rohner, M., Rohner, S., Romero, L., Rose, J., Rosierlees, S., Rosmalen, R., Rosselet, P., Rubbia, A., Rubio, J. A., Rykaczewski, H., Sachwitz, M., Sajan, E., Salicio, J., Salicio, J. M., Sanders, G. S., Santocchia, A., Sarakinos, M. S., Sartorelli, G., Sassowsky, M., Sauvage, G., Schegelsky, V., Schmiemann, K., Schmitz, D., Schmitz, P., Schneegans, M., Schopper, H., Schotanus, D. J., Shotkin, S., Schreiber, H. J., Shukla, J., Schulte, R., Schulte, S., Schultze, K., Schutte, J., Schwenke, J., Schwering, G., Sciacca, Crisostomo, Scott, I., Sehgal, R., Seiler, P. G., Sens, J. C., Servoli, L., Sheer, I., Shen, D. Z., Shevchenko, S., Shi, X. R., Shumilov, E., Shoutko, V., Soderstrom, E., Sopczak, A., Spartiotis, C., Spickermann, T., Spillantini, P., Starosta, R., Steuer, M., Stickland, D. P., Sticozzi, F., Stone, H., Strauch, K., Stringfellow, B. C., Sudhakar, K., Sultanov, G., Sumner, R. L., Sun, L. Z., Suter, H., Sutton, R. B., Swain, J. D., Syed, A. A., Tang, X. W., Taylor, L., Timmermans, C., S. C. C., Ting, S. M., Tonutti, M., Tonwar, S. C., Toth, J., Tsaregorodtsev, A., Tsipolitis, G., Tully, C., Tung, K. L., Ulbricht, J., Urban, L., Uwer, U., Valente, E., Vandewalle, R. T., Vetlitsky, I., Viertel, G., Vikas, P., Vikas, U., Vivargent, M., Vogel, H., Vogt, H., Vorobiev, I., Vorobyov, A. A., Vuilleumier, L., Wadhwa, M., Wallraff, W., Wang, C. R., Wang, G. H., Wang, J. H., Wang, Q. F., Wang, X. L., Wang, Y. F., Wang, Z. M., Weber, A., Weber, J., Weill, R., Wenaus, T. J., Wenninger, J., White, M., Willmott, C., Wittgenstein, F., Wright, D., R. J., Wu, S. X., Wu, Y. G., Wu, Wyslouch, B., Xie, Y. Y., Y. D., Xu, Z. Z., Xu, Xue, Z. L., Yan, D. S., Yan, X. J., Yang, B. Z., Yang, C. G., Yang, G., Yang, K. S., Yang, Q. Y., Yang, Z. Q., C. H., Ye, J. B., Ye, Ye, Q., Yeh, S. C., Yin, Z. W., You, J. M., Yunus, N., Yzerman, M., Zaccardelli, C., Zemp, P., Zeng, M., Zeng, Y., Zhang, D. H., Zhang, Z. P., Zhou, B., Zhou, J. F., Zhu, R. Y., Zhuang, H. L., Zichichi, A., and B. C. C.
Subjects: COLLIDER, E+E ANNIHILATION, PARTICLE, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Z0 DECAYS
Abstract: A more precise determination of the B0-B0BAR mixing parameter in Z0 decays based on a fourfold increase in statistics has been made using the 1990 and 1991 L3 data. The analysis of the dilepton events, muons and electrons, gives: chi(B) = 0. 121 +/- 0.017 (stat) +/- 0.006 (sys). Using the value of chi(d) measured at the UPSILON(4S) we derive the following limit for chi(s): chi(S) > 0.16 (90% CL).
Published: 1992

6. A Direct Determination of the Number of Light Neutrino Families from E+E--]Nu-Nu-Bar-Gamma at Lep

Author: Adeva, B, Adriani, O, Aguilarbenitez, M, Akbari, H, Alcaraz, J, Aloisio, A, Alverson, G, Alviggi, Mg, Ambrosi, G, An, Q, Anderhub, H, Anderson, Al, Andreev, Vp, Angelov, T, Antonov, L, Antreasyan, D, Arce, P, Arefiev, A, Atamanchuk, A, Azemoon, T, Aziz, T, Baba, Pvks, Bagnaia, Paolo, Bakken, Ja, Baksay, L, Ball, Rc, Banerjee, S, Bao, J, Barillere, R, Barone, Luciano Maria, Battiston, R, Bay, A, Becattini, F, Becker, U, Behner, F, Behrens, J, Beingessner, S, Bencze, Gl, Berdugo, J, Berges, P, Bertucci, B, Betev, Bl, Biasini, M, Biland, A, Bilei, Gm, Bizzarri, R, Blaising, Jj, Blomeke, P, Blumenfeld, B, Bobbink, Gj, Bocciolini, M, Bock, R, Bohm, A, Borgia, B, Bourilkov, D, Bourquin, M, Boutigny, D, Bouwens, B, Brambilla, E, Branson, Jg, Brock, Ic, Brooks, M, Bruyant, F, Buisson, C, Bujak, A, Burger, Jd, Burger, Wj, Burq, Jp, Busenitz, J, Cai, Xd, Capell, M, Caria, M, Carminati, F, Cartacci, Am, Cerrada, M, Cesaroni, F, Chang, Yh, Chaturvedi, Uk, Chemarin, M, Chen, A, Chen, C, Chen, Gm, Chen, Hf, Chen, Hs, Chen, J, Chen, M, Chen, Ml, Chen, Wy, Chiefari, G, Chien, Cy, Chmeissani, M, Civinini, C, Clare, I, Clare, R, Coan, Te, Cohn, Ho, Coignet, G, Colino, N, Contin, A, Crijns, F, Cui, Xy, Dai, Ts, Dalessandro, R, Deasmundis, R, Degre, A, Deiters, K, Denes, E, Denes, P, Denotaristefani, F, Dhina, M, Dibitonto, D, Diemoz, M, Dimitrov, Hr, Dionisi, C, Dova, Mt, Drago, E, Driever, T, Duchesneau, D, Duinker, P, Duran, I, Elmamouni, H, Engler, A, Eppling, Fj, Erne, Fc, Extermann, P, Fabbretti, R, Fabre, M, Falciano, S, Fan, Q, Fan, Sj, Fackler, O, Fay, J, Felcini, M, Ferguson, T, Fernandez, D, Fernandez, G, Ferroni, Fernando, Fesefeldt, H, Fiandrini, E, Field, J, Filthaut, F, Finocchiaro, G, Fisher, Ph, Forconi, G, Foreman, T, Freudenreich, K, Friebel, W, Fukushima, M, Gailloud, M, Galaktionov, Y, Gallo, E, Ganguli, Sn, Garciaabia, P, Gau, Ss, Gele, D, Gentile, Simonetta, Goldfarb, S, Gong, Zf, Gonzalez, E, Gordeev, A, Gottlicher, P, Goujon, D, Gratta, G, Grinnell, C, Gruenewald, M, Guanziroli, M, Guo, Jk, Gurtu, A, Gustafson, Hr, Gutay, Lj, Hangarter, K, Hasan, A, Hauschildt, D, He, Cf, Hebbeker, T, Hebert, M, Herten, G, Herten, U, Herve, A, Hilgers, K, Hofer, H, Hoorani, H, Hu, G, Hu, Gq, Ille, B, Ilyas, Mm, Innocente, V, Janssen, H, Jezequel, S, Jin, Bn, Jones, Lw, Kasser, A, Khan, Ra, Kamyshkov, Y, Kapinos, P, Kapustinsky, Js, Karyotakis, Y, Kaur, M, Khokhar, S, Kienzlefocacci, Mn, Kinnison, Ww, Kirkby, D, Kirsch, S, Kittel, W, Klimentov, A, Konig, Ac, Kornadt, O, Koutsenko, V, Koulbardis, A, Kraemer, Rw, Kramer, T, Krastev, Vr, Krenz, W, Krivshich, A, Krizmanic, J, Kumar, Ks, Kumar, V, Kunin, A, Landi, G, Lanius, K, Lanske, D, Lanzano, S, Lebrun, P, Lecomte, P, Lecoq, P, Lecoultre, P, Lee, Dm, Leedom, I, Legoff, Jm, Leistam, L, Leiste, R, Lenti, M, Leonardi, E, Lettry, J, Leytens, X, Li, C, Li, Ht, Li, Jf, Li, Pj, Li, Q, Li, Xg, Liao, Jy, Lin, Wt, Lin, Zy, Linde, Fl, Lindemann, B, Linnhofer, D, Liu, R, Liu, Y, Lohmann, W, Longo, E, Lu, Ys, Lubbers, Jm, Lubelsmeyer, K, Luci, Claudio, Luckey, D, Ludovici, L, Luminari, L, Ma, Wg, Macdermott, M, Malhotra, Pk, Malik, R, Malinin, A, Mana, C, Mao, Dn, Mao, Yf, Maolinbay, M, Marchesini, P, Martin, Jp, Martinezlaso, L, Marzano, F, Massaro, Ggg, Matsuda, T, Mazumdar, K, Mcbride, P, Mcmahon, T, Mcnally, D, Meinholz, T, Merk, M, Merola, L, Meschini, M, Metzger, Wj, Mi, Y, Mills, Gb, Mir, Y, Mirabelli, G, Mnich, J, Moller, M, Monteleoni, B, Morand, R, Morganti, S, Moulai, Ne, Mount, R, Muller, S, Nadtochy, A, Nagy, E, Napolitano, M, Newman, H, Neyer, C, Niaz, Ma, Niessen, L, Nowak, H, Organtini, Giovanni, Pandoulas, D, Pauluzzi, M, Pauss, F, Passaleva, G, Paoletti, S, Patricelli, S, Pei, Yj, Perretgallix, D, Perrier, J, Pevsner, A, Pieri, M, Piroue, Pa, Plasil, F, Plyaskin, V, Pohl, M, Pojidaev, V, Produit, N, Qian, Jm, Qureshi, Kn, Raghavan, R, Rahalcallot, G, Raven, G, Razis, P, Read, K, Ren, D, Ren, Z, Rescigno, M, Reucroft, S, Ricker, A, Riemann, S, Rind, O, Rizvi, Ha, Roe, Bp, Rohner, M, Rohner, S, Romero, L, Rose, J, Rosierlees, S, Rosmalen, R, Rosselet, P, Rubbia, A, Rubio, Ja, Rykaczewski, H, Sachwitz, M, Salicio, J, Salicio, Jm, Sanders, Gs, Santocchia, A, Sarakinos, Ms, Sartorelli, G, Sauvage, G, Savin, A, Schegelsky, V, Schmiemann, K, Schmitz, D, Schmitz, P, Schneegans, M, Schopper, H, Schotanus, Dj, Shotkin, S, Schreiber, Hj, Shukla, J, Schulte, R, Schulte, S, Schultze, K, Schutte, J, Schwenke, J, Schwering, G, Sciacca, C, Scott, I, Sehgal, R, Seiler, Pg, Sens, Jc, Servoli, L, Sheer, I, Shen, Dz, Shevchenko, S, Shi, Xr, Shmakov, K, Shumilov, E, Shoutko, V, Soderstrom, E, Sopczak, A, Spartiotis, C, Spickermann, T, Spillantini, P, Starosta, R, Steuer, M, Stickland, Dp, Sticozzi, F, Stone, H, Strauch, K, Stringfellow, Bc, Sudhakar, K, Sultanov, G, Sumner, Rl, Sun, Lz, Suter, H, Sutton, Rb, Swain, Jd, Syed, Aa, Tang, Xw, Tarkovsky, E, Taylor, L, Timmermans, C, Ting, Scc, Ting, Sm, Tonutti, M, Tonwar, Sc, Toth, J, Tsaregorodtsev, A, Tsipolitis, G, Tully, C, Tung, Kl, Ulbricht, J, Urban, L, Uwer, U, Valente, E, Vandewalle, Rt, Vetlitsky, I, Viertel, G, Vikas, P, Vikas, U, Vivargent, M, Vogel, H, Vogt, H, Vondardel, G, Vorobiev, I, Vorobyov, Aa, Vuilleumier, L, Wadhwa, M, Wallraff, W, Wang, Cr, Wang, Gh, Wang, Jh, Wang, Qf, Wang, Xl, Wang, Yf, Wang, Z, Wang, Zm, Weber, A, Weber, J, Weill, R, Wenaus, Tj, Wenninger, J, White, M, Willmott, C, Wittgenstein, F, Wright, D, Wu, Rj, Wu, Sl, Wu, Sx, Wu, Yg, Wyslouch, B, Xie, Yy, Xu, Yd, Xu, Zz, Xue, Zl, Yan, Ds, Yan, Xj, Yang, Bz, Yang, Cg, Yang, G, Yang, Ks, Yang, Qy, Yang, Zq, Ye, Ch, Ye, Jb, Ye, Q, Yeh, Sc, Yin, Zw, You, Jm, Yzerman, M, Zaccardelli, C, Zemp, P, Zeng, M, Zeng, Y, Zhang, Dh, Zhang, Zp, Zhou, Jf, Zhu, Ry, Zhuang, Hl, Zichichi, A., Longo, Egidio, B., Adeva, O., Adriani, M., Aguilarbenitez, H., Akbari, J., Alcaraz, Aloisio, Alberto, G., Alverson, Alviggi, Mariagrazia, G., Ambrosi, Q., An, H., Anderhub, A. L., Anderson, V. P., Andreev, T., Angelov, L., Antonov, D., Antreasyan, P., Arce, A., Arefiev, A., Atamanchuk, T., Azemoon, T., Aziz, P. V., K., P., Bagnaia, J. A., Bakken, L., Baksay, R. C., Ball, S., Banerjee, J., Bao, R., Barillere, L., Barone, R., Battiston, A., Bay, F., Becattini, U., Becker, F., Behner, J., Behren, S., Beingessner, G. L., Bencze, J., Berdugo, P., Berge, B., Bertucci, B. L., Betev, M., Biasini, A., Biland, G. M., Bilei, R., Bizzarri, J. J., Blaising, P., Blomeke, B., Blumenfeld, G. J., Bobbink, M., Bocciolini, R., Bock, A., Bohm, B., Borgia, D., Bourilkov, M., Bourquin, D., Boutigny, B., Bouwen, E., Brambilla, J. G., Branson, I. C., Brock, M., Brook, F., Bruyant, C., Buisson, A., Bujak, J. D., Burger, W. J., Burger, J. P., Burq, J., Busenitz, X. D., Cai, M., Capell, M., Caria, F., Carminati, A. M., Cartacci, M., Cerrada, F., Cesaroni, Y. H., Chang, U. K., Chaturvedi, M., Chemarin, A., Chen, C., Chen, G. M., Chen, H. F., Chen, H. S., Chen, J., Chen, M., Chen, M. L., Chen, W. Y., Chen, Chiefari, Giovanni, C. Y., Chien, M., Chmeissani, C., Civinini, I., Clare, R., Clare, T. E., Coan, H. O., Cohn, G., Coignet, N., Colino, A., Contin, F., Crijn, X. Y., Cui, T. S., Dai, R., Dalessandro, R., Deasmundi, A., Degre, K., Deiter, E., Dene, P., Dene, F., Denotaristefani, M., Dhina, D., Dibitonto, M., Diemoz, H. R., Dimitrov, C., Dionisi, M. T., Dova, E., Drago, T., Driever, D., Duchesneau, P., Duinker, I., Duran, H., Elmamouni, A., Engler, F. J., Eppling, F. C., Erne, P., Extermann, R., Fabbretti, M., Fabre, S., Falciano, Q., Fan, S. J., Fan, O., Fackler, J., Fay, M., Felcini, T., Ferguson, D., Fernandez, G., Fernandez, F., Ferroni, H., Fesefeldt, E., Fiandrini, J., Field, F., Filthaut, G., Finocchiaro, P. H., Fisher, G., Forconi, T., Foreman, K., Freudenreich, W., Friebel, M., Fukushima, M., Gailloud, Y., Galaktionov, E., Gallo, S. N., Ganguli, P., Garciaabia, S. S., Gau, D., Gele, S., Gentile, S., Goldfarb, Z. F., Gong, E., Gonzalez, A., Gordeev, P., Gottlicher, D., Goujon, G., Gratta, C., Grinnell, M., Gruenewald, M., Guanziroli, J. K., Guo, A., Gurtu, H. R., Gustafson, L. J., Gutay, K., Hangarter, A., Hasan, D., Hauschildt, C. F., He, T., Hebbeker, M., Hebert, G., Herten, U., Herten, A., Herve, K., Hilger, H., Hofer, H., Hoorani, G., Hu, G. Q., Hu, B., Ille, M. M., Ilya, V., Innocente, H., Janssen, S., Jezequel, B. N., Jin, L. W., Jone, A., Kasser, R. A., Khan, Y., Kamyshkov, P., Kapino, J. S., Kapustinsky, Y., Karyotaki, M., Kaur, S., Khokhar, M. N., Kienzlefocacci, W. W., Kinnison, D., Kirkby, S., Kirsch, W., Kittel, A., Klimentov, A. C., Konig, O., Kornadt, V., Koutsenko, A., Koulbardi, R. W., Kraemer, T., Kramer, V. R., Krastev, W., Krenz, A., Krivshich, J., Krizmanic, K. S., Kumar, V., Kumar, A., Kunin, G., Landi, K., Laniu, D., Lanske, S., Lanzano, P., Lebrun, P., Lecomte, P., Lecoq, P., Lecoultre, D. M., Lee, I., Leedom, J. M., Legoff, L., Leistam, R., Leiste, M., Lenti, E., Leonardi, J., Lettry, X., Leyten, C., Li, H. T., Li, J. F., Li, P. J., Li, Q., Li, X. G., Li, J. Y., Liao, W. T., Lin, Z. Y., Lin, F. L., Linde, B., Lindemann, D., Linnhofer, R., Liu, Y., Liu, W., Lohmann, E., Longo, Y. S., Lu, J. M., Lubber, K., Lubelsmeyer, C., Luci, D., Luckey, L., Ludovici, L., Luminari, W. G., Ma, M., Macdermott, P. K., Malhotra, R., Malik, A., Malinin, C., Mana, D. N., Mao, Y. F., Mao, M., Maolinbay, P., Marchesini, J. P., Martin, L., Martinezlaso, F., Marzano, G. G., G., T., Matsuda, K., Mazumdar, P., Mcbride, T., Mcmahon, D., Mcnally, T., Meinholz, M., Merk, Merola, Leonardo, M., Meschini, W. J., Metzger, Y., Mi, G. B., Mill, Y., Mir, G., Mirabelli, J., Mnich, M., Moller, B., Monteleoni, R., Morand, S., Morganti, N. E., Moulai, R., Mount, S., Muller, A., Nadtochy, E., Nagy, Napolitano, Marco, H., Newman, C., Neyer, M. A., Niaz, L., Niessen, H., Nowak, G., Organtini, D., Pandoula, M., Pauluzzi, F., Pau, G., Passaleva, S., Paoletti, Patricelli, Sergio, Y. J., Pei, D., Perretgallix, J., Perrier, A., Pevsner, M., Pieri, P. A., Piroue, F., Plasil, V., Plyaskin, M., Pohl, V., Pojidaev, N., Produit, J. M., Qian, K. N., Qureshi, R., Raghavan, G., Rahalcallot, G., Raven, P., Razi, K., Read, D., Ren, Z., Ren, M., Rescigno, S., Reucroft, A., Ricker, S., Riemann, O., Rind, H. A., Rizvi, B. P., Roe, M., Rohner, S., Rohner, L., Romero, J., Rose, S., Rosierlee, R., Rosmalen, P., Rosselet, A., Rubbia, J. A., Rubio, H., Rykaczewski, M., Sachwitz, J., Salicio, J. M., Salicio, G. S., Sander, A., Santocchia, M. S., Sarakino, G., Sartorelli, G., Sauvage, A., Savin, V., Schegelsky, K., Schmiemann, D., Schmitz, P., Schmitz, M., Schneegan, H., Schopper, D. J., Schotanu, S., Shotkin, H. J., Schreiber, J., Shukla, R., Schulte, S., Schulte, K., Schultze, J., Schutte, J., Schwenke, G., Schwering, Sciacca, Crisostomo, I., Scott, R., Sehgal, P. G., Seiler, J. C., Sen, L., Servoli, I., Sheer, D. Z., Shen, S., Shevchenko, X. R., Shi, K., Shmakov, E., Shumilov, V., Shoutko, E., Soderstrom, A., Sopczak, C., Spartioti, T., Spickermann, P., Spillantini, R., Starosta, M., Steuer, D. P., Stickland, F., Sticozzi, H., Stone, K., Strauch, B. C., Stringfellow, K., Sudhakar, G., Sultanov, R. L., Sumner, L. Z., Sun, H., Suter, R. B., Sutton, J. D., Swain, A. A., Syed, X. W., Tang, E., Tarkovsky, L., Taylor, C., Timmerman, S. C., C., S. M., Ting, M., Tonutti, S. C., Tonwar, J., Toth, A., Tsaregorodtsev, G., Tsipoliti, C., Tully, K. L., Tung, J., Ulbricht, L., Urban, U., Uwer, E., Valente, R. T., Vandewalle, I., Vetlitsky, G., Viertel, P., Vika, U., Vika, M., Vivargent, H., Vogel, H., Vogt, G., Vondardel, I., Vorobiev, A. A., Vorobyov, L., Vuilleumier, M., Wadhwa, W., Wallraff, C. R., Wang, G. H., Wang, J. H., Wang, Q. F., Wang, X. L., Wang, Y. F., Wang, Z., Wang, Z. M., Wang, A., Weber, J., Weber, R., Weill, T. J., Wenau, J., Wenninger, M., White, C., Willmott, F., Wittgenstein, D., Wright, R. J., Wu, S. L., Wu, S. X., Wu, Y. G., Wu, B., Wyslouch, Y. Y., Xie, Y. D., Xu, Z. Z., Xu, Z. L., Xue, D. S., Yan, X. J., Yan, B. Z., Yang, C. G., Yang, G., Yang, K. S., Yang, Q. Y., Yang, Z. Q., Yang, C. H., Ye, J. B., Ye, Q., Ye, S. C., Yeh, Z. W., Yin, J. M., You, M., Yzerman, C., Zaccardelli, P., Zemp, M., Zeng, Y., Zeng, D. H., Zhang, Z. P., Zhang, J. F., Zhou, R. Y., Zhu, H. L., Zhuang, and A., Zichichi
Subjects: SINGLE PHOTONS, SUPERSYMMETRIC PARTICLES, Physics::Instrumentation and Detectors, SEARCH, SCATTERING, High Energy Physics::Experiment, E+E COLLISIONS, Astrophysics::Cosmology and Extragalactic Astrophysics, ANNIHILATION, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract: The L3 detector at LEP has been used to determine the number of light neutrino families by measuring the cross section of single photon even in e+e- collisions at energies near the Z0 resonance. We have observed 61 single photon candidates with more than 1.5 GeV of deposited energy in the barrel electromagnetic calorimeter, for a total integrated luminosity of 3.0 pb-1. From a likelihood fit to the single photon cross sections, we determine N(nu) = 3.24 +/- 0.46 (statistical) +/- 0.22 (systematic).
Published: 1992

7. Electroweak parameters of the Z$^0$ resonance and the standard model

Author: DECAMP, D, Deschizeaux, B, Goy, C, Lees, JP, Minard, MN, Alemany, R, Crespo, JM, Delfino, M, Fernandez, E, Gaitan, V, Garrido, LI, Mir, LLM, Pacheco, A, Catanesi, MG, Creanza, D, de Palma, M, Farilla, A, Iaselli, G, Maggi, G, Maggi, M, Natali, S, Nuzzo, S, Quattromini, M, Ranieri, A, Raso, G, Romano, F, Ruggieri, F, Selvaggi, G, Silvestris, L, Tempesta, P, Zito, G, Gao, Y, Hu, H, Huang, D, Huang, X, Lin, J, Lou, J, Qiao, C, Ruan, T, Wang, T, Xie, Y, Xu, D, Xu, R, Zhang, J, Zhao, W, Atwood, WB, Bauerdick, LAT, Bird, F, Blucher, E, Bonvicini, G, Bossi, F, Boudreau, J, Brown, D, Burnett, TH, Drevermann, H, Forty, RW, Grab, C, Hagelberg, R, Haywood, S, Hilgart, J, Jost, B, Kasemann, M, Knobloch, J, Lacourt, A, Lancon, E, Lehraus, I, Lohse, T, Lusiani, A, Marchioro, A, Martinez, M, Mato, P, Menary, S, Minten, A, Miotto, A, Miquel, R, Moser, HG, Nash, J, Palazzi, P, Ranjard, F, Redlinger, G, Roth, A, Rothberg, J, Rotscheidt, H, Saich, M, St Denis, R, Schlatter, D, Takashima, M, Talby, M, Tejessy, W, Wachsmuth, H, Wasserbaech, S, Wheeler, S, Wiedenmann, W, Witzeling, W, Wotschack, J, Ajaltouni, Z, Bardadin-Otwinowska, M, El Fellous, R, Falvard, A, Gay, P, Harvey, J, Henrard, P, Jousset, J, Michel, B, Montret, JC, Pallin, D, Perret, P, Proriol, J, Prulhiere, F, Stimpfl, G, Hansen, JD, Hansen, JR, Hansen, PH, Mollerud, R, Nilsson, BS, Efthymiopoulos, I, Simopoulou, E, Vayaki, A, Badier, J, Blondel, A, Bonneaud, G, Bourotte, J, Braems, F, Brient, JC, Fouque, G, Gamess, A, Guirlet, R, Orteu, S, Rosowsky, A, Rouge, A, Rumpf, M, Tanaka, R, Videau, H, Candlin, DJ, Veitch, E, Parrini, G, Corden, M, Georgiopoulos, C, Ikeda, M, Lannutti, J, Levinthal, D, Mermikides, M, Sawyer, L, Antonelli, A, Baldini, R, Bencivenni, G, Bologna, G, Campana, P, Capon, G, Cerutti, F, Chiarella, V, D'Ettorre-Piazzoli, B, Felici, G, Laurelli, P, Mannocchi, G, Murtas, F, Murtas, GP, Nicoletti, G, Passalacqua, L, Pepe-Altarelli, M, Picchi, P, Zografou, P, Altoon, B, Boyle, O, Halley, AW, ten Have, I, Hearns, JL, Lynch, JG, Morton, WT, Raine, C, Scarr, JM, Smith, K, Thompson, AS, Turnbull, RM, Brandl, B, Braun, O, Geiges, R, Geweniger, C, Hanke, P, Hepp, V, Kluge, EE, Maumary, Y, Putzer, A, Rensch, B, Stahl, A, Tittel, K, Wunsch, M, Belk, AT, Beuselinck, R, Binnie, DM, Cameron, W, Cattaneo, M, Dornan, PJ, Dugeay, S, Greene, AM, Hassard, JF, Lieske, NM, Patton, SJ, Payne, DG, Phillips, MJ, Sedgbeer, JK, Taylor, G, Tomalin, IR, Wright, AG, Girtler, P, Kuhn, D, Rudolph, G, Bowdery, CK, Brodbeck, TJ, Finch, AJ, Foster, F, Hughes, G, Keemer, NR, Nuttall, M, Patel, A, Rowlingson, BS, Sloan, T, Snow, SW, Whelan, EP, Barczewski, T, Kleinknecht, K, Raab, J, Renk, B, Roehn, S, Sander, HG, Schmelling, M, Schmidt, H, Steeg, F, Walther, SM, Wolf, B, Albanese, JP, Aubert, JJ, Benchouk, C, Bernard, V, Bonissent, A, Courvoisier, D, Etienne, F, Papalexiou, S, Payre, P, Pietrzyk, B, Qian, Z, Becket, H, Blum, W, Cattaneo, P, Cowan, G, Dehning, B, Dietl, H, Dydak, F, Fernandez-Bosman, M, Hansl-Kozanecka, T, Jahn, A, Kozanecki, W, Lange, E, Lauber, J, Lutjens, G, Lutz, G, Manner, W, Pan, Y, Richter, R, Schroder, J, Schwarz, AS, Settles, R, Stierlin, U, Thomas, J, Wolf, G, Bertin, V, Boucrot, J, Callot, O, Chen, X, Cordier, A, Davier, M, Ganis, G, Grivaz, JF, Heusse, P, Janot, P, Kim, DW, Le Diberder, F, Lefrancois, J, Lutz, AM, Veillet, JJ, Videau, I, Zhang, Z, Zomer, F, Abbaneo, D, Amendolia, SR, Bagliesi, G, Batignani, G, Bosisio, L, Bottigli, U, Bradaschia, C, Carpinelli, M, Ciocci, MA, Dell'Orso, R, Ferrante, I, Fidecaro, F, Foa, L, Focardi, E, Forti, F, Gatto, C, Giassi, A, Giorgi, MA, Ligabue, F, Mannelli, EB, Marrocchesi, PS, Messineo, A, Moneta, L, Palla, F, Sanguinetti, G, Steinberger, J, Tenchini, R, Tonelli, G, Triggiani, G, Vannini, C, Venturi, A, Verdini, PG, Walsh, J, Carter, JM, Green, MG, March, PV, Medcalf, T, Quazi, IS, Strong, JA, Thomas, RM, West, LR, Wildish, T, Botterill, DR, Clift, RW, Edgecock, TR, Edwards, M, Fisher, SM, Jones, TJ, Norton, PR, Salmon, DP, Thompson, JC, Bloch-Devaux, B, Colas, P, Klopfenstein, C, Locci, E, Loucatos, S, Monnier, E, Perez, P, Perlas, JA, Pettier, F, Rander, J, Renardy, JF, Roussarie, A, Schuller, JP, Schwindling, J, Vallage, B, Ashman, JG, Booth, CN, Buttar, C, Carney, R, Cartwright, S, Combley, F, Dinsdale, M, Dogru, M, Hatfield, F, Martin, J, Parker, D, Reeves, P, Thomson, LF, Barberio, E, Brandt, S, Burkhardt, H, Grupen, C, Meinhard, H, Mirabito, L, Schaifer, U, Seywerd, H, Apollinari, G, Giannini, G, Gobbo, B, Liello, F, Ragusa, F, Rolandi, L, Stiegler, U, Bellantoni, L, Cinabro, D, Conway, JS, Cowen, DF, Feng, Z, Ferguson, DPS, Gao, YS, Grahl, J, Harton, JL, Jacobsen, JE, Jared, RC, Johnson, RP, Le Claire, BW, Pan, YB, Pater, JR, Saadi, Y, Sharma, V, Shi, ZH, Tang, YH, Walsh, AM, Wear, JA, Weber, FV, Whitney, MH, Wu, SL, Zobernig, G, ABREU, P, Adam, W, Adami, F, Adye, T, Akesson, T, Alekseev, GD, Allen, P, Almehed, S, Alted, F, Alvsvaag, SJ, Amaldi, U, Anassontzis, EG, Antilogus, P, Apel, WD, Asman, B, Astier, P, Augustin, JE, Augustinus, A, Baillon, P, Bambade, P, Barao, F, Barbiellini, G, Bardin, DY, Baroncelli, A, Barring, O, Bartl, W, Battaglia, M, Bates, MJ, Baubillier, M, Becks, KH, Beeston, CJ, Begalli, M, Beilliere, P, Belokopytov, YA, Beltran, P, Benedic, D, Benlloch, JM, Berggren, M, Bertrand, D, Biagi, SF, Bianchi, F, Bibby, JH, Bilenky, SM, Billoir, P, Bjarne, J, Bloch, D, Blyth, S, Bogolubov, PN, Bolognese, T, Bonapart, M, Bonesini, M, Bonivento, W, Booth, PSL, Boratav, M, Borgeaud, P, Borisov, G, Borner, H, Bosio, C, Botner, O, Bouquet, B, Bozzo, M, Braibant, S, Branchini, P, Brand, KD, Brenner, RA, Bricman, C, Brown, RCA, Brummer, N, Brunet, JM, Bugge, L, Buran, T, Burmeister, H, Buytaert, J, Caccia, M, Calvi, M, Camacho-Rozas, AJ, Campagne, JE, Campion, A, Camporesi, T, Canale, V, Cao, F, Carroll, L, Caso, C, Castelli, E, Castillo-Gimenez, MV, Cattai, A, Cavallo, FR, Cerrito, L, Chapkin, MM, Charpentier, P, Checchia, P, Chelkov, GA, Chevalier, L, Chliapnikov, PV, Chorowicz, V, Cirio, R, Clara, MP, Collins, P, Contreras, JL, Contri, R, Cosme, G, Couchot, F, Crawley, HB, Crennell, DJ, Crosetti, G, Crosland, N, Crozon, M, Cuevas-Maestro, J, Czellar, S, Dagoret, S, Dahl-Jensen, E, D'Almagne, B, Dam, M, Damgaard, G, Darbo, G, Daubie, E, Dauncey, PD, Davenport, M, David, P, De Angelis, A, De Beer, M, De Boeck, H, de Boer, W, De Clercq, C, De Fez Laso, MDM, De Groot, N, de La Vaissiere, C, De Lotto, B, Defoix, C, Delikaris, D, Delorme, S, Delpierre, PA, Demaria, N, Demin, A, Derkaoui, JE, Di Ciaccio, L, Dijkstra, H, Djama, F, Dolbeau, J, Donszelmann, M, Doroba, K, Dracos, M, Drees, J, Dris, M, Dufour, Y, Dulinski, W, Dzhelyadin, RI, Eek, L, Eerola, PAM, Ekelof, TJC, Ekspong, G, Elliot-Peisert, A, Engel, JP, Fassouliotis, D, Fernandez-Alonso, M, Ferrer, A, Filippas-Tassos, A, Firestone, A, Foth, H, Fokitis, E, Folegati, P, Fontanelli, F, Forsbach, H, Franek, BJ, Frenkiel, P, Fries, DEC, Frodesen, AG, Fruhwirth, R, Fulda-Quenzer, F, Furnival, K, Furstenau, H, Fuster, JA, Gago, JM, Galeazzi, G, Gamba, D, Garcia, C, Garcia, J, Gasparini, U, Gavillet, P, Gazis, EN, Gerber, JP, Giacomelli, P, Glitza, KW, Gokieli, R, Golovatyuk, VM, Gomez-Cadenas, JJ, Goobar, A, Gopal, GP, Gian, P, Gorski, M, Gracco, V, Grant, A, Grard, F, Graziani, E, Gros, MH, Grosdidier, G, Grossetete, B, Gumenyuk, SA, Guy, J, Hahn, F, Hahn, M, Haider, S, Hajduk, Z, Hakansson, A, Hallgren, A, Hamacher, K, Hamel de Monchenault, G, Harris, FJ, Heck, BW, Herbst, I, Hernandez, JJ, Herquet, P, Herr, H, Hietanen, I, Higon, E, Hilke, HJ, Hodgson, SD, Hofmokl, T, Holmes, R, Holmgren, SO, Holthuizen, DJ, Honore, PF, Hooper, JE, Houlden, MA, Hrubec, J, Hulth, PO, Hultqvist, K, Husson, D, Hyams, BD, Ioannou, P, Isenhower, D, Iversen, PS, Jackson, JN, Jalocha, P, Jarlskog, G, Jarry, P, Jean-Marie, B, Johansson, EK, Johnsson, D, Jonker, M, Jonsson, LB, Juillot, P, Kalkanis, G, Kalmus, GE, Kantardjian, G, Kapusta, F, Kapusta, P, Katsanevas, S, Katsoufis, EC, Keranen, R, Kesteman, J, Khomenko, BA, Khovanskii, NN, King, BJ, Kjaer, NJ, Klein, H, Klempt, W, Klovning, A, Kluit, PM, Kohne, JH, Kone, B, Kokkinias, P, Kopf, M, Koratzinos, M, Korcyl, K, Korytov, AV, Korzen, B, Kostukhin, V, Kourkoumelis, C, Kreuzberger, T, Krolikowski, J, Kruner-Marquis, U, Krupinski, W, Kucewicz, W, Kulka, K, Kurvinen, KL, Lacasta, C, Lambropoulos, C, Lamsa, J, Lanceri, L, Lapin, V, Laugier, JP, Lauhakangas, R, Leder, G, Ledroit, F, Lemonne, J, Lenzen, G, Lepeltier, V, Letessier-Selvon, AA, Liko, D, Lieb, EH, Lillethun, E, Lindgren, J, Lipniacka, A, Lippi, I, Llosa, R, Lorstad, B, Lokajicek, M, Loken, JG, Lopez-Aguera, MA, Lopez-Fernandez, A, Los, ME, Loukas, D, Lounis, A, Lozano-Bahilo, J, Lucock, R, Lutz, P, Lyons, L, Maehlum, G, Maillard, J, Maltezos, A, Maltezos, S, Mandl, F, Marco, J, Margoni, M, Marin, JC, Markou, A, Mathis, LG, Matorras, F, Matteuzzi, C, Matthiae, G, Mazzucato, M, McCubbin, ML, McKay, R, McNulty, R, Menichetti, E, Meola, G, Meroni, C, Meyer, WT, Michelotto, M, Mitaroff, WA, Mitselmakher, G, Mjornmark, U, Moa, T, Moller, R, Monig, K, Monge, MR, Morettini, P, Murray, WJ, Myatt, G, Naraghi, F, Nau-Korzen, U, Navarria, FL, Negri, P, Nielsen, BS, Nijjhar, B, Nikolaenko, V, Obraztsov, VF, Olshevskii, AG, Orava, R, Ostankov, AP, Ouraou, A, Pain, R, Palka, H, Papadopoulou, TD, Pape, L, Passeri, A, Pegoraro, M, Perevozchikov, V, Pernicka, M, Perrotta, A, Pierre, F, Pimenta, M, Pingot, O, Pinsent, AC, Pol, ME, Polok, G, Poropat, P, Privitera, P, Pullia, A, Pyyhtia, J, Radojicic, D, Ragazzi, S, Range, WH, Ratoff, PN, Read, AL, Redaelli, NG, Regler, M, Reid, D, Renton, PB, Resvanis, LK, Richard, F, Richardson, M, Ridky, J, Rinaudo, G, Roditi, I, Romero, A, Roncagliolo, I, Ronchese, P, Ronnqvist, C, Rosenberg, EI, Rossi, U, Rosso, E, Roudeau, P, Rovelli, T, Ruckstuhl, W, Ruhlmann, V, Ruiz, A, Rybicki, K, Saarikko, H, Sacquin, Y, Salt, J, Sanchez, E, Sanchez, J, Sannino, M, Schaffer, M, Schneider, H, Scuri, F, Segar, AM, Sekulin, RL, Sessa, MI, Sette, G, Seufert, R, Shellard, RC, Siegrist, P, Simonetti, S, Simonetto, F, Sissakian, AN, Skaali, TB, Skjevling, G, Smadja, G, Smith, GR, Smirnov, N, Sosnowski, R, Spassoff, T, Spiriti, E, Squarcia, S, Stack, H, Stanescu, C, Stavropoulos, GD, Stichelbaut, F, Stocchi, A, Strauss, J, Strub, R, Stubenrauch, CJ, Szczekowski, M, Szeptycka, M, Szymanski, P, Tabarelli de Fatis, T, Tavernier, S, Chikilev, OG, Theodosiou, GE, Tilquin, A, Timmermans, J, Timofeev, VG, Tkatchev, LG, Todorov, T, Toet, DZ, Tortora, L, Trainor, MT, Treille, D, Trevisan, U, Trischuk, W, Tristram, G, Troncon, C, Tsirou, AL, Tsyganov, EN, Turala, M, Turchetta, R, Turluer, ML, Tuuva, T, Tyapkin, IA, Tyndel, M, Tzamarias, S, Uberschar, B, Uberschar, S, Ullaland, O, Uvarov, V, Valenti, G, Vallazza, E, Valls Ferrer, JA, van Apeldoorn, GW, van Dam, P, Van Doninck, WK, van Eijndhoven, N, Van der Velde, C, Varela, J, Vaz, P, Vegni, G, Velasco, J, Ventura, L, Venus, WA, Verbeure, F, Vertogradov, LS, Vibert, L, Vilanova, D, Vlasov, EV, Vodopyanov, AS, Vollmer, M, Volponi, S, Voulgaris, G, Voutilainen, M, Vrba, V, Wahlen, H, Walck, C, Waldner, F, Wayne, M, Weilhammer, P, Werner, J, Wetherell, AM, Wickens, JH, Wikne, J, Wilkinson, GR, Williams, WSC, Winter, M, Wormald, D, Wormser, G, Woschnagg, K, Yamdagni, N, Yepes, P, Zaitsev, A, Zalewska-Bak, A, Zalewski, P, Zevgolatakos, E, Zhang, G, Zimin, NI, Zito, M, Zitoun, R, Zukanovich-Funchal, R, Zumerle, G, Zuniga, J, ADEVA, B, Adriani, O, Aguilar-Benitez, M, Akbari, H, Alcaraz, J, Aloisio, A, Alverson, G, Alviggi, MG, An, Q, Anderhub, H, Anderson, AL, Andreev, VP, Angelov, T, Antonov, L, Antreasyan, D, Arce, P, Arefev, A, Azemoon, T, Aziz, T, Baba, PVKS, Bagnaia, P, Bakken, JA, Baksay, L, Ball, RC, Banerjee, S, Bao, J, Barone, L, Bay, A, Becker, U, Behrens, J, Beingessner, S, Bencze, GL, Berdugo, J, Berges, P, Bertucci, B, Betev, BL, Biland, A, Bizzarri, R, Blaising, JJ, Bloemeke, P, Blumenfeld, B, Bobbink, GJ, Bocciolini, M, Boeck, RK, Boehm, A, Borgia, B, Bourilkov, D, Bourquin, M, Boutigny, D, Bouwens, BT, Branson, JG, Brock, IC, Bruyant, F, Buisson, C, Bujak, A, Burger, JD, Burq, JP, Busenitz, J, Cai, XD, Capell, M, Carbonara, F, Cardenal, F, Carminati, P, Catacci, AM, Cerrada, M, Cesaroni, F, Chang, YH, Chaturvedi, UK, Chemarin, M, Chen, A, Chen, C, Chen, GM, Chen, HF, Chen, HS, Chen, M, Chen, ML, Chen, WY, Chiefari, G, Chien, CY, Chollet, F, Civinini, C, Clare, I, Clare, R, Cohn, HO, Coignet, G, Colino, N, Commichau, V, Conforto, G, Contin, A, Crijns, F, Criscuolo, P, Cui, XY, Dai, TS, D'Alessandro, R, de Asmundis, R, Degre, A, Deiters, K, Denes, P, de Notaristefani, F, Dhina, M, DiBitonto, D, Diemoz, M, Diez Hedo, F, Dimitrov, HR, Dionisi, C, Divia, R, Dova, MT, Drago, E, Driever, T, Duchesneau, D, Duinker, P, Duran, I, El-Mamouni, H, Engler, A, Eppling, FJ, Erne, FC, Extermann, P, Fabbretti, R, Faber, G, Fabre, M, Falciano, S, Fan, Q, Fan, SJ, Fackler, O, Fay, J, Fehlmann, J, Ferguson, T, Fernandez, G, Ferroni, F, Fesefeldt, H, Field, J, Filthaut, F, Finocchiaro, G, Fisher, PH, Forconi, G, Foreman, T, Freudenreich, K, Friebel, W, Fukushima, M, Gailloud, M, Galaktionov, Y, Gallo, E, Ganguli, SN, Garcia-Abia, P, Gau, SS, Gele, D, Gentile, S, Glaubman, M, Goldfarb, S, Gong, ZF, Gonzalez, E, Gordeev, A, Goettlicher, P, Goujon, D, Gratta, G, Grinnell, C, Gruenewald, MW, Guanziroli, M, Guo, JK, Gurtu, H, Gustafson, R, Gutay, LJ, Haan, H, Hasan, A, Hauschildt, D, He, CF, Hebbeker, T, Hebert, M, Herten, G, Herten, U, Herve, A, Hilgers, K, Hofer, H, Hoorani, H, Hsu, LS, Hu, G, Hu, GQ, Ille, B, Ilyas, MM, Innocente, V, Isiksal, E, Janssen, H, Jin, BN, Jones, LW, Kasser, A, Khan, RA, Kamyshkov, Y, Karyotakis, Y, Kaur, M, Khokhar, S, Khoze, V, Kienzle-Focacci, MN, Kinnison, WW, Kirkby, D, Kittel, W, Klimentov, A, Koenig, AC, Kornadt, O, Koutsenko, V, Kraemer, RW, Kramer, T, Krastev, VR, Krenz, W, Krizmanic, JF, Kumar, KS, Kumar, V, Kunin, A, Lalieu, V, Landi, G, Lanske, D, Lanzano, S, Lebrun, P, Lecomte, P, Lecoq, P, Le Coultre, P, Lee, D, Leedom, I, Le Goff, JM, Leistam, L, Leiste, R, Lenti, M, Leonardi, E, Lettry, J, Levchenko, PM, Leytens, X, Li, C, Li, HT, Li, JF, Li, L, Li, PJ, Li, Q, Li, XG, Liao, JY, Lin, ZY, Linde, FL, Lindemann, B, Linnhoefer, D, Liu, R, Liu, Y, Lohmann, W, Longo, E, Lu, YS, Lubbers, JM, Luebelsmeyer, K, Luci, C, Luckey, D, Ludovici, L, Lue, X, Luminari, L, Ma, WG, MacDermott, M, Magahiz, R, Maire, M, Malhotra, K, Malik, R, Malinin, A, Mana, C, Mao, DN, Mao, YF, Maolinbay, M, Marchesini, P, Marchionni, A, Martin, B, Martinez-Lazo, L, Marzano, F, Massaro, GGG, Matsuda, T, Mazumdar, K, McBride, P, McMahon, T, McNally, D, Meinholz, T, Merk, M, Merola, L, Meschini, M, Metzger, WJ, Mi, Y, Mills, GB, Mir, Y, Mirabelli, G, Mnich, J, Moeller, M, Monteleoni, B, Morand, G, Morand, R, Morganti, S, Moulai, NE, Mount, R, Mueller, S, Nagy, E, Napolitano, M, Newman, H, Never, C, Niaz, MA, Niessen, L, Nowak, H, Pandoulas, D, Plasil, F, Passaleva, G, Paternoster, G, Patricelli, S, Pei, YJ, Perret-Galliz, D, Perrier, J, Pevsner, A, Pieri, M, Piccolo, D, Piroue, PA, Plyaskin, V, Pohl, M, Pozhidaev, V, Produit, N, Qian, JM, Quershi, KN, Raghavan, R, Rahal-Callot, G, Razis, P, Read, K, Ren, D, Ren, Z, Reucroft, S, Ricker, A, Riemann, S, Rind, O, Rippich, C, Rizvi, HA, Roe, BP, Roehner, M, Roehner, S, Roeser, U, Romero, L, Rose, J, Rosier-Lees, S, Rosmalen, R, Rosselet, P, Rubbia, C, Rubio, JA, Rubio, M, Rykaczewski, H, Sachwitz, M, Salicio, J, Salicio, JM, Sanders, G, Sarakinos, ME, Sartorelli, G, Sauvage, G, Savin, A, Shchegelskii, V, Schmiiemann, K, Schmitz, D, Schmitz, P, Schneegans, M, Schopper, H, Schotanus, DJ, Shotkin, S, Schreiber, HJ, Schulte, R, Schulte, S, Schultze, K, Schuette, J, Schwenke, J, Schwering, G, Sciacca, C, Scott, I, Sehgal, R, Seiler, PG, Sens, JC, Sheer, I, Shen, DZ, Shevchenko, V, Shevchenko, S, Shi, XR, Shmakov, K, Shoutko, V, Shumilov, E, Soederstroem, E, Sopczak, A, Spartiotis, C, Spickermann, T, Spiess, B, Spillantini, P, Starosta, R, Steuer, M, Stickland, DP, Sticozzi, F, Stoeffl, W, Stone, H, Strauch, K, Stringfellow, BC, Sudhakar, K, Sultanov, GG, Sumner, RL, Sun, LZ, Suter, H, Sutton, RB, Swain, JD, Syed, AA, Tang, XW, Tarkovsky, E, Taylor, L, Timmermans, C, Ting, SCC, Ting, SM, Tong, YP, Tonisch, F, Tonutti, M, Tonwar, SC, Toth, J, Trowitzsch, G, Tully, C, Tung, KL, Ulbricht, J, Urban, L, Uwer, U, Valenta, E, Van de Walle, RT, Vetlitskii, I, Viertel, G, Vikas, U, Vivargent, M, Vogel, H, Vogt, H, von Dardel, G, Vorobev, I, Vorobyov, AA, Vuilleumier, L, Wadhwa, M, Wallraff, W, Wang, CR, Wang, GH, Wang, JH, Wang, QF, Wang, XL, Wang, YF, Wang, Z, Wang, ZM, Weber, A, Weber, J, Weill, R, Wenaus, J, Wenninger, J, White, M, Willmott, C, Wittgenstein, F, Wright, D, Wu, RJ, Wu, SX, Wu, YG, Wyslouch, B, Xie, YY, Xu, YD, Xu, ZZ, Xue, ZL, Yan, DS, Yan, XJ, Yang, BZ, Yang, CG, Yang, G, Yang, KS, Yang, QY, Ye, CH, Ye, JB, Ye, Q, Yeh, SC, Yin, ZW, You, JM, Yzerman, M, Zaccardelli, C, Zehnder, L, Zemp, P, Zeng, M, Zeng, Y, Zhang, DH, Zhang, ZP, Zhou, JF, Zhu, RY, Zhuang, HL, Zichichi, A, Alexander, G, Allison, J, Allport, PP, Anderson, KJ, Arcelli, S, Armitage, JC, Ashton, P, Astbury, A, Axen, D, Azuelos, G, Bahan, GA, Baines, JTM, Ball, AH, Banks, J, Barker, GJ, Barlow, RJ, Batley, JR, Beaudoin, G, Beck, A, Becker, J, Behnke, T, Bell, KW, Bella, G, Betheke, S, Biebel, O, Binder, U, Bloodworth, IJ, Bock, P, Bosch, HM, Bougerolle, S, Brabson, B, Breuker, H, Brown, RM, Brun, R, Buijs, A, Burckhart, HJ, Capiluppi, P, Carnegie, RK, Carter, AA, Carter, JR, Chang, CY, Charlton, DG, Chrin, JTM, Clarke, PEL, Cohen, I, Collins, WJ, Conboy, JE, Cooper, M, Couch, M, Coupland, M, Cuffiani, M, Dado, S, Dallavalle, M, De Jong, S, Debu, P, Deninno, MM, Dieckmann, A, Dittmar, M, Dizit, MS, Duchovni, E, Duckeck, G, Duerdoth, IP, Dumas, DJP, Eckerlin, G, Elxombe, PA, Estabrooks, PG, Etzion, E, Fabbri, FL, Fincke-Keeler, M, Fischer, HM, Fong, DG, Fukunaga, C, Gaidot, A, Ganel, O, Gary, JW, Gascon, J, McGowan, RF, Geddes, NI, Geich-Gimbel, C, Gensler, MW, Gentit, FX, Giacomelli, G, Gibson, V, Gibson, WR, Gilles, JD, Goldberg, J, Goodrick, MJ, Gorn, W, Grandi, C, Gross, E, Hagemann, J, Hanson, GG, Hansroul, M, Hargrove, CK, Harrison, PF, Hart, J, Hattersley, PM, Hauschild, M, Hawkes, CM, Heflin, E, Hemingway, RJ, Heuer, RD, Hill, JC, Hillier, SJ, Hinshaw, DA, Ho, C, Hobbs, JD, Hobson, RR, Hochman, D, Holl, B, Homer, RJ, Hou, SR, Howarth, CP, Humbert, R, Hughes-Jones, RE, Igo-Kemenes, P, Ihssen, H, Imrie, DC, Janissen, L, Jawahery, A, Jeffreys, PW, Jeremie, H, Jimack, M, Jobes, M, Jones, RWL, Jovanovic, P, Karlen, D, Kawagoe, K, Kawamoto, T, Keeler, RK, Kellogg, RG, Kennedy, BW, Kleinwort, C, Klem, DE, Kobayashi, T, Kokott, TP, Komamiva, S, Koepke, L, Kowalewski, R, Kreutzmann, H, Von Krogh, J, Kroll, J, Kuwano, M, Kyberd, P, Lafferty, GD, Lamarche, F, Larson, WJ, Lavter, JG, Le Du, P, Leblanc, P, Lee, AM, Lehto, MH, Lellouch, D, Lennert, P, Leroy, C, Lessard, ML, Levegruen, S, Levinson, L, Lloyd, SL, Loebinger, FK, Lorah, JM, Lorazo, B, Losty, MJ, Lou, XC, Ludwig, J, Mannelli, M, Marcellini, S, Maringer, G, Martin, AJ, Martin, JP, Mashimo, T, Maettig, P, Maur, U, McMahon, TJ, McNutt, JR, Meijers, F, Menszner, D, Merritt, FS, Mes, H, Michelini, A, Middleton, RP, Mikenberg, G, Mildenberger, J, Miller, DJ, Milstene, C, Mir, R, Mohr, W, Moisan, C, Montanari, A, Mori, T, Moss, MW, Mouthuy, T, Murphy, PG, Nellen, B, Nguyen, HH, Nozaki, M, O'Neale, SW, O'Neill, BP, Oakham, FG, Odorici, F, Ogg, M, Ogren, HO, Oh, JH, Oram, CJ, Oreglia, MJ, Orito, S, Pansart, JP, Panzer-Steindel, B, Paschievici, P, Patrick, GN, Pawley, SJ, Pfister, P, Pilcher, JE, Pinfold, JL, Plane, DE, Poffenberger, PR, Poli, B, Pouladdej, A, Prebys, E, Pritchard, W, Przysiezniak, H, Quast, Q, Redmond, MW, Rees, DL, Riles, K, Robins, SA, Robinson, D, Rollnik, A, Roney, JM, Rossberg, S, Rossi, AM, Routenburg, P, Runge, K, Runolfsson, O, Rust, DR, Sanghera, S, Sasaki, M, Schaile, AD, Schappert, W, Scharff-Hansen, P, Schenk, P, Von der Schmitt, H, Schreiber, S, Schwarz, J, Scott, WG, Settles, M, Shen, BC, Sherwood, P, Shypit, R, Simon, A, Singh, P, Siroli, GP, Skuja, A, Smith, AM, Smith, TJ, Snow, GA, Sobie, RJ, Springer, RW, Sproston, M, Stephens, K, Stier, HE, Strom, D, Takeda, H, Takeshita, T, Taras, P, Tarem, S, Teixeira-Dias, P, Thackray, NJ, Tsukamoto, T, Turner, MF, Tysarczyk-Niemeyer, G, Van den plas, D, Van Kooten, R, VanDalen, GJ, Vasseur, G, Virtue, CJ, Wagner, A, Wahl, C, Walker, JP, Ward, CP, Ward, DR, Watkins, PM, Watson, AT, Watson, NK, Weber, M, Weisz, S, Wells, PS, Wermes, N, Weymann, M, Whalley, MA, Wilson, GW, Wilson, JA, Wingerter, I, Winterer, VH, Wood, NC, Wotten, SA, Wyatt, TR, Yaari, R, Yang, Y, Yekutieli, G, Zacharov, I, Zeuner, W, Zorn, GT, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique Corpusculaire - Clermont-Ferrand (LPC), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Leprince-Ringuet (LLR), Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Centre de Physique des Particules de Marseille (CPPM), Aix Marseille Université (AMU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Pierre et Marie Curie - Paris 6 (UPMC), Institut de Recherches Subatomiques (IReS), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Cancéropôle du Grand Est-Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), ALEPH, Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Bourquin, Maurice, Burger, William, Duchesneau, Dominique Robert, Extermann, Pierre, Field, John, Forconi, Gilles Raymond, Goujon, Didier, Hoorani, Hafeez-Ur-Rehman, Kienzle, Maria-Novella, Perrier, Jacques, Produit, Nicolas, Wenninger, Joerg Horst, Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), and Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Aix Marseille Université (AMU)
Subjects: Physics, Nuclear and High Energy Physics, 010308 nuclear & particles physics, High Energy Physics::Phenomenology, Wish, media, Context (language use), Temporality, ddc:500.2, temporalities, 01 natural sciences, elderly, Epistemology, Temporalities, Appropriation, Expression (architecture), 0103 physical sciences, Selection (linguistics), [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], High Energy Physics::Experiment, Media system dependency theory, 010306 general physics, uses, Particle Physics - Experiment, time
Abstract: Media temporalities of the elderly : evolutions in stability This article shows the context of analysis and the first results of a research on media temporalities of the elderly. Several works have finely analysed the diversity of the media practices and studied meanings of media uses. I wish to continue these analyses by insisting on the evolutionary and dynamic aspect of the practices and temporalities of users having expanded, enhanced, so called "interactive" radio and especially television programming. A priori, the elderly, upon retirement, have a "full-time free time". Their media practices seem strongly influenced by their first experiments ; the appropriation of the various peripheral accessories which gradually came with the media, to the latest digital ones, seems to reinforce their habits of watching television. Their representations and relations with times and media are very far away from the image of television like omnipresent media or "devourer of time". Rather, their media practices are to be understood like a temporality of the occupation, according to the expression of Gerard Derèze, characterized by interest and utility. A particular glance at the users who do not carry out a systematic selection of the programs, accepting the unforeseen, highlights an approach of media and time that allow "useful encounter" which I would qualify in a first stage by : "chance and encounter" and "random and the following". The few points presented here make me assume that the global relation of the autonomous elderly persons to the media can evolve when confronted to their new temporal framework and the new program offer, whereas their representations and use of the media remain quite stable.
Published: 1992

8. THE CONSTRUCTION OF THE L3 EXPERIMENT

Author: Adeva, B, Aguilarbenitez, M, Akbari, H, Alcaraz, J, Aloisio, A, Alvareztaviel, J, Alverson, G, Alviggi, Mg, Anderhub, H, Anderson, Al, Angelov, Am, Angelov, Th, Antchev, Gh, Antonov, L, Antreasyan, D, Arefiev, A, Atanasov, Ih, Auroy, B, Ayad, R, Ayranov, Ol, Azemoon, T, Aziz, T, Bachmann, U, Bahler, P, Bakken, Ja, Baksay, L, Baldinger, H, Ball, Rc, Ballansat, J, Banerjee, S, Bao, J, Barbier, G, Barone, L, Basti, G, Bay, A, Beauvais, F, Becker, U, Beissel, R, Bendig, S, Bene, P, Berdugo, J, Berges, P, Berthet, M, Bertsch, Y, Betev, Bl, Biland, A, Bischoff, A, Bischops, M, Bizzarri, R, Blaising, Jj, Blanc, M, Blomeke, P, Blumenfeld, B, Bobbink, Gj, Bocciolini, M, Boffin, Kd, Bohlen, W, Bohm, A, Bohringer, T, Bonnefon, H, Bopp, C, Borgia, B, Bosseler, K, Bottolier, Jf, Bourquin, M, Boutigny, D, Bowditch, P, Branson, Jg, Braun, D, Brock, Jc, Bruyant, F, Buchholz, M, Bucken, B, Bulgeroni, W, Burel, R, Burger, Jd, Burgos, C, Burq, Jp, Caiazzo, L, Caillat, M, Camberlin, B, Campana, D, Camps, C, Canale, V, Capell, M, Carbonara, F, Carminati, F, Cartacci, Am, Cerrada, M, Cesaroni, F, Chang, Yh, Chapman, Jw, Chemarin, M, Chen, A, Chen, C, Chen, Hf, Chen, Hs, Chen, M, Chen, Ml, Chendvankar, Sr, Chevenier, G, Chidzik, S, Chiefari, G, Chien, Cy, Chollet, F, Chumakov, M, Civinini, C, Clare, I, Clare, R, Coignet, G, Colino, N, Commichau, V, Conforto, G, Cristofori, P, Crijns, F, Cui, Xy, Dai, Ts, Dalessandro, R, Daniel, M, Debouard, X, Debye, B, Decreuse, G, Degre, A, Deiters, K, Denes, E, Denes, P, Denotaristefani, F, Deutschmann, M, Dhina, M, Didierjean, B, Diemoz, M, Dietrich, M, Dimitrov, Ha, Dionisi, C, Dittus, F, Dohmen, M, Dolin, R, Donahue, Jf, Donat, A, Drago, E, Dreger, Kh, Driever, T, Dromby, G, Duinker, P, Duran, I, Elkacimi, M, Elmamouni, H, Engler, A, Eppling, Fj, Erne, Fc, Erne, I, Esser, H, Extermann, P, Fabbretti, R, Faber, G, Falciano, S, Falk, T, Fan, Sj, Favre, M, Fay, J, Feher, S, Fehlmann, J, Feldmann, M, Fenker, H, Ferguson, T, Fernandez, M, Ferroni, Fernando, Fesefeldt, H, Field, J, Figarola, Jm, Figueroa, Cf, Filipov, Ga, Foligne, B, Forconi, G, Foreman, T, Franzke, V, Frei, W, Freudenreich, K, Friebel, W, Fukushima, M, Gaillard, G, Gailloud, M, Galaktionov, Y, Gallo, E, Ganguli, Sn, Garelick, D, Gau, Ss, Gavrilov, G, Gennari, E, Gentile, Simonetta, Gettner, M, Girard, C, Glaubman, M, Goldfarb, S, Gong, Zf, Gonzalez, E, Gordeev, A, Gorodkov, Y, Gottlicher, P, Goy, C, Goyot, M, Gratta, G, Grimes, A, Grinnell, C, Gruenewald, M, Guanziroli, M, Guerra, S, Guillon, C, Gurtu, A, Gusewell, D, Gustafson, Hr, Haensli, M, Haan, M, Haller, C, Hamacher, T, Hammers, H, Hangarter, K, Hancke, S, Harris, M, Harting, D, Hartjes, Fg, He, Cf, Heavey, A, Hebbeker, T, Hebert, M, Heller, R, Helmrath, C, Herrmann, J, Herten, G, Herten, U, Herve, A, Hesser, H, Hilgers, G, Hilgers, K, Hofer, H, Hofer, M, Hofer, T, Hoffmann, F, Horisberger, U, Horvath, I, Hsu, Ls, Hu, Gq, Ille, B, Ilyas, Mm, Improta, G, Innocente, V, Isiksal, E, Jagel, E, Jin, Bn, Jones, Lw, Jongmanns, M, Jung, H, Kaaret, P, Kaelin, O, Kaestli, W, Kamyshkov, Y, Kaplan, D, Karpinski, W, Karyotakis, Y, Kertzer, W, Khoze, V, Kirchhoff, G, Kittel, W, Klimentov, A, Klok, Pf, Kollek, M, Koller, M, Konig, Ac, Kornadt, O, Koutsenko, V, Kraemer, Rw, Krastev, Vr, Kratel, A, Krenz, W, Kuhn, A, Kunin, A, Kwan, S, Lacotte, J, Lamarra, M, Landi, G, Lange, W, Lanius, K, Lanske, D, Lanzano, S, Legoff, Jm, Lemarec, Jc, Lea, D, Lebeau, M, Lebrun, P, Lecomte, P, Lecoq, J, Lecoq, P, Lecoultre, P, Leedom, I, Leger, A, Lehmann, F, Leistam, L, Leiste, R, Lejeune, E, Leoni, B, Lettry, J, Leytens, X, Li, C, Li, Ht, Li, L, Li, Pj, Li, Xg, Liao, Jy, Lin, Zy, Linde, Fl, Linnhofer, D, Loftin, E, Lohmann, W, Lokos, S, Longo, E, Lu, Ys, Lubbers, Jm, Lubelsmeyer, K, Luci, Claudio, Luckey, D, Lue, X, Luminari, L, Lunadei, G, Lurken, F, Ma, H, Ma, Wg, Macdermott, M, Madjar, N, Magahiz, R, Maire, M, Malhotra, Pk, Malinin, A, Mana, C, Manna, F, Manto, G, Mao, Yf, Maolinbay, M, Marchesini, P, Marchionni, A, Markwalder, M, Marsden, P, Martin, Jp, Martinez, L, Martyn, Hu, Marzano, F, Marzullo, V, Masciocchi, F, Massaro, Ggg, Massonnet, L, Matsuda, T, Maurelli, G, Mazumdar, K, Mcbride, P, Medici, G, Meier, H, Meinholz, T, Merk, M, Mermod, R, Merola, L, Meschini, M, Metzger, Wj, Micke, M, Micke, U, Mills, Gb, Mnich, J, Moeller, M, Molinero, A, Montanet, L, Monteleoni, B, Montino, R, Morand, G, Morand, R, Morganti, S, Morgunov, V, Mount, R, Moynot, M, Mugnier, P, Nageli, W, Nagy, E, Napolitano, M, Neboux, S, Newman, H, Neyer, C, Nguyen, K, Niessen, L, Nikitin, A, Nowak, Wd, Okle, M, Olmos, P, Onvlee, J, Osborne, D, Ossmann, J, Pandoulas, D, Paprotny, H, Parmentola, A, Passeggio, G, Paternoster, G, Patricelli, S, Pei, Yj, Peng, Y, Perretgallix, D, Perrier, J, Perrin, E, Perrot, G, Petitpas, P, Petschner, P, Pevsner, A, Pieramory, J, Pieri, M, Pieri, V, Pierschel, G, Piroue, Pa, Plyaskin, V, Pohl, M, Pojidaev, V, Pols, Cla, Ponomareff, T, Potyka, J, Produit, N, Prokofiev, P, Pruja, F, Putz, G, Qian, Jm, Raghavan, R, Razis, P, Read, K, Reddick, P, Reissmann, K, Ren, D, Reucroft, S, Rey, D, Reynaud, M, Ricadonna, X, Richeux, Jp, Rippich, C, Rinsche, U, Rocco, R, Rodriguez, S, Roe, Bp, Rohner, M, Rohner, S, Rombach, T, Romero, L, Rose, J, Roser, U, Rosierlees, S, Rubio, Ja, Ruckstuhl, W, Rykaczewski, H, Sahuc, P, Salicio, J, Saran, S, Sauvage, G, Savin, A, Schaad, T, Schafheitle, B, Schegelsky, V, Schetkovsky, A, Schild, F, Schillsott, R, Schmitt, P, Schmitz, D, Schmitz, P, Schneegans, M, Schneider, M, Schneevogt, E, Schontag, M, Schotanus, Dj, Schuijlenburg, H, Schulte, R, Vondratzig, As, Schultze, K, Schwenke, J, Schwering, G, Sciacca, C, Seiler, Pg, Sens, Jc, Sheer, I, Shevchenko, V, Shevchenko, S, Shi, Xr, Shmakov, K, Shoutko, V, Shumilov, E, Siedling, R, Smirnov, N, Souvorov, V, Souyri, C, Spangler, I, Spickermann, T, Spiess, B, Spillantini, P, Starosta, R, Steuer, M, Stickland, Dp, Stohr, B, Stone, H, Strauch, K, Sudhakar, K, Sumner, Rl, Suter, H, Sutton, Rb, Szczesny, H, Tang, J, Tang, Xw, Tarkovsky, E, Tavenrath, A, Tchudakov, V, Thenard, Jm, Thomas, E, Thon, T, Thuerig, H, Thulen, M, Timmermans, C, Ting, Scc, Ting, Sm, Tonisch, F, Tong, Yp, Tonutti, M, Tonwar, Sc, Toth, J, Toth, W, Trowitzsch, G, Tung, Kl, Ulbricht, J, Urban, L, Valente, E, Vandewalle, Rt, Vandergraaf, H, Vanzanella, V, Vergain, M, Vetlitsky, I, Vey, H, Viertel, G, Vivargent, M, Vogel, H, Volkov, S, Vollmar, M, Vongunten, Hp, Vorobiev, I, Vorobyov, A, Vuilleumier, L, Waldmeier, S, Walk, W, Wallraff, W, Wang, Cy, Wang, Gh, Wang, Jh, Wang, Qf, Wang, Xl, Wang, Yf, Wang, Zm, Wassenberg, D, Wegmann, D, Weill, R, Wenaus, Tj, Wenger, P, Wenninger, J, White, M, Wilhelm, R, Willmott, C, Wirth, Hp, Wittgenstein, F, Wu, Rj, Wu, Sx, Wu, Yg, Wyslouch, B, Xi, Fy, Xu, Zz, Xue, Zl, Yan, Ds, Yanev, Kd, Yang, Bz, Yang, Cg, Yang, Ks, Yang, Qy, Yang, Zq, Ye, Ch, Yeh, Sc, Yin, Zw, Zabounidis, C, Zehnder, L, Zeng, Y, Zhang, Dh, Zhang, Sy, Zhang, Zp, Zhou, B, Zhou, Jf, Zhou, Zp, Zhu, Ry, Zichichi, A, Zofka, M, and Zoll, J.
Published: 1990

9. MEASUREMENT OF GAMMA-B(B)OVER-BAR/GAMMA(HAD) FROM HADRONIC DECAYS OF THE Z

Author: Adriani, O, Aguilarbenitez, M, Ahlen, S, Alcaraz, J, Aloisio, A, Alverson, G, Alviggi, Mg, Ambrosi, G, An, Q, Anderhub, H, Anderson, Al, Andreev, Vp, Antonov, L, Antreasyan, D, Arce, P, Arefiev, A, Atamanchuk, A, Azemoon, T, Aziz, T, Baba, Pvks, Bachmann, S, Bagnaia, Paolo, Bakken, Ja, Baksay, L, Ball, Rc, Banerjee, S, Bao, J, Barillere, R, Barone, Luciano Maria, Baschirotto, A, Battiston, R, Bay, A, Becattini, F, Becker, U, Behner, F, Behrens, J, Bencze, Gl, Berdugo, J, Berges, P, Bertucci, B, Betev, Bl, Biasini, M, Biland, A, Bilei, Gm, Bizzarri, R, Blaising, Jj, Bobbink, Gj, Bock, R, Bohm, A, Borgia, B, Bosetti, M, Bourilkov, D, Bourquin, M, Boutigny, D, Bouwens, B, Brambilla, E, Branson, Jg, Brock, Ic, Brooks, M, Bujak, A, Burger, Jd, Burger, Wj, Busenitz, J, Buytenhuijs, A, Cai, Xd, Capell, M, Caria, M, Carlino, G, Cartacci, Am, Castello, R, Cerrada, M, Cesaroni, F, Chang, Yh, Chaturvedi, Uk, Chemarin, M, Chen, A, Chen, C, Chen, Gm, Chen, Hf, Chen, Hs, Chen, M, Chen, Wy, Chiefari, G, Chien, Cy, Choi, Mt, Chung, S, Civinini, C, Clare, I, Clare, R, Coan, Te, Cohn, Ho, Coignet, G, Colino, N, Contin, A, Cui, Xt, Cui, Xy, Dai, Ts, Dalessandro, R, Deasmundis, R, Degre, A, Deiters, K, Denes, E, Denes, P, Denotaristefani, F, Dhina, M, Dibitonto, D, Diemoz, M, Dimitrov, Hr, Dionisi, C, Djambazov, L, Dova, Mt, Drago, E, Duchesneau, D, Duinker, P, Duran, I, Easo, S, Elmamouni, He, Engler, A, Eppling, Fj, Erne, Fc, Extermann, P, Fabbretti, R, Fabre, M, Falciano, S, Fan, Sj, Fackler, O, Fay, J, Felcini, M, Ferguson, T, Fernandez, D, Fernandez, G, Ferroni, Fernando, Fesefeldt, H, Fiandrini, E, Field, J, Filthaut, F, Finocchiaro, G, Fisher, Ph, Forconi, G, Foreman, T, Freudenreich, K, Friebel, W, Fukushima, M, Gailloud, M, Galaktionov, Y, Gallo, E, Ganguli, Sn, Garciaabia, P, Gele, D, Gentile, Simonetta, Goldfarb, S, Gong, Zf, Gonzalez, E, Gougas, A, Goujon, D, Gratta, G, Gruenewald, M, Gu, C, Guanziroli, M, Guo, Jk, Gupta, Vk, Gurtu, A, Gustafson, Hr, Gutay, Lj, Hangarter, K, Hasan, A, Hauschildt, D, He, Cf, He, Jt, Hebbeker, T, Hebert, M, Herten, G, Herve, A, Hilgers, K, Hofer, H, Hoorani, H, Hu, G, Hu, Gq, Ille, B, Ilyas, Mm, Innocente, V, Janssen, H, Jezequel, S, Jin, Bn, Jones, Lw, Kasser, A, Khan, Ra, Kamyshkov, Y, Kapinos, P, Kapustinsky, Js, Karyotakis, Y, Kaur, M, Khokhar, S, Kienzlefocacci, Mn, Kim, Jk, Kim, Sc, Kim, Yg, Kinnison, Ww, Kirkby, A, Kirkby, D, Kirsch, S, Kittel, W, Klimentov, A, Konig, Ac, Koffeman, E, Kornadt, O, Koutsenko, V, Koulbardis, A, Kraemer, Rw, Kramer, T, Krastev, Vr, Krenz, W, Krivshich, A, Kuijten, H, Kumar, Ks, Kunin, A, Landi, G, Lanske, D, Lanzano, S, Lebrun, P, Lecomte, P, Lecoq, P, Lecoultre, P, Lee, Dm, Leedom, I, Leggett, C, Legoff, Jm, Leiste, R, Lenti, M, Leonardi, E, Leytens, X, Li, C, Li, Ht, Li, Pj, Liao, Jy, Lin, Wt, Lin, Zy, Linde, Fl, Lindemann, B, Lista, L, Liu, Y, Lohmann, W, Longo, E, Lu, Ys, Lubbers, Jm, Lubelsmeyer, K, Luci, Claudio, Luckey, D, Ludovici, L, Luminari, L, Lustermann, W, Ma, Jm, Ma, Wg, Macdermott, M, Malhotra, Pk, Malik, R, Malinin, A, Mana, C, Maolinbay, M, Marchesini, P, Marion, F, Marin, A, Martin, Jp, Martinezlaso, L, Marzano, F, Massaro, Ggg, Mazumdar, K, Mcbride, P, Mcmahon, T, Mcnally, D, Merk, M, Merola, L, Meschini, M, Metzger, Wj, Mi, Y, Mills, Gb, Mir, Y, Mirabelli, G, Mnich, J, Moller, M, Monteleoni, B, Morand, R, Morganti, S, Moulai, Ne, Mount, R, Muller, S, Nadtochy, A, Nagy, E, Napolitano, M, Nessitedaldi, F, Newman, H, Neyer, C, Niaz, Ma, Nippe, A, Nowak, H, Organtini, Giovanni, Pandoulas, D, Paoletti, S, Paolucci, P, Pascala, G, Passaleva, G, Patricelli, S, Paul, T, Pauluzzi, M, Paus, C, Pauss, F, Pei, Yj, Pensotti, S, Perretgallix, D, Perrier, J, Pevsner, A, Piccolo, D, Pieri, M, Piroue, Pa, Plasil, F, Plyaskin, V, Pohl, M, Pojidaev, V, Postema, H, Qi, Zd, Qian, Jm, Qureshi, Kn, Raghavan, R, Rahalcallot, G, Rancoita, Pg, Rattaggi, M, Raven, G, Razis, P, Read, K, Ren, D, Ren, Z, Rescigno, M, Reucroft, S, Ricker, A, Riemann, S, Riemers, Bc, Riles, K, Rind, O, Rizvi, Ha, Rodriguez, Fj, Roe, Bp, Rohner, M, Rohner, S, Romero, L, Rose, J, Rosierlees, S, Rosmalen, R, Rosselet, P, Vanrossum, W, Roth, S, Rubbia, A, Rubio, Ja, Rykaczewski, H, Sachwitz, M, Salicio, J, Salicio, Jm, Sanders, Gs, Santocchia, A, Sarakinos, Ms, Sartorelli, G, Sassowsky, M, Sauvage, G, Schafer, C, Schegelsky, V, Schmitz, D, Schmitz, P, Schneegans, M, Schopper, H, Schotanus, Dj, Shotkin, S, Schreiber, Hj, Shukla, J, Schulte, R, Schulte, S, Schultze, K, Schwenke, J, Schwering, G, Sciacca, C, Scott, I, Sehgal, R, Seiler, Pg, Sens, Jc, Servoli, L, Sheer, I, Shen, Dz, Shevchenko, S, Shi, Xr, Shumilov, E, Shoutko, V, Son, D, Sopczak, A, Spartiotis, C, Spickermann, T, Spillantini, P, Starosta, R, Steuer, M, Stickland, Dp, Sticozzi, F, Stone, H, Strauch, K, Stringfellow, Bc, Sudhakar, K, Sultanov, G, Sun, Lz, Suter, H, Swain, Jd, Syed, Aa, Tang, Xw, Taylor, L, Terzi, G, Ting, Scc, Ting, Sm, Tonutti, M, Tonwar, Sc, Toth, J, Tsaregorodtsev, A, Tsipolitis, G, Tully, C, Tung, Kl, Ulbricht, J, Urban, L, Uwer, U, Valente, E, Vandewalle, Rt, Vetlitsky, I, Viertel, G, Vikas, P, Vikas, U, Vivargent, M, Vogel, H, Vogt, H, Vorobiev, I, Vorobyov, Aa, Vuilleumier, L, Wadhwa, M, Wallraff, W, Wang, C, Wang, Cr, Wang, Gh, Wang, Xl, Wang, Yf, Wang, Zm, Weber, A, Weber, J, Weill, R, Wenaus, Tj, Wenninger, J, White, M, Willmott, C, Wittgenstein, F, Wright, D, Wu, Sx, Wynhoff, S, Wyslouch, B, Xie, Yy, Xu, Jg, Xu, Zz, Xue, Zl, Yan, Ds, Yang, Bz, Yang, Cg, Yang, G, Ye, Ch, Ye, Jb, Ye, Q, Yeh, Sc, Yin, Zw, You, Jm, Yunus, N, Yzerman, M, Zaccardelli, C, Zemp, P, Zeng, M, Zeng, Y, Zhang, Dh, Zhang, Zp, Zhou, B, Zhou, Gj, Zhou, Jf, Zhu, Ry, Zichichi, A, Vanderzwaan, Bcc, Adriani, O., Aguilarbenitez, M., Ahlen, S., Alcaraz, J., Aloisio, Alberto, Alverson, G., Alviggi, Mariagrazia, Ambrosi, G., An, Q., Anderhub, H., Anderson, A. L., Andreev, V. P., Antonov, L., Antreasyan, D., Arce, P., Arefiev, A., Atamanchuk, A., Azemoon, T., Aziz, T., P. V. K., Bachmann, S., Bagnaia, P., Bakken, J. A., Baksay, L., Ball, R. C., Banerjee, S., Bao, J., Barillere, R., Barone, L., Baschirotto, A., Battiston, R., Bay, A., Becattini, F., Becker, U., Behner, F., Behrens, J., Bencze, G. L., Berdugo, J., Berges, P., Bertucci, B., Betev, B. L., Biasini, M., Biland, A., Bilei, G. M., Bizzarri, R., Blaising, J. J., Bobbink, G. J., Bock, R., Bohm, A., Borgia, B., Bosetti, M., Bourilkov, D., Bourquin, M., Boutigny, D., Bouwens, B., Brambilla, E., Branson, J. G., Brock, I. C., Brooks, M., Bujak, A., Burger, J. D., Burger, W. J., Busenitz, J., Buytenhuijs, A., Cai, X. D., Capell, M., Caria, M., Carlino, G., Cartacci, A. M., Castello, R., Cerrada, M., Cesaroni, F., Chang, Y. H., Chaturvedi, U. K., Chemarin, M., Chen, A., Chen, C., Chen, G. M., Chen, H. F., Chen, H. S., Chen, M., Chen, W. Y., Chiefari, Giovanni, Chien, C. Y., Choi, M. T., Chung, S., Civinini, C., Clare, I., Clare, R., Coan, T. E., Cohn, H. O., Coignet, G., Colino, N., Contin, A., Cui, X. T., Cui, X. Y., Dai, T. S., Dalessandro, R., Deasmundis, R., Degre, A., Deiters, K., Denes, E., Denes, P., Denotaristefani, F., Dhina, M., Dibitonto, D., Diemoz, M., Dimitrov, H. R., Dionisi, C., Djambazov, L., Dova, M. T., Drago, E., Duchesneau, D., Duinker, P., Duran, I., Easo, S., Elmamouni, H. E., Engler, A., Eppling, F. J., Erne, F. C., Extermann, P., Fabbretti, R., Fabre, M., Falciano, S., Fan, S. J., Fackler, O., Fay, J., Felcini, M., Ferguson, T., Fernandez, D., Fernandez, G., Ferroni, F., Fesefeldt, H., Fiandrini, E., Field, J., Filthaut, F., Finocchiaro, G., Fisher, P. H., Forconi, G., Foreman, T., Freudenreich, K., Friebel, W., Fukushima, M., Gailloud, M., Galaktionov, Y., Gallo, E., Ganguli, S. N., Garciaabia, P., Gele, D., Gentile, S., Goldfarb, S., Gong, Z. F., Gonzalez, E., Gougas, A., Goujon, D., Gratta, G., Gruenewald, M., Gu, C., Guanziroli, M., Guo, J. K., Gupta, V. K., Gurtu, A., Gustafson, H. R., Gutay, L. J., Hangarter, K., Hasan, A., Hauschildt, D., C. F., He, J. T., He, Hebbeker, T., Hebert, M., Herten, G., Herve, A., Hilgers, K., Hofer, H., Hoorani, H., Hu, G., G. Q., Hu, Ille, B., Ilyas, M. M., Innocente, V., Janssen, H., Jezequel, S., Jin, B. N., Jones, L. W., Kasser, A., Khan, R. A., Kamyshkov, Y., Kapinos, P., Kapustinsky, J. S., Karyotakis, Y., Kaur, M., Khokhar, S., Kienzlefocacci, M. N., Kim, J. K., Kim, S. C., Kim, Y. G., Kinnison, W. W., Kirkby, A., Kirkby, D., Kirsch, S., Kittel, W., Klimentov, A., Konig, A. C., Koffeman, E., Kornadt, O., Koutsenko, V., Koulbardis, A., Kraemer, R. W., Kramer, T., Krastev, V. R., Krenz, W., Krivshich, A., Kuijten, H., Kumar, K. S., Kunin, A., Landi, G., Lanske, D., Lanzano, S., Lebrun, P., Lecomte, P., Lecoq, P., Lecoultre, P., Lee, D. M., Leedom, I., Leggett, C., Legoff, J. M., Leiste, R., Lenti, M., Leonardi, E., Leytens, X., Li, C., H. T., Li, P. J., Li, Liao, J. Y., Lin, W. T., Lin, Z. Y., Linde, F. L., Lindemann, B., Lista, L., Liu, Y., Lohmann, W., Longo, E., Y. S., Lu, Lubbers, J. M., Lubelsmeyer, K., Luci, C., Luckey, D., Ludovici, L., Luminari, L., Lustermann, W., J. M., Ma, W. G., Ma, Macdermott, M., Malhotra, P. K., Malik, R., Malinin, A., Mana, C., Maolinbay, M., Marchesini, P., Marion, F., Marin, A., Martin, J. P., Martinezlaso, L., Marzano, F., G. G. G., Mazumdar, K., Mcbride, P., Mcmahon, T., Mcnally, D., Merk, M., Merola, Leonardo, Meschini, M., Metzger, W. J., Mi, Y., Mills, G. B., Mir, Y., Mirabelli, G., Mnich, J., Moller, M., Monteleoni, B., Morand, R., Morganti, S., Moulai, N. E., Mount, R., Muller, S., Nadtochy, A., Nagy, E., Napolitano, Marco, Nessitedaldi, F., Newman, H., Neyer, C., Niaz, M. A., Nippe, A., Nowak, H., Organtini, G., Pandoulas, D., Paoletti, S., Paolucci, P., Pascala, G., Passaleva, G., Patricelli, Sergio, Paul, T., Pauluzzi, M., Paus, C., Pauss, F., Pei, Y. J., Pensotti, S., Perretgallix, D., Perrier, J., Pevsner, A., Piccolo, D., Pieri, M., Piroue, P. A., Plasil, F., Plyaskin, V., Pohl, M., Pojidaev, V., Postema, H., Z. D., Qi, Qian, J. M., Qureshi, K. N., Raghavan, R., Rahalcallot, G., Rancoita, P. G., Rattaggi, M., Raven, G., Razis, P., Read, K., Ren, D., Ren, Z., Rescigno, M., Reucroft, S., Ricker, A., Riemann, S., Riemers, B. C., Riles, K., Rind, O., Rizvi, H. A., Rodriguez, F. J., Roe, B. P., Rohner, M., Rohner, S., Romero, L., Rose, J., Rosierlees, S., Rosmalen, R., Rosselet, P., Vanrossum, W., Roth, S., Rubbia, A., Rubio, J. A., Rykaczewski, H., Sachwitz, M., Salicio, J., Salicio, J. M., Sanders, G. S., Santocchia, A., Sarakinos, M. S., Sartorelli, G., Sassowsky, M., Sauvage, G., Schafer, C., Schegelsky, V., Schmitz, D., Schmitz, P., Schneegans, M., Schopper, H., Schotanus, D. J., Shotkin, S., Schreiber, H. J., Shukla, J., Schulte, R., Schulte, S., Schultze, K., Schwenke, J., Schwering, G., Sciacca, Crisostomo, Scott, I., Sehgal, R., Seiler, P. G., Sens, J. C., Servoli, L., Sheer, I., Shen, D. Z., Shevchenko, S., Shi, X. R., Shumilov, E., Shoutko, V., Son, D., Sopczak, A., Spartiotis, C., Spickermann, T., Spillantini, P., Starosta, R., Steuer, M., Stickland, D. P., Sticozzi, F., Stone, H., Strauch, K., Stringfellow, B. C., Sudhakar, K., Sultanov, G., Sun, L. Z., Suter, H., Swain, J. D., Syed, A. A., Tang, X. W., Taylor, L., Terzi, G., S. C. C., Ting, S. M., Tonutti, M., Tonwar, S. C., Toth, J., Tsaregorodtsev, A., Tsipolitis, G., Tully, C., Tung, K. L., Ulbricht, J., Urban, L., Uwer, U., Valente, E., Vandewalle, R. T., Vetlitsky, I., Viertel, G., Vikas, P., Vikas, U., Vivargent, M., Vogel, H., Vogt, H., Vorobiev, I., Vorobyov, A. A., Vuilleumier, L., Wadhwa, M., Wallraff, W., Wang, C., Wang, C. R., Wang, G. H., Wang, X. L., Wang, Y. F., Wang, Z. M., Weber, A., Weber, J., Weill, R., Wenaus, T. J., Wenninger, J., White, M., Willmott, C., Wittgenstein, F., Wright, D., S. X., Wu, Wynhoff, S., Wyslouch, B., Xie, Y. Y., J. G., Xu, Z. Z., Xu, Xue, Z. L., Yan, D. S., Yang, B. Z., Yang, C. G., Yang, G., C. H., Ye, J. B., Ye, Ye, Q., Yeh, S. C., Yin, Z. W., You, J. M., Yunus, N., Yzerman, M., Zaccardelli, C., Zemp, P., Zeng, M., Zeng, Y., Zhang, D. H., Zhang, Z. P., Zhou, B., Zhou, G. J., Zhou, J. F., Zhu, R. Y., Zichichi, A., and B. C. C.
Subjects: PHYSICS, Z-RESONANCE, JETS, TOP, NEURAL NETWORKS, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract: We report a measurement of R(b) = GAMMA(bbBAR)GAMMA(had) from Z --> qqBAR events at LEP. Z --> bbBAR events are identified using a multidimensional analysis based on a neural network approach. We obtain 60% sample purity with an efficiency of 35%. Our measured value of R(b) is 0.222 +/- 0.003 +/- 0.007.

10. ISOLATED HARD PHOTON-EMISSION IN HADRONIC Z0 DECAYS

Author: Adriani, O., Aguilarbenitez, M., Ahlen, S., Akbari, H., Alcaraz, J., Aloisio, A., Alverson, G., Alviggi, Mg, Ambrosi, G., An, Q., Anderhub, H., Anderson, Al, Andreev, Vp, Angelov, T., Antonov, L., Antreasyan, D., Arce, P., Arefiev, A., Atamanchuk, A., Azemoon, T., Aziz, T., Baba, Pvks, Bagnaia, P., Bakken, Ja, Baksay, L., Ball, Rc, Banerjee, S., Bao, J., Barillere, R., Barone, L., Battiston, R., Bay, A., Becattini, F., Becker, U., Behner, F., Behrens, J., Beingessner, S., Bencze, Gl, Berdugo, J., Berges, P., Bertucci, B., Betev, Bl, Biasini, M., Biland, A., Bilei, Gm, Bizzarri, R., Blaising, Jj, Blumenfeld, B., Bobbink, Gj, Bocciolini, M., Bock, R., Bohm, A., Borgia, B., Bourilkov, D., Bourquin, M., Boutigny, D., Bouwens, B., Brambilla, E., Branson, Jg, Brock, Ic, Brooks, M., Buisson, C., Bujak, A., Burger, Jd, Burger, Wj, Burq, Jp, Busenitz, J., Cai, Xd, Capell, M., Caria, M., Carlino, G., Carminati, F., Cartacci, Am, Cerrada, M., Cesaroni, F., Chang, Yh, Chaturvedi, Uk, Chemarin, M., Chen, A., Chen, C., Chen, Gm, Chen, Hf, Chen, Hs, Chen, J., Chen, M., Chen, Ml, Chen, Wy, Chiefari, G., Chien, Cy, Chmeissani, M., Chung, S., Civinini, C., Clare, I., Clare, R., Coan, Te, Cohn, Ho, Coignet, G., Colino, N., Contin, A., Crijns, F., Cui, Xt, Cui, Xy, Dai, Ts, Dalessandro, R., Deasmundis, R., Degre, A., Deiters, K., Denes, E., Denes, P., Denotaristefani, F., Dhina, M., Dibitonto, D., Diemoz, M., Dimitrov, Hr, Dionisi, C., Dova, Mt, Drago, E., Driever, T., Duchesneau, D., Duinker, P., Duran, I., Elmamouni, H., Engler, A., Eppling, Fj, Erne, Fc, Extermann, P., Fabbretti, R., Fabre, M., Falciano, S., Fan, Sj, Fackler, O., Fay, J., Felcini, M., Ferguson, T., Fernandez, D., Fernandez, G., Ferroni, F., Fesefeldt, H., Fiandrini, E., Field, J., Filthaut, F., Finocchiaro, G., Fisher, Ph, Forconi, G., Foreman, T., Freudenreich, K., Friebel, W., Fukushima, M., Gailloud, M., Galaktionov, Y., Gallo, E., Ganguli, Sn, Garciaabia, P., Gau, Ss, Gele, D., Gentile, S., Goldfarb, S., Gong, Zf, Gonzalez, E., Gottlicher, P., Gougas, A., Goujon, D., Gratta, G., Grinnell, C., Gruenewald, M., Gu, C., Guanziroli, M., Guo, Jk, Gupta, Vk, Gurtu, A., Gustafson, Hr, Gutay, Lj, Hangarter, K., Hasan, A., Hauschildt, D., He, Cf, Hebbeker, T., Hebert, M., Herten, G., Herten, U., Herve, A., Hilgers, K., Hofer, H., Hoorani, H., Hu, G., Hu, Gq, Ille, B., Ilyas, Mm, Innocente, V., Janssen, H., Jezequel, S., Jin, Bn, Jones, Lw, Kasser, A., Khan, Ra, Kamyshkov, Y., Kapinos, P., Kapustinsky, Js, Karyotakis, Y., Kaur, M., Khokhar, S., Kienzlefocacci, Mn, Kinnison, Ww, Kirkby, D., Kirsch, S., Kittel, W., Klimentov, A., Konig, Ac, Koffeman, E., Kornadt, O., Koutsenko, V., Koulbardis, A., Kraemer, Rw, Kramer, T., Krastev, Vr, Krenz, W., Krivshich, A., Kuijten, H., Kumar, Ks, Kunin, A., Landi, G., Lanske, D., Lanzano, S., Lebrun, P., Lecomte, P., Lecoq, P., Lecoultre, P., Lee, Dm, Leedom, I., Legoff, Jm, Leiste, R., Lenti, M., Leonardi, E., Lettry, J., Leytens, X., Li, C., Li, Ht, Li, Pj, Li, Xg, Liao, Jy, Lin, Wt, Lin, Zy, Linde, Fl, Lindemann, B., Linnhofer, D., Lista, L., Liu, Y., Lohmann, W., Longo, E., Lu, Ys, Lubbers, Jm, Lubelsmeyer, K., Luci, C., Luckey, D., Ludovici, L., Luminari, L., Lustermann, W., Ma, Jm, Ma, Wg, Macdermott, M., Malhotra, Pk, Malik, R., Malinin, A., Mana, C., Mao, Dn, Mao, Yf, Maolinbay, M., Marchesini, P., Marion, F., Marin, A., Martin, Jp, Martinezlaso, L., Marzano, F., Massaro, Ggg, Matsuda, T., Mazumdar, K., Mcbride, P., Mcmahon, T., Mcnally, D., Meinholz, T., Merk, M., Merola, L., Meschini, M., Metzger, Wj, Mi, Y., Mills, Gb, Mir, Y., Mirabelli, G., Mnich, J., Moller, M., Monteleoni, B., Morand, R., Morganti, S., Moulai, Ne, Mount, R., Muller, S., Nadtochy, A., Nagy, E., Napolitano, M., Newman, H., Neyer, C., Niaz, Ma, Nippe, A., Nowak, H., Organtini, G., Pandoulas, D., Paoletti, S., Paolucci, P., Passaleva, G., Patricelli, S., Paul, T., Pauluzzi, M., Pauss, F., Pei, Yj, Perretgallix, D., Perrier, J., Pevsner, A., Piccolo, D., Pieri, M., Piroue, Pa, Plasil, F., Plyaskin, V., Pohl, M., Pojidaev, V., Produit, N., Qian, Jm, Qureshi, Kn, Raghavan, R., Rahalcallot, G., Raven, G., Razis, P., Read, K., Ren, D., Ren, Z., Rescigno, M., Reucroft, S., Ricker, A., Riemann, S., Rind, O., Rizvi, Ha, Rodriguez, Fj, Roe, Bp, Rohner, M., Rohner, S., Romero, L., Rose, J., Rosierlees, S., Rosmalen, R., Rosselet, P., Rubbia, A., Rubio, Ja, Rykaczewski, H., Sachwitz, M., Sajan, E., Salicio, J., Salicio, Jm, Sanders, Gs, Santocchia, A., Sarakinos, Ms, Sartorelli, G., Sassowsky, M., Sauvage, G., Schegelsky, V., Schmiemann, K., Schmitz, D., Schmitz, P., Schneegans, M., Schopper, H., Schotanus, Dj, Shotkin, S., Schreiber, Hj, Shukla, J., Schulte, R., Schulte, S., Schultze, K., Schutte, J., Schwenke, J., Schwering, G., Sciacca, C., Scott, I., Sehgal, R., Seiler, Pg, Sens, Jc, Servoli, L., Sheer, I., Shen, Dz, Shevchenko, S., Shi, Xr, Shumilov, E., Shoutko, V., Soderstrom, E., Sopczak, A., Spartiotis, C., Spickermann, T., Spillantini, P., Starosta, R., Steuer, M., Stickland, Dp, Sticozzi, F., Stone, H., Strauch, K., Stringfellow, Bc, Sudhakar, K., Sultanov, G., Sumner, Rl, Sun, Lz, Suter, H., Sutton, Rb, Swain, Jd, Syed, Aa, Tang, Xw, Taylor, L., Timmermans, C., Ting, Scc, Ting, Sm, Tonutti, M., Tonwar, Sc, Toth, J., Tsaregorodtsev, A., Tsipolitis, G., Tully, C., Tung, Kl, Ulbricht, J., Urban, L., Uwer, U., Valente, E., Vandewalle, Rt, Vetlitsky, I., Viertel, G., Vikas, P., Vikas, U., Vivargent, M., Vogel, H., Vogt, H., Vorobiev, I., Vorobyov, Aa, Vuilleumier, L., Wadhwa, M., Wallraff, W., Wang, Cr, Wang, Gh, Wang, Jh, Wang, Qf, Wang, Xl, Wang, Yf, Wang, Zm, Weber, A., Weber, J., Weill, R., Wenaus, Tj, Wenninger, J., White, M., Willmott, C., Wittgenstein, F., Wright, D., Wu, Rj, Wu, Sx, Wu, Yg, Wyslouch, B., Xie, Yy, Xu, Yd, Xu, Zz, Xue, Zl, Yan, Ds, Yan, Xj, Yang, Bz, Yang, Cg, Yang, G., Yang, Ks, Yang, Qy, Yang, Zq, Ye, Ch, Ye, Jb, Ye, Q., Yeh, Sc, Yin, Zw, You, Jm, Yunus, N., Yzerman, M., Zaccardelli, C., Zemp, P., Zeng, M., Zeng, Y., Zhang, Dh, Zhang, Zp, Zhou, B., Zhou, Jf, Zhu, Ry, Zhuang, Hl, Zichichi, A., Vanderzwaan, Bcc, Adriani, O., Aguilarbenitez, M., Ahlen, S., Akbari, H., Alcaraz, J., Aloisio, Alberto, Alverson, G., Alviggi, Mariagrazia, Ambrosi, G., An, Q., Anderhub, H., Anderson, A. L., Andreev, V. P., Angelov, T., Antonov, L., Antreasyan, D., Arce, P., Arefiev, A., Atamanchuk, A., Azemoon, T., Aziz, T., P. V. K., Bagnaia, P., Bakken, J. A., Baksay, L., Ball, R. C., Banerjee, S., Bao, J., Barillere, R., Barone, L., Battiston, R., Bay, A., Becattini, F., Becker, U., Behner, F., Behrens, J., Beingessner, S., Bencze, G. L., Berdugo, J., Berges, P., Bertucci, B., Betev, B. L., Biasini, M., Biland, A., Bilei, G. M., Bizzarri, R., Blaising, J. J., Blumenfeld, B., Bobbink, G. J., Bocciolini, M., Bock, R., Bohm, A., Borgia, B., Bourilkov, D., Bourquin, M., Boutigny, D., Bouwens, B., Brambilla, E., Branson, J. G., Brock, I. C., Brooks, M., Buisson, C., Bujak, A., Burger, J. D., Burger, W. J., Burq, J. P., Busenitz, J., Cai, X. D., Capell, M., Caria, M., Carlino, G., Carminati, F., Cartacci, A. M., Cerrada, M., Cesaroni, F., Chang, Y. H., Chaturvedi, U. K., Chemarin, M., Chen, A., Chen, C., Chen, G. M., Chen, H. F., Chen, H. S., Chen, J., Chen, M., Chen, M. L., Chen, W. Y., Chiefari, Giovanni, Chien, C. Y., Chmeissani, M., Chung, S., Civinini, C., Clare, I., Clare, R., Coan, T. E., Cohn, H. O., Coignet, G., Colino, N., Contin, A., Crijns, F., Cui, X. T., Cui, X. Y., Dai, T. S., Dalessandro, R., Deasmundis, R., Degre, A., Deiters, K., Denes, E., Denes, P., Denotaristefani, F., Dhina, M., Dibitonto, D., Diemoz, M., Dimitrov, H. R., Dionisi, C., Dova, M. T., Drago, E., Driever, T., Duchesneau, D., Duinker, P., Duran, I., Elmamouni, H., Engler, A., Eppling, F. J., Erne, F. C., Extermann, P., Fabbretti, R., Fabre, M., Falciano, S., Fan, S. J., Fackler, O., Fay, J., Felcini, M., Ferguson, T., Fernandez, D., Fernandez, G., Ferroni, F., Fesefeldt, H., Fiandrini, E., Field, J., Filthaut, F., Finocchiaro, G., Fisher, P. H., Forconi, G., Foreman, T., Freudenreich, K., Friebel, W., Fukushima, M., Gailloud, M., Galaktionov, Y., Gallo, E., Ganguli, S. N., Garciaabia, P., Gau, S. S., Gele, D., Gentile, S., Goldfarb, S., Gong, Z. F., Gonzalez, E., Gottlicher, P., Gougas, A., Goujon, D., Gratta, G., Grinnell, C., Gruenewald, M., Gu, C., Guanziroli, M., Guo, J. K., Gupta, V. K., Gurtu, A., Gustafson, H. R., Gutay, L. J., Hangarter, K., Hasan, A., Hauschildt, D., C. F., He, Hebbeker, T., Hebert, M., Herten, G., Herten, U., Herve, A., Hilgers, K., Hofer, H., Hoorani, H., Hu, G., G. Q., Hu, Ille, B., Ilyas, M. M., Innocente, V., Janssen, H., Jezequel, S., Jin, B. N., Jones, L. W., Kasser, A., Khan, R. A., Kamyshkov, Y., Kapinos, P., Kapustinsky, J. S., Karyotakis, Y., Kaur, M., Khokhar, S., Kienzlefocacci, M. N., Kinnison, W. W., Kirkby, D., Kirsch, S., Kittel, W., Klimentov, A., Konig, A. C., Koffeman, E., Kornadt, O., Koutsenko, V., Koulbardis, A., Kraemer, R. W., Kramer, T., Krastev, V. R., Krenz, W., Krivshich, A., Kuijten, H., Kumar, K. S., Kunin, A., Landi, G., Lanske, D., Lanzano, S., Lebrun, P., Lecomte, P., Lecoq, P., Lecoultre, P., Lee, D. M., Leedom, I., Legoff, J. M., Leiste, R., Lenti, M., Leonardi, E., Lettry, J., Leytens, X., Li, C., H. T., Li, P. J., Li, X. G., Li, Liao, J. Y., Lin, W. T., Lin, Z. Y., Linde, F. L., Lindemann, B., Linnhofer, D., Lista, L., Liu, Y., Lohmann, W., Longo, E., Y. S., Lu, Lubbers, J. M., Lubelsmeyer, K., Luci, C., Luckey, D., Ludovici, L., Luminari, L., Lustermann, W., J. M., Ma, W. G., Ma, Macdermott, M., Malhotra, P. K., Malik, R., Malinin, A., Mana, C., Mao, D. N., Mao, Y. F., Maolinbay, M., Marchesini, P., Marion, F., Marin, A., Martin, J. P., Martinezlaso, L., Marzano, F., G. G. G., Matsuda, T., Mazumdar, K., Mcbride, P., Mcmahon, T., Mcnally, D., Meinholz, T., Merk, M., Merola, Leonardo, Meschini, M., Metzger, W. J., Mi, Y., Mills, G. B., Mir, Y., Mirabelli, G., Mnich, J., Moller, M., Monteleoni, B., Morand, R., Morganti, S., Moulai, N. E., Mount, R., Muller, S., Nadtochy, A., Nagy, E., Napolitano, Marco, Newman, H., Neyer, C., Niaz, M. A., Nippe, A., Nowak, H., Organtini, G., Pandoulas, D., Paoletti, S., Paolucci, P., Passaleva, G., Patricelli, Sergio, Paul, T., Pauluzzi, M., Pauss, F., Pei, Y. J., Perretgallix, D., Perrier, J., Pevsner, A., Piccolo, D., Pieri, M., Piroue, P. A., Plasil, F., Plyaskin, V., Pohl, M., Pojidaev, V., Produit, N., Qian, J. M., Qureshi, K. N., Raghavan, R., Rahalcallot, G., Raven, G., Razis, P., Read, K., Ren, D., Ren, Z., Rescigno, M., Reucroft, S., Ricker, A., Riemann, S., Rind, O., Rizvi, H. A., Rodriguez, F. J., Roe, B. P., Rohner, M., Rohner, S., Romero, L., Rose, J., Rosierlees, S., Rosmalen, R., Rosselet, P., Rubbia, A., Rubio, J. A., Rykaczewski, H., Sachwitz, M., Sajan, E., Salicio, J., Salicio, J. M., Sanders, G. S., Santocchia, A., Sarakinos, M. S., Sartorelli, G., Sassowsky, M., Sauvage, G., Schegelsky, V., Schmiemann, K., Schmitz, D., Schmitz, P., Schneegans, M., Schopper, H., Schotanus, D. J., Shotkin, S., Schreiber, H. J., Shukla, J., Schulte, R., Schulte, S., Schultze, K., Schutte, J., Schwenke, J., Schwering, G., Sciacca, Crisostomo, Scott, I., Sehgal, R., Seiler, P. G., Sens, J. C., Servoli, L., Sheer, I., Shen, D. Z., Shevchenko, S., Shi, X. R., Shumilov, E., Shoutko, V., Soderstrom, E., Sopczak, A., Spartiotis, C., Spickermann, T., Spillantini, P., Starosta, R., Steuer, M., Stickland, D. P., Sticozzi, F., Stone, H., Strauch, K., Stringfellow, B. C., Sudhakar, K., Sultanov, G., Sumner, R. L., Sun, L. Z., Suter, H., Sutton, R. B., Swain, J. D., Syed, A. A., Tang, X. W., Taylor, L., Timmermans, C., S. C. C., Ting, S. M., Tonutti, M., Tonwar, S. C., Toth, J., Tsaregorodtsev, A., Tsipolitis, G., Tully, C., Tung, K. L., Ulbricht, J., Urban, L., Uwer, U., Valente, E., Vandewalle, R. T., Vetlitsky, I., Viertel, G., Vikas, P., Vikas, U., Vivargent, M., Vogel, H., Vogt, H., Vorobiev, I., Vorobyov, A. A., Vuilleumier, L., Wadhwa, M., Wallraff, W., Wang, C. R., Wang, G. H., Wang, J. H., Wang, Q. F., Wang, X. L., Wang, Y. F., Wang, Z. M., Weber, A., Weber, J., Weill, R., Wenaus, T. J., Wenninger, J., White, M., Willmott, C., Wittgenstein, F., Wright, D., R. J., Wu, S. X., Wu, Y. G., Wu, Wyslouch, B., Xie, Y. Y., Y. D., Xu, Z. Z., Xu, Xue, Z. L., Yan, D. S., Yan, X. J., Yang, B. Z., Yang, C. G., Yang, G., Yang, K. S., Yang, Q. Y., Yang, Z. Q., C. H., Ye, J. B., Ye, Ye, Q., Yeh, S. C., Yin, Z. W., You, J. M., Yunus, N., Yzerman, M., Zaccardelli, C., Zemp, P., Zeng, M., Zeng, Y., Zhang, D. H., Zhang, Z. P., Zhou, B., Zhou, J. F., Zhu, R. Y., Zhuang, H. L., Zichichi, A., B. C. C., Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), L3, and IHEF (IoP, FNWI)
Subjects: Physics, Quantum chromodynamics, Nuclear and High Energy Physics, Particle physics, Photon, E+E ANNIHILATION, 010308 nuclear & particles physics, LUND MONTE-CARLO, ENERGIES, Physics beyond the Standard Model, Electron–positron annihilation, Hadron, High Energy Physics::Phenomenology, QUARK, 01 natural sciences, QCD, Photon emission, SEARCH, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], High Energy Physics::Experiment, 010306 general physics, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Particle Physics - Experiment
Abstract: We report on a study of energetic, isolated photons in a sample of approximately 320 000 Z0 hadronic decays. Energetic isolated photons probe the short-distance structure of QCD. We compare our data with the prediction of several QCD-based calculations. A search for new processes with one or two photons in the hadronic final state is also presented. No evidence for physics beyond the standard model is found.

11. Pro-CRISPR PcrIIC1-associated Cas9 system for enhanced bacterial immunity.

Author: Zhang S, Sun A, Qian JM, Lin S, Xing W, Yang Y, Zhu HZ, Zhou XY, Guo YS, Liu Y, Meng Y, Jin SL, Song W, Li CP, Li Z, Jin S, Wang JH, Dong MQ, Gao C, Chen C, Bai Y, and Liu JG
Subjects: Chryseobacterium genetics, Chryseobacterium immunology, Chryseobacterium virology, DNA Cleavage, Genetic Loci genetics, Models, Molecular, Protein Domains, Bacteria virology, Bacteria genetics, Bacteria immunology, Bacteriophages genetics, Bacteriophages immunology, CRISPR-Associated Protein 9 chemistry, CRISPR-Associated Protein 9 genetics, CRISPR-Associated Protein 9 metabolism, CRISPR-Cas Systems genetics, CRISPR-Cas Systems immunology
Abstract: The CRISPR system is an adaptive immune system found in prokaryotes that defends host cells against the invasion of foreign DNA 1 . As part of the ongoing struggle between phages and the bacterial immune system, the CRISPR system has evolved into various types, each with distinct functionalities 2 . Type II Cas9 is the most extensively studied of these systems and has diverse subtypes. It remains uncertain whether members of this family can evolve additional mechanisms to counter viral invasions 3,4 . Here we identify 2,062 complete Cas9 loci, predict the structures of their associated proteins and reveal three structural growth trajectories for type II-C Cas9. We found that novel associated genes (NAGs) tended to be present within the loci of larger II-C Cas9s. Further investigation revealed that CbCas9 from Chryseobacterium species contains a novel β-REC2 domain, and forms a heterotetrameric complex with an NAG-encoded CRISPR-Cas-system-promoting (pro-CRISPR) protein of II-C Cas9 (PcrIIC1). The CbCas9-PcrIIC1 complex exhibits enhanced DNA binding and cleavage activity, broader compatibility for protospacer adjacent motif sequences, increased tolerance for mismatches and improved anti-phage immunity, compared with stand-alone CbCas9. Overall, our work sheds light on the diversity and 'growth evolutionary' trajectories of II-C Cas9 proteins at the structural level, and identifies many NAGs-such as PcrIIC1, which serves as a pro-CRISPR factor to enhance CRISPR-mediated immunity., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Published: 2024
Full Text: View/download PDF

12. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.

Author: Chaunzwa TL, Qian JM, Li Q, Ricciuti B, Nuernberg L, Johnson JW, Weiss J, Zhang Z, MacKay J, Kagiampakis I, Bikiel D, Di Federico A, Alessi JV, Mak RH, Jacob E, Awad MM, and Aerts HJWL
Subjects: Humans, Female, Male, Middle Aged, Aged, Progression-Free Survival, Adult, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms therapy, Lung Neoplasms pathology, Lung Neoplasms mortality, Immunotherapy methods, Body Composition
Abstract: Importance: The association between body composition (BC) and cancer outcomes is complex and incompletely understood. Previous research in non-small-cell lung cancer (NSCLC) has been limited to small, single-institution studies and yielded promising, albeit heterogeneous, results., Objectives: To evaluate the association of BC with oncologic outcomes in patients receiving immunotherapy for advanced or metastatic NSCLC., Design, Setting, and Participants: This comprehensive multicohort analysis included clinical data from cohorts receiving treatment at the Dana-Farber Brigham Cancer Center (DFBCC) who received immunotherapy given alone or in combination with chemotherapy and prospectively collected data from the phase 1/2 Study 1108 and the chemotherapy arm of the phase 3 MYSTIC trial. Baseline and follow-up computed tomography (CT) scans were collected and analyzed using deep neural networks for automatic L3 slice selection and body compartment segmentation (skeletal muscle [SM], subcutaneous adipose tissue [SAT], and visceral adipose tissue). Outcomes were compared based on baseline BC measures or their change at the first follow-up scan. The data were analyzed between July 2022 and April 2023., Main Outcomes and Measures: Hazard ratios (HRs) for the association of BC measurements with overall survival (OS) and progression-free survival (PFS)., Results: A total of 1791 patients (878 women [49%]) with NSCLC were analyzed, of whom 487 (27.2%) received chemoimmunotherapy at DFBCC (DFBCC-CIO), 825 (46.1%) received ICI monotherapy at DFBCC (DFBCC-IO), 222 (12.4%) were treated with durvalumab monotherapy on Study 1108, and 257 (14.3%) were treated with chemotherapy on MYSTIC; median (IQR) ages were 65 (58-74), 66 (57-71), 65 (26-87), and 63 (30-84) years, respectively. A loss in SM mass, as indicated by a change in the L3 SM area, was associated with worse oncologic outcome across patient groups (HR, 0.59 [95% CI, 0.43-0.81] and 0.61 [95% CI, 0.47-0.79] for OS and PFS, respectively, in DFBCC-CIO; HR, 0.74 [95% CI, 0.60-0.91] for OS in DFBCC-IO; HR, 0.46 [95% CI, 0.33-0.64] and 0.47 [95% CI, 0.34-0.64] for OS and PFS, respectively, in Study 1108; HR, 0.76 [95% CI, 0.61-0.96] for PFS in the MYSTIC trial). This association was most prominent among male patients, with a nonsignificant association among female patients in the MYSTIC trial and DFBCC-CIO cohorts on Kaplan-Meier analysis. An increase of more than 5% in SAT density, as quantified by the average CT attenuation in Hounsfield units of the SAT compartment, was associated with poorer OS in 3 patient cohorts (HR, 0.61 [95% CI, 0.43-0.86] for DFBCC-CIO; HR, 0.62 [95% CI, 0.49-0.79] for DFBCC-IO; and HR, 0.56 [95% CI, 0.40-0.77] for Study 1108). The change in SAT density was also associated with PFS for DFBCC-CIO (HR, 0.73; 95% CI, 0.54-0.97). This was primarily observed in female patients on Kaplan-Meier analysis., Conclusions and Relevance: The results of this multicohort study suggest that loss in SM mass during systemic therapy for NSCLC is a marker of poor outcomes, especially in male patients. SAT density changes are also associated with prognosis, particularly in female patients. Automated CT-derived BC measurements should be considered in determining NSCLC prognosis.
Published: 2024
Full Text: View/download PDF

13. Large language models to identify social determinants of health in electronic health records.

Author: Guevara M, Chen S, Thomas S, Chaunzwa TL, Franco I, Kann BH, Moningi S, Qian JM, Goldstein M, Harper S, Aerts HJWL, Catalano PJ, Savova GK, Mak RH, and Bitterman DS
Abstract: Social determinants of health (SDoH) play a critical role in patient outcomes, yet their documentation is often missing or incomplete in the structured data of electronic health records (EHRs). Large language models (LLMs) could enable high-throughput extraction of SDoH from the EHR to support research and clinical care. However, class imbalance and data limitations present challenges for this sparsely documented yet critical information. Here, we investigated the optimal methods for using LLMs to extract six SDoH categories from narrative text in the EHR: employment, housing, transportation, parental status, relationship, and social support. The best-performing models were fine-tuned Flan-T5 XL for any SDoH mentions (macro-F1 0.71), and Flan-T5 XXL for adverse SDoH mentions (macro-F1 0.70). Adding LLM-generated synthetic data to training varied across models and architecture, but improved the performance of smaller Flan-T5 models (delta F1 + 0.12 to +0.23). Our best-fine-tuned models outperformed zero- and few-shot performance of ChatGPT-family models in the zero- and few-shot setting, except GPT4 with 10-shot prompting for adverse SDoH. Fine-tuned models were less likely than ChatGPT to change their prediction when race/ethnicity and gender descriptors were added to the text, suggesting less algorithmic bias (p < 0.05). Our models identified 93.8% of patients with adverse SDoH, while ICD-10 codes captured 2.0%. These results demonstrate the potential of LLMs in improving real-world evidence on SDoH and assisting in identifying patients who could benefit from resource support., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

14. Pyroptosis burden is associated with anti-TNF treatment outcome in inflammatory bowel disease: new insights from bioinformatics analysis.

Author: Gao X, Wang C, Shen XT, Li CY, Li YC, Gao H, Qian JM, and Zhang XL
Subjects: Humans, Pyroptosis, Inflammasomes genetics, Treatment Outcome, Computational Biology, Tumor Necrosis Factor Inhibitors, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases genetics
Abstract: Biological agents known as anti-tumor necrosis factor (TNF) drugs are frequently utilized in the treatment of inflammatory bowel disease (IBD). In this study, we analyzed the shared processes of pyroptosis in Ulcerative colitis (UC) and Crohn's disease (CD), as well as explored the correlation between the burden of pyroptosis and the results of anti-TNF treatment based on bioinformatics analyses. We identified CAPS1, CASP5, GSDMD, AIM2, and NLRP3 as the hub genes, with AIM2 being the most effective indicator for predicting the response to anti-TNF therapy. We also noticed that non-responders received anti-TNF therapy exhibited elevated AIM2 protein expression. Subsequently, we conducted a cluster analysis based on AIM2-inflammasome-related genes and discovered that patients with a higher burden of AIM2 inflammasome displayed stronger immune function and a poor response to anti-TNF therapy. Overall, our study elucidates the pathway of pyroptosis in IBD and reveals AIM2 expression level as a potential biomarker for predicting the effectiveness of anti-TNF therapy., (© 2023. Springer Nature Limited.)
Published: 2023
Full Text: View/download PDF

15. Decoding biological age from face photographs using deep learning.

Author: Zalay O, Bontempi D, Bitterman DS, Birkbak N, Shyr D, Haugg F, Qian JM, Roberts H, Perni S, Prudente V, Pai S, Dekker A, Haibe-Kains B, Guthier C, Balboni T, Warren L, Krishan M, Kann BH, Swanton C, Ruysscher D, Mak RH, and Aerts HJ
Abstract: Because humans age at different rates, a person's physical appearance may yield insights into their biological age and physiological health more reliably than their chronological age. In medicine, however, appearance is incorporated into medical judgments in a subjective and non-standardized fashion. In this study, we developed and validated FaceAge, a deep learning system to estimate biological age from easily obtainable and low-cost face photographs. FaceAge was trained on data from 58,851 healthy individuals, and clinical utility was evaluated on data from 6,196 patients with cancer diagnoses from two institutions in the United States and The Netherlands. To assess the prognostic relevance of FaceAge estimation, we performed Kaplan Meier survival analysis. To test a relevant clinical application of FaceAge, we assessed the performance of FaceAge in end-of-life patients with metastatic cancer who received palliative treatment by incorporating FaceAge into clinical prediction models. We found that, on average, cancer patients look older than their chronological age, and looking older is correlated with worse overall survival. FaceAge demonstrated significant independent prognostic performance in a range of cancer types and stages. We found that FaceAge can improve physicians' survival predictions in incurable patients receiving palliative treatments, highlighting the clinical utility of the algorithm to support end-of-life decision-making. FaceAge was also significantly associated with molecular mechanisms of senescence through gene analysis, while age was not. These findings may extend to diseases beyond cancer, motivating using deep learning algorithms to translate a patient's visual appearance into objective, quantitative, and clinically useful measures.
Published: 2023
Full Text: View/download PDF

16. [Clinical and pathological characteristics of immune-mediated liver injury caused by immune checkpoint inhibitors].

Author: Zeng YL, Li Y, Tang H, Xu Y, Chen MJ, Li Y, Wang MZ, Tan B, and Qian JM
Subjects: Male, Humans, Adult, Middle Aged, Aged, Retrospective Studies, Liver, Glucocorticoids therapeutic use, Immune Checkpoint Inhibitors adverse effects, Antineoplastic Agents, Immunological adverse effects
Abstract: Objective: Cancer immunotherapy can lead to various side effects, termed immune-related adverse events (irAE). This study summarized and analyzed the clinical and pathological characteristics of immune-mediated liver injury caused by immune checkpoint inhibitors (ILICI). Methods: This is a retrospective case series study involving 11 patients diagnosed with ILICI at the Peking Union Medical College Hospital from November 2019 to November 2021. Patient demographic information and clinical data, including gender, age, ILICI onset, clinical and radiological manifestations, pathological features, treatment, and resumption of ICI were retrospectively collected and analyzed. Results: The patients were primarily males (9/11) with a median age of 65 (range: 32-73) years. ICI mainly resulted in either partial remission (4/11) or stable disease (3/11). ILICI occurred after a median of two cycles of anti-programmed cell death-1 (PD-1) therapy, with a median time from the initial and last anti-PD-1 therapy to ILICI onset of 57 days and 17 days, respectively. ILICI was mostly severe (3/11) or very severe (6/11). While the clinical and radiological manifestations were non-specific, the pathological features were active lobular hepatitis and portal inflammation, with prominent CD8 + T lymphocyte infiltration. The basic treatment was hepatoprotective drugs (10/11). Glucocorticoids were used as the primary therapy (9/11) but were ineffective in 4 of 9 cases. Of these, 3 of 9 cases received combined treatment with mycophenolate mofetil (MMF), only one of whom achieved remission. By the end of the study, 2 of 11 cases had resumed ICI and neither had experienced an ILICI relapse. Conclusion: The ILICI patients in this study had a corresponding history of ICI treatment and pathological features. The main treatment included hepatoprotective drugs and glucocorticoids. Immunosuppressive drugs were added for some cases but had poor efficacy.
Published: 2023
Full Text: View/download PDF

17. Endoscopic features help to identify the histopathological patterns of colorectal polyps in Cronkhite-Canada syndrome.

Author: Xu QS, You Y, Liu S, You W, Zhang SY, Li JN, Yang AM, Li J, and Qian JM
Subjects: Humans, Colonoscopy, Intestinal Polyps complications, Colonic Polyps diagnosis, Intestinal Polyposis complications, Adenoma complications, Adenoma diagnosis
Abstract: Objectives: Cronkhite-Canada syndrome (CCS) is a rare nonhereditary gastrointestinal hamartomatous polyposis syndrome with a high risk of colorectal cancerogenesis. It is challenging to discriminate adenomas from nonneoplastic colorectal polyps macroscopically. This study aimed to explore the endoscopic features of different histopathological patterns of colorectal polyps in CCS., Methods: Sixty-seven lesions from 23 CCS patients were prospectively biopsied or resected during the colonoscopic examination for histopathological analysis. The Fisher's exact test and multivariate logistical analysis were conducted to reveal the predictive endoscopic features of CCS polyps with low-grade dysplasia (LGD) and adenomas., Results: There were seven (10.4%) adenomas, 20 (29.9%) CCS-LGD, and 40 (59.7%) nonneoplastic CCS polyps. Polyps were large (>20 mm) in none of the adenomas, 30.0% of CCS-LGD polyps, and 2.5% of nonneoplastic CCS polyps (P < 0.001). The color of the polyps was whitish for 71.4% of adenomas, 10.0% of CCS-LGD polyps, and 15.0% of nonneoplastic CCS polyps (P = 0.004). Pedunculated polyps were detected in 42.9% of adenomas, 45.0% of CCS-LGD polyps, and 5.0% of nonneoplastic CCS polyps (P < 0.001). The proportions of types IV and V I in the Kudo classification were 42.9%, 95.0%, and 35.0% in adenomatous, CCS-LGD, and nonneoplastic CCS polyps, respectively (P = 0.002). The endoscopic activity was in remission for 71.4% of adenomas, 5.0% of CCS-LGD polyps, and 10.0% of nonneoplastic CCS polyps (P < 0.001)., Conclusion: Endoscopic features, including the size, color, sessility, Kudo's pit pattern classification of polyps, and endoscopic activity, help identify the histopathological patterns of colorectal polyps in CCS., (© 2023 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
Published: 2023
Full Text: View/download PDF

18. The metabolic syndrome and its components as prognostic factors in colorectal cancer: A meta-analysis and systematic review.

Author: Lu B, Qian JM, and Li JN
Subjects: Humans, Obesity, Prognosis, Risk Factors, Colorectal Neoplasms, Metabolic Syndrome
Abstract: Background and Aim: Metabolic syndrome (MetS) increases the risk of colorectal cancer (CRC), and the impact of MetS on CRC prognosis remains controversial after the diagnosis of CRC has been established. This study aimed to explore the impact of the individual components and synergies of MetS on the prognosis of patients with CRC., Methods: We searched articles published before August 3, 2022, in four databases, including PubMed, Embase, Cochrane Library, and ScienceDirect. The random-effects model inverse variance method was used to estimate the summarized effect size., Results: Patients with CRC with MetS were 1.342 times more likely to experience all-cause mortality than those without MetS, and the 95% confidence interval (CI) of hazard ratio (HR) was 1.107-1.627 (P = 0.003). CRC-specific mortality in patients with CRC with MetS was 2.122 times higher than in those without MetS, and the 95% CI of HR was 1.080-4.173 (P = 0.029). CRC-specific mortality exhibited an increasing trend of risk with increased metabolic risk factors. The HR of CRC-specific mortality for one, two, and three metabolic risk factors was 1.206 (95% CI, 1.034-1.407; P = 0.017), 1.881 (95% CI, 1.253-2.824; P = 0.002), and 2.327 (95% CI, 1.262-4.291; P = 0.007), respectively., Conclusions: Metabolic syndrome increased all-cause and CRC-specific mortality in patients with CRC. As a single component of MetS, diabetes mellitus increased overall mortality in patients with CRC, while obesity increased CRC-specific mortality in patients with CRC, with a significant difference from non-MetS. Moreover, the risk of CRC-specific mortality increased with increasing number of metabolic risk factors., (© 2022 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
Published: 2023
Full Text: View/download PDF

19. Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology.

Author: Liu XY, Tang H, Zhou QY, Zeng YL, Chen D, Xu H, Li Y, Tan B, and Qian JM
Subjects: Humans, Precision Medicine adverse effects, Biomarkers, Technology, Artificial Intelligence, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases therapy
Abstract: There is great heterogeneity among inflammatory bowel disease (IBD) patients in terms of pathogenesis, clinical manifestation, response to treatment, and prognosis, which requires the individualized and precision management of patients. Many studies have focused on prediction biomarkers and models for assessing IBD disease type, activity, severity, and prognosis. During the era of biologics, how to predict the response and side effects of patients to different treatments and how to quickly recognize the loss of response have also become important topics. Multiomics is a promising area for investigating the complex network of IBD pathogenesis. Integrating numerous amounts of data requires the use of artificial intelligence., Competing Interests: Conflict-of-interest statement: The authors declare no conflicts of interest., (©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.)
Published: 2023
Full Text: View/download PDF

20. [Diagnostic value of different serological markers and correlation analysis with disease phenotype in inflammatory bowel disease].

Author: Tang H, Tan B, Shen BB, Zhang SL, and Qian JM
Subjects: Male, Female, Humans, Antibodies, Antineutrophil Cytoplasmic, Retrospective Studies, Constriction, Pathologic, Autoantibodies, Phenotype, Biomarkers, Colitis, Ulcerative diagnosis, Crohn Disease diagnosis, Inflammatory Bowel Diseases diagnosis
Abstract: Objective: To explore the diagnostic value of different serological markers and the correlation with disease phenotype in inflammatory bowel disease (IBD). Methods: The clinical data of 445 IBD patients in Peking Union Medical College Hospital from June 2010 to December 2020 were retrospectively collected, including 223 cases of ulcerative colitis (UC) [111 males, 112 females, with a median age of 46(20,79) years] and 222 cases of Crohn's disease (CD) [147 males, 75 females, with a median age of 39 (19, 72) years]. The positive rates of serum anti-neutrophil cytoplasmic antibodies (ANCA), anti-Saccharomyces cerevisiae antibodies (ASCA), goblet cell autoantibodies (GAB) and pancreatic autoantibodies (PAB) in the two groups were analyzed. The sensitivity, specificity, positive predictive value and negative predictive value of UC and CD were calculated. Logistic regression was performed to analyze the relationship between different combinations of antibodies and disease phenotype. Results: The positive rates of ASCA and PAB in CD patients were 34.7% (77/222) and 38.3% (85/222), respectively, which were higher than those in UC patients [10.3% (23/223) and 4.5% (10/223), P <0.001]. The positive rate of ANCA in UC patients was 50.2% (112/223), which was higher than that in CD patients [5.4% (12/222), P <0.001]. The positive rates of serum GAB in CD and UC patients were 21.6% (48/222) and 28.3% (63/223), respectively, with no significant difference ( P =0.760). In patients with CD, the sensitivity of mono-marker ASCA (+), dual-marker ASCA (+) ANCA (-), quadruple-marker ASCA (+) ANCA (-) PAB (+) GAB (-) in diagnosing CD was 34.7%, 32.9%, 20.7%, the specificity was 89.7%, 95.5%, 100.0%, the positive predictive value was 77.0%, 90.1%, 100.0%, and the negative predictive value was 58.0%, 58.7%, 55.9%, respectively. In patients with UC, the sensitivity of mono-marker ANCA (+), dual-marker ANCA (+) ASCA (-), quadruple-marker ANCA (+) ASCA (-) PAB (-) GAB (+) in diagnosing UC was 50.2%, 40.4%, 24.2%, the specificity was 94.6%, 95.5%, 100.0%, the positive predictive value was 90.3%, 90.0%, 100.0%, and the negative predictive value was 65.4%, 61.4%, 56.8%, respectively. Mono-marker ASCA (+) ( OR =3.39, 95% CI : 1.59-7.21), dual-marker ASCA (+) ANCA (-) ( OR =2.87, 95% CI : 1.34-6.14), triple-marker ASCA (+) ANCA (-) GAB (-) ( OR =3.09, 95% CI : 1.31-7.31) and quadruple-marker ASCA (+) ANCA (-) PAB (+) GAB (-) ( OR =3.15, 95% CI : 1.56-8.03) were associated with stenosis and/or penetrating type CD. The mono-marker ANCA (+) ( OR =2.69, 95% CI : 1.42-5.12) and dual-marker ANCA (+) ASCA (-) ( OR =2.11, 95% CI : 1.03-4.16) were associated with extensive colonic lesions in UC. Conclusion: Based on ASCA or ANCA, the combination with PAB or GAB, is conducive to IBD diagnosis, and is associated with stenosis and/or penetrating type of CD and extensive type of UC.
Published: 2022
Full Text: View/download PDF

21. [Characteristic analysis of patients with type 2 diabetes mellitus combined with advanced stage chronic liver disease: a community population-based cross-sectional study in Heping District, Shenyang City (CHESS-LN 2101)].

Author: Lyu C, Fu WL, Gu Y, Wang LS, Wang XM, Liu X, Qian JM, Tao Z, Chen Y, Liu C, He RL, Guan X, Wang Y, Wang Y, and Qi XL
Subjects: Humans, Liver Cirrhosis complications, Cross-Sectional Studies, Liver pathology, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease epidemiology, Non-alcoholic Fatty Liver Disease pathology, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 complications, Elasticity Imaging Techniques, Hypertension, Portal complications
Abstract: Objective: To investigate the prevalence and independent risk factors of non-alcoholic fatty liver disease (NAFLD) and advanced chronic liver disease among the type 2 diabetes mellitus (T2DM) population in the Shenyang community, so as to provide evidence for the prevention and control of T2DM combined with NAFLD. Methods: This cross-sectional study was conducted in July 2021. 644 T2DM cases from 13 communities in Heping District, Shenyang City were selected. All the surveyed subjects underwent physical examination (measurements of height, body mass index, neck circumference, waist circumference, abdominal circumference, hip circumference, and blood pressure), infection screening (excluding hepatitis B and C, AIDS, and syphilis), random fingertip blood glucose, controlled attenuation parameter (CAP), and liver stiffness measurement (LSM). The study subjects were divided into the non-advanced chronic liver disease group and the advanced chronic liver disease group according to whether the LSM value was greater than 10 kPa. Cirrhotic portal hypertension development was indicated in patients with LSM ≥ 15 kPa. The comparison of multiple mean values among the sample groups was performed by analysis of variance when the normal distribution was met. Results: In the T2DM community population, there were 401 cases (62.27%) combined with NAFLD, 63 cases (9.78%) combined with advanced chronic liver disease, and 14 cases (2.17%) combined with portal hypertension. There were 581 cases in the non-advanced chronic liver disease group and 63 cases (9.78%) in the advanced chronic liver disease group (LSM ≥10 kPa), including 49 cases (7.61%) with 10 kPa≤LSM<15 kPa, 11 cases (1.71%) with 15 kPa ≤LSM<25 kPa, and 3 cases (0.47%) with LSM ≥ 25 kPa. Age, body mass, body mass index, neck circumference, waist circumference, hip circumference, waist-to-height ratio, systolic blood pressure, and CAP were all statistically different between the non-advanced chronic liver disease group and the advanced chronic liver disease group ( F =-1.983,-2.598,-4.091,-2.062,-3.909, -4.581,-4.295,-2.474, and -5.191, respectively; P <0.05). There was a statistically significant difference in terms of whether or not there was combined cerebrovascular disease (2=4.632, P =0.031); however, there were no statistically significant differences in terms of lifestyle, diabetes complications, and other complications ( P >0.05). Conclusion: Patients with T2DM have a higher prevalence of NAFLD (62.27%) than those with advanced chronic liver disease (9.78%). 2.17% of T2DM cases in the community may not have had early diagnosis and early intervention, and they might have been combined with cirrhotic portal hypertension. So, the management of these patients should be strengthened.
Published: 2022
Full Text: View/download PDF

22. Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.

Author: Mahmood U, Huynh MA, Killoran JH, Qian JM, Bent EH, Aizer AA, Mak RH, Mamon HJ, Balboni TA, Gunasti L, Ott PA, Awad MM, and Schoenfeld JD
Subjects: B7-H1 Antigen therapeutic use, Humans, Immune Checkpoint Inhibitors therapeutic use, Retrospective Studies, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy
Abstract: Purpose: We retrospectively evaluated outcomes after radiation therapy for patients with oligoprogression on immune checkpoint inhibitors (ICI)., Methods and Materials: We identified patients irradiated to ≤5 progressive lesions while receiving ICI between 2010 and 2020. We excluded patients whose systemic therapy was switched after radiation but before progression. We evaluated predictors of local control (LC), progression-free survival (PFS) and overall survival (OS)., Results: We screened 1423 patients and identified 120 who were eligible; the most common histologies were lung cancer (n = 59) and melanoma (n = 36). The median number of oligoprogressive lesions was 1. For the median LC of irradiated oligoprogressive lesions, PFS and OS were not reached at 6.41 (4.67-7.66) and 29.80 (22.54-43.33) months, respectively. Tumor histology, radiated site, or radiation modality were not associated with LC, PFS, or OS. Local response to radiation (P < .0001) and radiation of newly developed lesions (P = .02) were associated with LC. Predictors of PFS on univariate and multivariate analyses were best response to radiation (P = .006) and high programmed death ligand 1 tumor proportion score (P = .02). On multivariate analyses, OS was associated with cumulative oligoprogressive lesion volumes (P = .02) and duration of ICI before oligoprogression (P = .03)., Conclusions: Promising outcomes were observed among patients irradiated for oligoprogression on ICI, especially those with a favorable local response, high tumor programmed death ligand 1 expression, and those receiving ICI for longer periods before oligoprogression. These data can help identify patients well suited for radiation therapy versus those who should switch systemic treatment., (Copyright © 2022 Elsevier Inc. All rights reserved.)
Published: 2022
Full Text: View/download PDF

23. [Short-term efficacy and safety of vedolizumab in patients with inflammatory bowel disease].

Author: Lu B, Liu ZS, Zheng WY, Bai XY, Yang H, and Qian JM
Subjects: Male, Female, Humans, Adult, Middle Aged, Gastrointestinal Agents therapeutic use, Retrospective Studies, Remission Induction, Treatment Outcome, Chronic Disease, Crohn Disease drug therapy, Inflammatory Bowel Diseases drug therapy, Colitis, Ulcerative
Abstract: Objective: To evaluate the short-term efficacy and safety of vedolizumab in patients with inflammatory bowel disease (IBD). Methods: Patients with moderate and severe active IBD at the first use of vedolizumab from May 1 to October 31, 2021 were retrospectively enrolled. Then the clinical characteristics, and the efficacy and safety of vedolizumab were evaluated. Meanwhile, the clinical response rate, biological response rate and endoscopic response rate were calculated. Multivariate analysis was used to evaluate the independent influencing factors of short-term clinical efficacy and safety. Results: A total of 78 patients (44 males and 34 females) with IBD were enrolled, with a mean age of (40.5±11.9) years. The clinical remission rate, clinical response rate, biological remission rate, biological response rate and endoscopic remission rate was 60.3% (47/78), 85.9% (67/78), 70.5% (55/78), 43.6% (34/78) and 47.0% (31/66) respectively after 14 weeks of treatment. Body mass index (BMI) ≥ 18.5 kg/m 2 ( HR =5.04, 95% CI : 1.50-16.91, P =0.009) and biological remission at 6 weeks of treatment ( HR =15.22, 95% CI : 3.16-73.38, P =0.001) were predictors of endoscopic remission at 14 weeks of treatment. Adverse reactions occurred in 57 patients, with an incidence of 73.1%. The main manifestations were liver and kidney damage (37.2%) and infection (26.9%). Conclusions: More than half of patients with moderate and severe active IBD can achieve clinical remission after 14 weeks of vedolizumab treatment. Baseline BMI level and biological remission at 6 weeks of treatment are predictors of mucosal healing at 14 weeks. The incidence of adverse reactions is not low, although serious adverse reactions are rare in short-term treatment.
Published: 2022
Full Text: View/download PDF

24. Gut microbiota shed new light on the management of immune-related adverse events.

Author: Tan B, Liu YX, Tang H, Chen D, Xu Y, Chen MJ, Li Y, Wang MZ, and Qian JM
Subjects: Animals, Anti-Bacterial Agents, Humans, Immune Checkpoint Inhibitors adverse effects, Mice, Prebiotics, Colitis chemically induced, Colitis therapy, Gastrointestinal Microbiome
Abstract: Immunotherapy has dramatically revolutionized the therapeutic landscape for patients with cancer. Although immune checkpoint inhibitors are now accepted as effective anticancer therapies, they introduce a novel class of toxicity, termed immune-related adverse events, which can lead to the temporary or permanent discontinuation of immunotherapy and life-threatening tumor progression. Therefore, the effective prevention and treatment of immune-related adverse events is a clinical imperative to maximize the utility of immunotherapies. Immune-related adverse events are related to the intestinal microbiota, baseline gut microbiota composition is an important determinant of immune checkpoint inhibitor-related colitis, and antibiotics exacerbate these undesirable side-effects. Supplementation with specific probiotics reduces immune checkpoint inhibitor-related colitis in mice, and fecal microbiota transplantation has now been shown to effectively treat refractory immune checkpoint inhibitor-related colitis in the clinic. Hence, modifying the microbiota holds great promise for preventing and treating immune-related adverse events. Microbiomes and their metabolites play important roles in the potential underlying mechanisms through interactions with both innate and adaptive immune cells. Here we review the gut microbiota and immune regulation; the changes occurring in the microbiota during immune checkpoint inhibitor therapy; the relationship between the microbiota and immune-related adverse events, antibiotics, probiotics/prebiotics, and fecal microbiota transplantation in immune checkpoint inhibitor-related colitis; and the protective mechanisms mediated by the microbiome and metabolites in immune-related adverse events., (© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
Published: 2022
Full Text: View/download PDF

25. Development and validation of novel models for the prediction of intravenous corticosteroid resistance in acute severe ulcerative colitis using logistic regression and machine learning.

Author: Yu S, Li H, Li Y, Xu H, Tan B, Tian BW, Dai YM, Tian F, and Qian JM
Abstract: Background: The early prediction of intravenous corticosteroid (IVCS) resistance in acute severe ulcerative colitis (ASUC) patients remains an unresolved challenge. This study aims to construct and validate a model that accurately predicts IVCS resistance., Methods: A retrospective cohort was established, with consecutive inclusion of patients who met the diagnosis criteria of ASUC and received IVCS during index hospitalization in Peking Union Medical College Hospital between March 2012 and January 2020. The primary outcome was IVCS resistance. Classification models, including logistic regression and machine learning-based models, were constructed. External validation was conducted in an independent cohort from Shengjing Hospital of China Medical University., Results: A total of 129 patients were included in the derivation cohort. During index hospitalization, 102 (79.1%) patients responded to IVCS and 27 (20.9%) failed; 18 (14.0%) patients underwent colectomy in 3 months; 6 received cyclosporin as rescue therapy, and 2 eventually escalated to colectomy; 5 succeeded with infliximab as rescue therapy. The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and C-reactive protein (CRP) level at Day 3 are independent predictors of IVCS resistance. The areas under the receiver-operating characteristic curves (AUROCs) of the logistic regression, decision tree, random forest, and extreme-gradient boosting models were 0.873 (95% confidence interval [CI], 0.704-1.000), 0.648 (95% CI, 0.463-0.833), 0.650 (95% CI, 0.441-0.859), and 0.604 (95% CI, 0.416-0.792), respectively. The logistic regression model achieved the highest AUROC value of 0.703 (95% CI, 0.473-0.934) in the external validation., Conclusions: In patients with ASUC, UCEIS and CRP levels at Day 3 of IVCS treatment appeared to allow the prompt prediction of likely IVCS resistance. We found no evidence of better performance of machine learning-based models in IVCS resistance prediction in ASUC. A nomogram based on the logistic regression model might aid in the management of ASUC patients., (© The Author(s) 2022. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University.)
Published: 2022
Full Text: View/download PDF

26. Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study.

Author: Yang H, Ran Z, Jin M, and Qian JM
Subjects: Asia, Hepatitis B Surface Antigens, Humans, Retrospective Studies, Surveys and Questionnaires, Clostridioides difficile, Cytomegalovirus Infections diagnosis, Inflammatory Bowel Diseases, Opportunistic Infections diagnosis
Abstract: Background/aims: Opportunistic infection in inflammatory bowel disease (IBD) has become a serious problem. However, its status of doctors' opinions and test equipment in hospitals are unclear. The aim of the study was to investigate these issues to improve the prognosis of IBD patients., Methods: This retrospective, multicenter study was conducted by 83 investigators who were members of the Asian Organization for Crohn's and Colitis. Data on opportunistic infection were collected from hospital databases between January 2017 and December 2017. The survey consisted of 11 items., Results: Most physicians appreciated the diagnostic value of tissue cytomegalovirus (CMV) DNA, accounting for 86.1% of members in China, 37.5% in Japan, 52.9% in South Korea, and 66.7% in Southeast Asia. Only 83.1% of hospitals had the ability to test for CMV immunohistochemistry in Asia. Hepatitis B surface antigen (HBsAg) screening was recommended by all members. However, only 66.7% in China, 70.6% in South Korea, and 66.7% in Southeast Asia agreed to routinely vaccinate IBD patients when HBsAg tested negative. Most members preferred metronidazole (74.7%) as the first choice for patients with Clostridium difficile infection. However, the proportion of stool C. difficile toxin test was lower in China than in other areas (75.0% in China vs 95.8% in Japan and 100% in South Korea and Southeast Asia, p<0.05)., Conclusions: Opportunistic infection from CMV, hepatitis B virus, and C. difficile should be of high concern for IBD patients. More efforts are needed, such as understanding consensus in clinical practice and improving testing facilities in hospitals.
Published: 2022
Full Text: View/download PDF

27. Clinical validation of deep learning algorithms for radiotherapy targeting of non-small-cell lung cancer: an observational study.

Author: Hosny A, Bitterman DS, Guthier CV, Qian JM, Roberts H, Perni S, Saraf A, Peng LC, Pashtan I, Ye Z, Kann BH, Kozono DE, Christiani D, Catalano PJ, Aerts HJWL, and Mak RH
Subjects: Algorithms, Artificial Intelligence, Humans, Positron Emission Tomography Computed Tomography, United States, Carcinoma, Non-Small-Cell Lung, Deep Learning, Lung Neoplasms
Abstract: Background: Artificial intelligence (AI) and deep learning have shown great potential in streamlining clinical tasks. However, most studies remain confined to in silico validation in small internal cohorts, without external validation or data on real-world clinical utility. We developed a strategy for the clinical validation of deep learning models for segmenting primary non-small-cell lung cancer (NSCLC) tumours and involved lymph nodes in CT images, which is a time-intensive step in radiation treatment planning, with large variability among experts., Methods: In this observational study, CT images and segmentations were collected from eight internal and external sources from the USA, the Netherlands, Canada, and China, with patients from the Maastro and Harvard-RT1 datasets used for model discovery (segmented by a single expert). Validation consisted of interobserver and intraobserver benchmarking, primary validation, functional validation, and end-user testing on the following datasets: multi-delineation, Harvard-RT1, Harvard-RT2, RTOG-0617, NSCLC-radiogenomics, Lung-PET-CT-Dx, RIDER, and thorax phantom. Primary validation consisted of stepwise testing on increasingly external datasets using measures of overlap including volumetric dice (VD) and surface dice (SD). Functional validation explored dosimetric effect, model failure modes, test-retest stability, and accuracy. End-user testing with eight experts assessed automated segmentations in a simulated clinical setting., Findings: We included 2208 patients imaged between 2001 and 2015, with 787 patients used for model discovery and 1421 for model validation, including 28 patients for end-user testing. Models showed an improvement over the interobserver benchmark (multi-delineation dataset; VD 0·91 [IQR 0·83-0·92], p=0·0062; SD 0·86 [0·71-0·91], p=0·0005), and were within the intraobserver benchmark. For primary validation, AI performance on internal Harvard-RT1 data (segmented by the same expert who segmented the discovery data) was VD 0·83 (IQR 0·76-0·88) and SD 0·79 (0·68-0·88), within the interobserver benchmark. Performance on internal Harvard-RT2 data segmented by other experts was VD 0·70 (0·56-0·80) and SD 0·50 (0·34-0·71). Performance on RTOG-0617 clinical trial data was VD 0·71 (0·60-0·81) and SD 0·47 (0·35-0·59), with similar results on diagnostic radiology datasets NSCLC-radiogenomics and Lung-PET-CT-Dx. Despite these geometric overlap results, models yielded target volumes with equivalent radiation dose coverage to those of experts. We also found non-significant differences between de novo expert and AI-assisted segmentations. AI assistance led to a 65% reduction in segmentation time (5·4 min; p<0·0001) and a 32% reduction in interobserver variability (SD; p=0·013)., Interpretation: We present a clinical validation strategy for AI models. We found that in silico geometric segmentation metrics might not correlate with clinical utility of the models. Experts' segmentation style and preference might affect model performance., Funding: US National Institutes of Health and EU European Research Council., Competing Interests: Declaration of interests AH reports consultancy fees for Altis Labs; and owning stock in Altis Labs. HJWLA reports being a scientific adviser and shareholder for Onc.Ai, Love Health, Health-AI, and Bristol Myers Squibb. RHM reports a research grant from ViewRay; honoraria from NewRT and ViewRay; is on an advisory board for AstraZeneca; and reports travel expenses from NewRT. DEK reports honoraria from RefleXion; and is a consultant and on an advisory board for Genentech. All other authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Published: 2022
Full Text: View/download PDF

28. External validation of the Paddington International Virtual Electronic ChromoendoScopy ScOre as a good endoscopic score to define mucosal healing and predict long-term clinical outcomes in ulcerative colitis.

Author: Ruan GC, Jin X, Zhou WX, You Y, Iacucci M, Ghosh S, Gui XY, Li J, and Qian JM
Subjects: Humans, Colonoscopy, Prospective Studies, Severity of Illness Index, Intestinal Mucosa diagnostic imaging, Intestinal Mucosa pathology, Electronics, Colitis, Ulcerative diagnostic imaging, Colitis, Ulcerative pathology
Abstract: Objectives: To define endoscopic and histological remission in ulcerative colitis (UC) accurately, several scoring systems have been established. A novel virtual electronic chromoendoscopy score, the Paddington International Virtual ChromoendoScopy ScOre (PICaSSO), was developed, validated, and reproduced to assess inflammation grade and predict patient prognosis. We externally verified and validated the clinical value of PICaSSO in UC patients., Methods: This prospective study enrolled 63 UC patients. The Mayo endoscopic score (MES), UC Endoscopic Index of Severity (UCEIS), and PICaSSO were adopted for endoscopic evaluation. All biopsy samples were scored using the Robarts histological index (RHI), Nancy histological index (NHI), and "Extent, Chronicity, Activity, Plus additional findings" (ECAP) score. Patients with an endoscopic MES of 0-1 at baseline were followed up during a median time of 23.5 months., Results: PICaSSO was strongly correlated with other endoscopic and histological scoring systems. PICaSSO ≤3 had advantages in assessing histological remission (HR), with the highest accuracy of 88.9% for ECAP-HR. Relapse-free survival rates were significantly different between patients with MES 0 and MES 1 and patients with PICaSSO ≤3 and >3 (P = 0.010 and 0.018, respectively)., Conclusions: PICaSSO was externally validated with strong correlations with other endoscopic and histological scoring systems in UC, and PICaSSO-ER might potentially predict a better long-term clinical outcome in UC patients., (© 2022 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
Published: 2022
Full Text: View/download PDF

29. Identification and Validation of Prognosis-Related Necroptosis Genes for Prognostic Prediction in Hepatocellular Carcinoma.

Author: Gao X, Huang D, Li SG, Wang WX, Sun DL, Qian JM, and Zhang XL
Abstract: Background: The prediction of hepatocellular carcinoma (HCC) survival is challenging because of its rapid progression. In recent years, necroptosis was found to be involved in the progression of multiple cancer types. However, the role of necroptosis in HCC remains unclear., Methods: Clinicopathological parameters and transcriptomic data of 370 HCC patients were obtained from TCGA-LIHC dataset. Prognosis-related necroptosis genes (PRNGs) were identified and utilized to construct a LASSO risk model. The GEO cohorts (GSE54236 and GSE14520) were used for external validation. We evaluated the distribution of HCC patients, the difference in prognosis, and the accuracy of the prognostic prediction of the LASSO risk model. The immune microenvironment and functional enrichment of different risk groups were further clarified. Finally, we performed a drug sensitivity analysis on the PRNGs that constructed the LASSO model and verified their mRNA expression levels in vitro. Results: A total of 48 differentially expressed genes were identified, 23 of which were PRNGs. We constructed the LASSO risk model using nine genes: SQSTM1 , FLT3 , HAT1 , PLK1 , MYCN , KLF9 , HSP90AA1 , TARDBP , and TNFRSF21 . The outcomes of low-risk patients were considerably better than those of high-risk patients in both the training and validation cohorts. In addition, stronger bile acid metabolism, xenobiotic metabolism, and more active immune cells and immune functions were observed in low-risk patients, and high expressions of TARDBP , PLK1 , and FLT3 were associated with greater drug sensitivity. With the exception of FLT3 , the mRNA expression of the other eight genes was verified in Huh7 and 97H cells . Conclusions . The PRNG signature provides a novel and effective method for predicting the outcome of HCC as well as potential targets for further research., Competing Interests: There are no potential conflicts of interest for the authors to disclose., (Copyright © 2022 Xin Gao et al.)
Published: 2022
Full Text: View/download PDF

30. [SAPHO Syndrome Complicated with Ulcerative Colitis:Report of One Case].

Author: Xie YH, You Y, Li YT, Liu S, Li L, Lai YM, Yang H, and Qian JM
Subjects: China, Humans, Acne Vulgaris complications, Acquired Hyperostosis Syndrome complications, Colitis complications, Colitis, Ulcerative complications
Abstract: Synovitis,acne,pustulosis,hyperostosis,and osteitis (SAPHO) syndrome is a rare disease. The previous literature demonstrated that about 10% of the patients with SAPHO syndrome were complicated with inflammatory bowel disease.So far,few cases of SAPHO syndrome complicated with inflammatory bowel disease have been reported in China.Herein,we reported a SAPHO syndrome case complicated with ulcerative colitis. The patient suffered from recurrent attacks of colitis following treatment of SAPHO syndrome with etanercept.
Published: 2022
Full Text: View/download PDF

31. Deep Learning-based Detection of Intravenous Contrast Enhancement on CT Scans.

Author: Ye Z, Qian JM, Hosny A, Zeleznik R, Plana D, Likitlersuang J, Zhang Z, Mak RH, Aerts HJWL, and Kann BH
Abstract: Identifying the presence of intravenous contrast material on CT scans is an important component of data curation for medical imaging-based artificial intelligence model development and deployment. Use of intravenous contrast material is often poorly documented in imaging metadata, necessitating impractical manual annotation by clinician experts. Authors developed a convolutional neural network (CNN)-based deep learning platform to identify intravenous contrast enhancement on CT scans. For model development and validation, authors used six independent datasets of head and neck (HN) and chest CT scans, totaling 133 480 axial two-dimensional sections from 1979 scans, which were manually annotated by clinical experts. Five CNN models were trained first on HN scans for contrast enhancement detection. Model performances were evaluated at the patient level on a holdout set and external test set. Models were then fine-tuned on chest CT data and externally validated. This study found that Digital Imaging and Communications in Medicine metadata tags for intravenous contrast material were missing or erroneous for 1496 scans (75.6%). An EfficientNetB4-based model showed the best performance, with areas under the curve (AUCs) of 0.996 and 1.0 in HN holdout ( n = 216) and external ( n = 595) sets, respectively, and AUCs of 1.0 and 0.980 in the chest holdout ( n = 53) and external ( n = 402) sets, respectively. This automated, scan-to-prediction platform is highly accurate at CT contrast enhancement detection and may be helpful for artificial intelligence model development and clinical application. Keywords: CT, Head and Neck, Supervised Learning, Transfer Learning, Convolutional Neural Network (CNN), Machine Learning Algorithms, Contrast Material Supplemental material is available for this article. © RSNA, 2022., Competing Interests: Disclosures of conflicts of interest: Z.Y. No relevant relationships. J.M.Q. No relevant relationships. A.H. Consultant for Altis Labs; shareholder in Altis Labs. R.Z. No relevant relationships. D.P. No relevant relationships. J.L. No relevant relationships. Z.Z. No relevant relationships. R.H.M. Contract/grant from ViewRay; consulting for ViewRay and AstraZeneca; payment for expert testimony from U.S. District Attorney's Office of New York. H.J.W.L.A. No relevant relationships. B.H.K. RSNA Research Scholar Award NIH K08DE030216., (© 2022 by the Radiological Society of North America, Inc.)
Published: 2022
Full Text: View/download PDF

32. The genomic landscape of Cronkhite-Canada syndrome: Possible clues for pathogenesis.

Author: Liu S, Zhang RF, You Y, You W, Ruan GC, Liu YP, Zhang SY, Li Y, Feng YL, Yan XM, Zhou WX, Li JN, Li J, and Qian JM
Subjects: Genomics, Germ-Line Mutation, Humans, Intestinal Polyposis genetics
Abstract: Objectives: Cronkhite-Canada syndrome (CCS) is a rare hamartomatous polyposis syndrome with a proposed association with chronic autoimmune inflammation. To date, genetic background of patients with CCS remains less investigated. In this study we aimed to explore the genomic landscape of CCS., Methods: Whole exome sequencing was performed on peripheral blood samples extracted from 18 patients with CCS. Potential function-impacting germline variants were filtered by R software. Through systematic data analysis, a number of genetic variants were identified. Enrichment analysis was performed using the R package ClusterProfiler., Results: Overall, 3960 low-frequency (<0.05 or not reported in the Exome Aggregation Consortium East Asian, 1000 Genomes, or ESP6500 database) potentially function-impacting germline variants were identified, with 18 genes (FDFT1, LOC400863, MUC3A, MUC4, ZNF806, GXYLT1, MUC6, PABPC3, PSPH, ZFPM1, CIC, LOC283710, ARSD, GOLGA6L2, LOC388282, SLC25A5, TMEM247, WDR89) involved over half the patients. Functional enrichment of these genes revealed several biological processes in relation to innate immune responses and glycosylation. Only one likely pathogenic germline variant of an hamartomatous polyposis syndrome-associated gene, PTCH1, was detected in one patient., Conclusions: CCS has genomic alteration patterns completely distinct from those of traditional hamartomatous polyposis syndrome. The germline mutation landscape indicates potential roles of innate immune responses and glycosylation in the pathogenesis of CCS., (© 2022 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
Published: 2022
Full Text: View/download PDF

33. Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition).

Author: Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, Chen MH, Chen WC, Chen Y, Fang JY, Gao HJ, Guo MZ, Han Y, Hou XH, Hu FL, Jiang B, Jiang HX, Lan CH, Li JN, Li Y, Li YQ, Liu J, Li YM, Lyu B, Lu YY, Miao YL, Nie YZ, Qian JM, Sheng JQ, Tang CW, Wang F, Wang HH, Wang JB, Wang JT, Wang JP, Wang XH, Wu KC, Xia XZ, Xie WF, Xie Y, Xu JM, Yang CQ, Yang GB, Yuan Y, Zeng ZR, Zhang BY, Zhang GY, Zhang GX, Zhang JZ, Zhang ZY, Zheng PY, Zhu Y, Zuo XL, Zhou LY, Lyu NH, Yang YS, and Li ZS
Subjects: Adolescent, Adult, Aged, Child, Child, Preschool, China, Consensus, Delphi Technique, Helicobacter Infections diagnosis, Helicobacter Infections transmission, Humans, Infant, Middle Aged, Young Adult, Family Health, Helicobacter Infections prevention & control, Helicobacter pylori, Infection Control organization & administration
Abstract: Objective: Helicobacter pylori infection is mostly a family-based infectious disease. To facilitate its prevention and management, a national consensus meeting was held to review current evidence and propose strategies for population-wide and family-based H. pylori infection control and management to reduce the related disease burden., Methods: Fifty-seven experts from 41 major universities and institutions in 20 provinces/regions of mainland China were invited to review evidence and modify statements using Delphi process and grading of recommendations assessment, development and evaluation system. The consensus level was defined as ≥80% for agreement on the proposed statements., Results: Experts discussed and modified the original 23 statements on family-based H. pylori infection transmission, control and management, and reached consensus on 16 statements. The final report consists of three parts: (1) H. pylori infection and transmission among family members, (2) prevention and management of H. pylori infection in children and elderly people within households, and (3) strategies for prevention and management of H. pylori infection for family members. In addition to the 'test-and-treat' and 'screen-and-treat' strategies, this consensus also introduced a novel third 'family-based H. pylori infection control and management' strategy to prevent its intrafamilial transmission and development of related diseases., Conclusion: H. pylori is transmissible from person to person, and among family members. A family-based H. pylori prevention and eradication strategy would be a suitable approach to prevent its intra-familial transmission and related diseases. The notion and practice would be beneficial not only for Chinese residents but also valuable as a reference for other highly infected areas., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Published: 2022
Full Text: View/download PDF

34. Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors.

Author: Qian JM, Akama-Garren E, Shin J, Gunasti L, Bang A, Pike LRG, Grassberger C, and Schoenfeld JD
Abstract: Purpose: Radiation therapy (RT)-associated lymphopenia may adversely affect treatment outcomes, particularly in the era of immunotherapy. We sought to determine dosimetric factors correlated with lymphopenia after palliative RT in a cohort of patients with advanced cancer treated with anti-PD-1 immune checkpoint inhibitors., Methods and Materials: We included patients with metastatic lung cancer, melanoma, or renal cell carcinoma who were treated with either pembrolizumab or nivolumab and received palliative RT to an extracranial site. Baseline and nadir absolute lymphocyte counts (ALCs) within 6 weeks of RT were recorded. Dosimetric factors were extracted from the corresponding dose-volume histograms and also used to model the dose to circulating lymphocytes via a whole-body blood flow model that simulates the spatiotemporal distribution of blood particles in major organs during RT., Results: We analyzed 55 patients who underwent 80 total courses of palliative RT; most (94%) were treated with 3-dimensional conformal RT. Doses to the whole body, bone, and large blood vessels (LBVs) were negatively correlated with the ALC nadir, with the strongest correlations seen at V15 (r s , -0.38, -0.43, and -0.37, and P = .0004, .0001, and .0008, respectively). Doses to other organs were not significantly correlated with the ALC nadir. The modeled dose to circulating lymphocytes was also negatively correlated with the ALC nadir and percent ALC change (for D2%, r s , -0.31 and -0.44, and P = .005 and .0001, respectively). Grade ≥3 lymphopenia was associated with LBV V15 (odds ratio [OR], 1.16; 95% CI, 1.07-1.26; P < .001), bone V15 (OR, 1.04; 95% CI, 1.01-1.08; P = .03), body V15 (OR, 1.003; 95% CI, 1.001-1.006; P = .008), and modeled lymphocyte dose (OR, 1.45; 95% CI, 1.16-1.82; P < .001)., Conclusions: The RT dose to the whole body, bone, and LBVs and the modeled dose to circulating lymphocytes were correlated with lymphopenia in patients treated with palliative RT and anti-PD-1 immune checkpoint inhibitors. These findings may inform future radiation planning in this setting., (© 2021 The Authors.)
Published: 2021
Full Text: View/download PDF

35. Gastrointestinal manifestations and possible mechanisms of COVID-19 in different periods.

Author: Zhang MM, Chen LN, and Qian JM
Subjects: Gastrointestinal Tract, Humans, Pandemics, SARS-CoV-2, COVID-19
Abstract: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become a pandemic worldwide. Although COVID-19 mainly affects the respiratory system, gastrointestinal (GI) manifestations have been frequently reported in such cases, even as initial symptoms. There have been several studies on different GI manifestations in patients with mild and severe disease or in remission. In this review article we summarized different GI manifestations of COVID-19 at various disease stages and the possible mechanisms based on published literatures, as well as the significance of GI manifestations in systemic inflammatory injury., (© 2021 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
Published: 2021
Full Text: View/download PDF

36. Stuck on you: Bacterial-auxin-mediated bacterial colonization of plant roots.

Author: Qian JM and Bai Y
Subjects: Bacteria, Symbiosis, Indoleacetic Acids, Plant Roots
Abstract: Auxin secreted by root-associated bacteria promotes plant growth, yet benefits to bacteria themselves are ill-defined. In this issue of Cell Host & Microbe, Tzipilevich et al. (2021) demonstrate that auxin and plant EFR-triggered response are essential for root colonization of B. velezensis, indicating potential co-evolution of plants and root commensal bacteria., (Copyright © 2021 Elsevier Inc. All rights reserved.)
Published: 2021
Full Text: View/download PDF

37. Autoimmune enteropathy and primary biliary cholangitis after proctocolectomy for ulcerative colitis: A case report and review of the literature.

Author: Zhou QY, Zhou WX, Sun XY, Wu B, Zheng WY, Li Y, and Qian JM
Subjects: Female, Humans, Middle Aged, Polyendocrinopathies, Autoimmune, Colitis, Ulcerative complications, Colitis, Ulcerative surgery, Colonic Pouches, Liver Cirrhosis, Biliary surgery, Proctocolectomy, Restorative adverse effects
Abstract: Background: Autoimmune enteropathy (AIE) and primary biliary cholangitis (PBC) are both immune-mediated diseases. AIE or PBC complicated with ulcerative colitis (UC) are rare. There are no cases of AIE and PBC diagnosed after proctocolectomy for UC reported before, and the pathogenesis of these comorbidities has not been revealed., Case Summary: A middle-aged woman diagnosed with UC underwent subtotal colectomy and ileostomy due to the steroid-resistant refractory disease, and a restorative proctectomy with ileal pouch-anal anastomosis and proximal neoileostomy was postponed due to active residual rectal inflammation in January 2016. A few months after the neoileostomy, she began to suffer from recurrent episodes of watery diarrhea. She was diagnosed with postcolectomy enteritis and stoma closure acquired a good therapeutic effect. However, her symptoms of diarrhea relapsed in 2019, with different histological features of endoscopic biopsies compared with 2016, which showed apoptotic bodies, a lack of goblet and Paneth cells, and villous blunting. A diagnosis of AIE was established, and the patient's stool volume decreased dramatically with the treatment of methylprednisolone 60 mg/d for 1 wk and tacrolimus 3 mg/d for 4 d. Meanwhile, her constantly evaluated cholestatic enzymes and high titers of antimitochondrial antibodies indicated the diagnosis of PBC, and treatment with ursodeoxycholic acid (16 mg/kg per day) achieved satisfactory results., Conclusion: Some immune-mediated diseases may be promoted by operation due to microbial alterations in UC patients. Continuous follow-up is essential for UC patients with postoperative complications., Competing Interests: Conflict-of-interest statement: Dr. Li Y reports grants from Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, during the conduct of the study., (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
Published: 2021
Full Text: View/download PDF

38. Hamartomatous polyposis syndrome associated malignancies: Risk, pathogenesis and endoscopic surveillance.

Author: Liu S, Ma Y, You W, Li J, Li JN, and Qian JM
Subjects: Humans, Intestinal Polyps, Neoplastic Syndromes, Hereditary complications, Neoplastic Syndromes, Hereditary genetics, Peutz-Jeghers Syndrome complications, Peutz-Jeghers Syndrome genetics, Hamartoma Syndrome, Multiple complications, Hamartoma Syndrome, Multiple genetics, Intestinal Polyposis complications, Intestinal Polyposis genetics
Abstract: Hamartomatous polyposis syndromes (HPS) are a heterogeneous spectrum of diseases that are characterized by diffuse hamartomatous polyps lining the gastrointestinal (GI) tract together with extra-GI manifestations. Classical HPS includes juvenile polyposis syndrome, Peutz-Jeghers syndrome, PTEN hamartoma tumor syndrome and hereditary mixed polyposis syndrome. Patients with HPS have a higher risk of GI and extra-GI malignancies than the general population, although the underlying mechanisms remain unclear and are obviously different from the carcinogenesis of classical adenocarcinoma and colitis-associated malignancy. In this review we aimed to clarify the risks, possible mechanism and endoscopic surveillance of HPS-associated GI malignancies., (© 2021 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
Published: 2021
Full Text: View/download PDF

39. Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events.

Author: Tan B, Chen MJ, Guo Q, Tang H, Li Y, Jia XM, Xu Y, Zhu L, Wang MZ, and Qian JM
Subjects: Adult, Aged, Female, Humans, Male, Middle Aged, Gastrointestinal Microbiome physiology, Pancreatitis diagnostic imaging, Pancreatitis physiopathology
Abstract: Background: The pancreatic immune-related adverse event (irAE) is a rare but increasingly occurrence disease with limited knowledge, which was associated with the use of immune checkpoint inhibitors (ICIs)., Methods: In this case series study of pancreatic irAE patients, clinical and radiological manifestations are summarized. Baseline and post-treatment fecal microbiota of immune-related acute pancreatitis (irAP) patients were analyzed by the 16 s rDNA amplicon sequencing method., Results: A total of six patients were enrolled into the study, and the onset of pancreatic irAEs occurred a median of 105 days after a median of 4.5 cycles with immune checkpoint inhibitors (ICIs). All patients had an effective response to ICIs. Abdominal pain was the main clinical manifestation. Serum amylase (sAMY) and lipase (sLIP) had dynamic changes parallel to clinical severity. Contrast-enhanced computed tomography (CT) did not accurately reveal the level of inflammation. However, magnetic resonance imaging (MRI) was a sensitive imaging method which showed decreased and increased signal intensity of pancreatic parenchyma in T1-weighted fat-saturated and diffusion-weighted imaging, respectively. Glucocorticoids were the main treatment with a rapid initial effect followed by a slow improvement. After reinitiation of ICI therapy, pancreatic irAEs either deteriorated, remained stable or the patient developed severe pancreatic β-cell destruction without irAP recurrence. The baseline microbiota of irAP had low Bacteroidetes/Firmicutes ratio at phylum level, low relative abundance of Alistipes, Bacteroides and high Lachnospiraceae at genus level, compared to levels of pancreatic β-cell destruction and post-treatment of irAP., Conclusions: Pancreatic irAE patients had corresponding abdominal pain and increase in sAMY/sLIP. MRI was found to be an ideal imaging modality. Treatment with glucocorticoids were the main approach. The microbiota showed relative changes at baseline and during treatment., (© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
Published: 2021
Full Text: View/download PDF

40. [Adult Hirschsprung's allied disease presented with colonic ulcer accompanied Clostridium difficile infection].

Author: Tang H, Tan B, Zhou WX, and Qian JM
Subjects: Adult, Humans, Infant, Ulcer, Clostridium Infections complications, Enterocolitis, Pseudomembranous, Hirschsprung Disease complications
Published: 2021
Full Text: View/download PDF

41. [The 488th case: chronic diarrhea and abnormal liver function].

Author: Sun LX, Wang Q, You Y, Chang XY, Bai W, Ruan GR, Chen M, Wang X, Feng YL, and Qian JM
Subjects: Biopsy, Female, Humans, Intestinal Mucosa, Liver, Middle Aged, Diarrhea, Polyendocrinopathies, Autoimmune
Abstract: A 56-year-old female was admitted to Department of Gastroenterology at Peking Union Medical College Hospital with diarrhea for seven months, and abnormal liver function for six months. She had a history of type 1 diabetes. The main clinical manifestations were recurrent fatty diarrhea and abnormal liver function, accompanied by abdominal and retroperitoneal lymphadenopathy, elevated CA19-9 and CEA. Progressive impairment of hepatic synthetic function and shrinkage of liver developed in a short period of time. The pathology of liver biopsy suggested that nodular regeneration of hepatocytes was followed by hyperplasia of thin bile ducts after submassive necrosis. Intestinal mucosa biopsies were performed twice. The pathology showed that the intestinal villi were completely blunt, accompanied with crypt hyperplasia. Goblet cells disappeared with reduced mucin. Paneth cells were barely seen without intraepithelial infiltration of lymphocytes. Rifaximin was not effective, while glucocorticoids improved clinical situation. The diagnosis of autoimmune enteropathy was finally confirmed by multidisciplinary team including departments of gastroenterology, pathology, endocrinology, hematology, infectious diseases, and rheumatology. With the administration of glucocorticoid and sirolimus, diarrhea relieved and liver function returned to normal.
Published: 2021
Full Text: View/download PDF

42. Association of Serum Immunoglobulins Levels With Specific Disease Phenotypes of Crohn's Disease: A Multicenter Analysis in China.

Author: Song DJ, Shen J, Chen MH, Liu ZJ, Cao Q, Hu PJ, Gao X, Qian JM, Wu KC, Lai LJ, and Ran ZH
Abstract: Background and Aim: Serum immunoglobulins were reported to be associated with clinical characteristics of inflammatory bowel disease. However, whether a difference exists in the serum immunoglobulins levels in patients with Crohn's disease (CD) with different disease location and behavior phenotypes remains unclear. Therefore, this study aimed to explore the associations of serum immunoglobulins levels with specific CD phenotypes. Methods: Patients with CD having recorded serum immunoglobulins levels were recruited through multicenter collaborative efforts. The associations between serum immunoglobulins levels and distinct phenotypes of CD were evaluated using multiple logistic regression models. Results: A total of 608 patients with CD were included in the study. Elevated (above the upper limit of normal) serum immunoglobulin G (IgG), IgA, IgM, and IgG4 were identified in 24.5, 17.4, 2.1, and 8.2% of patients, respectively. Elevated serum IgG4 levels negatively correlated with complicated disease behavior [odds ratio (OR) 0.49, 95% confidence interval (CI) 0.26-0.92]. Elevated serum IgG was linked to isolated ileal disease with an OR of 0.37 (95% CI 0.23-0.61). The ORs of isolated ileal disease progressively reduced across increasing quartiles of IgG ( P for trend < 0.001). The adjusted ORs of isolated ileal disease for increasing quartiles of IgM were 1.82 (1.07-3.1), 1.92 (1.14-3.24), 1.17 (0.69-1.98), and 1 ( P for trend = 0.008). Besides, serum IgA and IgG levels significantly correlated with several disease activity indices. Conclusions: These results suggested that certain serum immunoglobulins were associated with specific disease phenotypes of CD. Further investigations to account for the associations are warranted., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Song, Shen, Chen, Liu, Cao, Hu, Gao, Qian, Wu, Lai and Ran.)
Published: 2021
Full Text: View/download PDF

43. Endoscopic resection for non-polypoid dysplasia in inflammatory bowel disease: a systematic review and meta-analysis.

Author: Chen W, Zhang YL, Zhao Y, Yang AM, Qian JM, and Wu D
Subjects: Aged, Humans, Middle Aged, Endoscopic Mucosal Resection methods, Inflammatory Bowel Diseases surgery
Abstract: Background: This systematic review and meta-analysis aims to evaluate efficacy and safety of endoscopic treatment for the non-polypoid dysplasia in patients with long-standing IBD., Methods: Medline, Embase, Cochrane, and clinicaltrials.gov registry were comprehensively searched. Pooled estimates of curative, R0, en-bloc resection rates, CRC, metachronous dysplasia, and local recurrence rates were calculated. Subgroup analysis according to areas, lesion size, endoscopic resection techniques, and grades of dysplasia were conducted. Data synthesis was completed in R using the package "meta"., Results: Of the 973 studies initially identified, 7 met the inclusion/exclusion criteria. These were all single-arm cohorts and included a total of 202 patients with IBD and non-polypoid dysplasia. The combined R0 and en-bloc resection rate were 0.70 (95% CI 0.55-0.81) and 0.86 (95% CI 0.65-0.95), respectively, with a recurrence rate of 0.08 (95% CI 0.05-0.13). CRC and metachronous dysplasia incidences were pooled as 32.53 (95% CI 12.21-86.67) and 90.24 (95% CI 44.91-181.33) per 1000 patient years., Conclusions: Non-polypoid dysplasia associated with IBD can be resected endoscopically, especially by ESD. However, these patients have higher CRC and metachronous dysplasia incidence rates than patients with polypoid dysplasia, indicating a closer endoscopic surveillance.
Published: 2021
Full Text: View/download PDF

44. [Potential mechanism of N6-methyladenosine on immune modulation in inflammatory bowel disease].

Author: Zhang MM, Yang H, and Qian JM
Subjects: Adenosine analogs & derivatives, Humans, Colitis, Inflammatory Bowel Diseases
Published: 2021
Full Text: View/download PDF

45. Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges.

Author: Qian JM and Schoenfeld JD
Abstract: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment over the past decade. However, although the immune landscape suggests a strong rationale for the use of these agents in patients with head and neck squamous cell carcinoma, the available clinical evidence indicates that most patients currently do not respond to ICI monotherapy. Radiotherapy is a primary treatment modality for many patients with locally advanced head and neck cancer. While ionizing radiation traditionally has been thought to act in a purely cytotoxic fashion, a growing body of preclinical studies have demonstrated additional profound immunomodulatory effects. Consequently, there has been a surge of interest in the potential synergy between radiotherapy and immunotherapy, both the potential for radiotherapy to augment the systemic anti-tumor immune response and the potential for immunotherapy to improve in-field tumor response to radiation. In this review, we summarize the current preclinical and clinical evidence for radioimmunotherapy, with a particular focus on studies directly relevant to head and neck squamous cell carcinoma, as well as existing challenges and future directions for this emerging field., Competing Interests: JS reports consulting and scientific advisory board fees from Immunitas, Debiopharm, BMS, Nanobiotix, Tilos, AstraZeneca, LEK, Catenion, ACI Clinical, as well as research funding from Merck, BMS, and Regeneron. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Qian and Schoenfeld.)
Published: 2021
Full Text: View/download PDF

46. Predicting Mucosal Proliferation in Ulcerative Colitis by Assessing Mucosal Vascular Pattern Under Narrow Band Imaging Colonoscopy.

Author: Guo T, Qian JM, Yang AM, Li Y, and Zhou WX
Subjects: Cell Proliferation, Colonoscopy, Humans, Inflammation, Intestinal Mucosa, Ki-67 Antigen, Narrow Band Imaging, Severity of Illness Index, Colitis, Ulcerative diagnostic imaging, Colorectal Neoplasms
Abstract: Background: Proliferative abnormalities are believed to represent an early phase of colorectal carcinogenesis. Narrow band imaging (NBI) colonoscopy allows visual assessment of the mucosal vascular pattern (MVP) without dyeing. The aim of this study was to investigate the predictive value of MVP for mucosal proliferation in ulcerative colitis (UC)., Methods: A total of 119 colorectal lesions were analyzed from 42 patients with UC who underwent NBI colonoscopy. Both the MVP and the Mayo endoscopic score (MES) were assessed. The mucosal inflammation was histologically graded using a colitis score. The proliferation marker Ki-67 was assessed by immunohistochemical staining., Results: The results showed that MVP correlated well with the MES (r = 0.796, P < .001). There was moderate correlation between the distribution of Ki-67 staining and MVP (r = 0.492, P < .001), and the Ki-67 labeling index increased with the orderly patterns of MVP (P < .001). An expansion of Ki-67 staining upward from the crypt base may be caused by active inflammation., Conclusion: MVP based on NBI colonoscopy can predict mucosal proliferation which is associated with inflammation in patients with UC.
Published: 2021
Full Text: View/download PDF

47. [Clinical and genetic characteristics of patients with chronic enteropathy associated with SLCO2A1 gene].

Author: Wang Q, Xu H, Li Y, Liu YP, Wu D, Zhou WX, Yang H, Xia WB, and Qian JM
Subjects: Humans, Male, Ulcer, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Organic Anion Transporters, Osteoarthropathy, Primary Hypertrophic
Abstract: Objective: To determine the clinical features and genetic characters of patients with chronic enteropathy associated SLCO2A1 gene (CEAS). Methods: Five CEAS patients diagnosed at Peking Union Medical College Hospital from January 2012 to December 2019 were enrolled in this study. The clinical manifestations, laboratory test, radiological and endoscopic findings, gene detections, treatments and prognosis of these patients were reviewed and analyzed. Results: Five male patients presented gastrointestinal symptoms after puberty, including abdominal pain, diarrhea, intermittent melena or hematochezia, incomplete bowel obstruction, anemia, hypoalbuminemia and hypokalemia. The whole gastrointestinal tract except esophagus could be involved, especially the stomach and ileum. Intestinal lesions were characterized by multiple shallow ulcers with stenosis in the layers of mucosa and submucosa. Five patients were all accompanied with primary hypertrophic osteoarthropathy (PHO), and 1 with myelofibrosis and thoracic duct dysplasia. All patients were homozygous or compound heterozygous mutations of SLCO2A1 gene. Conventional treatment of inflammatory bowel disease and COX-2 inhibitors were ineffective. Conclusions: CEAS is an autosomal recessive genetic disease which widely involves the gastrointestinal tract, and can be associated with skin and bone involvement. There is no effective treatment for CEAS at present. CEAS is a different entity from other inflammatory gastrointestinal diseases.
Published: 2021
Full Text: View/download PDF

48. [Correlation between Vitamin D Status and Gut Microbiota in Patients with Inflammatory Bowel Disease].

Author: Chen D, Li Y, Sun H, Xiao M, Zhang RL, Qiu L, Tan B, and Qian JM
Subjects: Bacteria classification, Feces microbiology, Humans, RNA, Ribosomal, 16S genetics, Gastrointestinal Microbiome, Inflammatory Bowel Diseases blood, Inflammatory Bowel Diseases microbiology, Vitamin D blood
Abstract: Objective To investigate the correlation between serum total 25-hydroxyvitamin D[T-25(OH)D]level and fecal microbiota in patients with inflammatory bowel disease(IBD). Methods Twenty-three patients with IBD completed the tests for serum T-25(OH)D,and the fecal microbiota was studied using V4 hypervariable region of 16S ribosomal RNA(rRNA)gene sequencing.According to serum T-25(OH)D level,the patients were divided into three groups including vitamin D normal group( n =5),vitamin D insufficiency group( n =5),and vitamin D deficiency group( n =13). Results There was no significant difference between these three groups in Alpha diversity or Beta diversity.Ternary pot at phylum level revealed that the abundance of Proteobacteria was the highest in the vitamin D deficiency group and Actinomycete was the highest in the vitamin D sufficiency group.Spearman correlation analysis showed that at the phylum level serum T-25(OH)D level was negatively correlated with the abundance of Proteobacteria ( r =-0.445, P =0.033)and positively correlated with the abundance of Actinomycetes ( r =0.447, P =0.033);at family level it was positively correlated with the abundance of Lachnospiraceae ( r =0.414, P =0.049), Bifidobacteriaceae ( r =0.468, P =0.024), Erysipelotrichacea ( r =0.584, P =0.003),and Eggerthellaceae ( r =0.507, P =0.014)and negatively correlated with the abundance of Aerococcaceae ( r =-0.514, P =0.012);and at genus level it was positively correlated with the abundance of Blautia ( r =0.459, P =0.028), Bifidobacterium ( r =0.468, P =0.024),unidentified Erysipelotrichacea ( r =0.485, P =0.019), Faecalitalea ( r =0.544, P =0.007), Anaerostipes ( r =0.475, P =0.022), Romboutsia ( r =0.510, P =0.013), Flavonifractor ( r =0.455, P =0.029),and Erysipelatoclostridium ( r =0.617, P =0.002). Conclusions The fecal microbiota composition varies in IBD patients with different serum T-25(OH)D levels.The abundance of Proteobacteria increases and the abundance of Actinomyces decreases in IBD patients with vitamin D deficiency compared with IBD patients with normal vitamin D level.Serum T-25(OH)D level is negatively correlated with the abundance of some harmful bacteria(e.g. Proteobacteria )but is positively correlated with the abundance of some probiotics such as Lachnospiraceae , Bifidobacteriaceae ,and Anaerostipes .
Published: 2020
Full Text: View/download PDF

49. Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases.

Author: Qian JM, Martin AM, Martin K, Hammoudeh L, Catalano PJ, Hodi FS, Cagney DN, Haas-Kogan DA, Schoenfeld JD, and Aizer AA
Subjects: Aged, Chemoradiotherapy, Disease Progression, Female, Humans, Immune Checkpoint Inhibitors, Male, Middle Aged, Neoplasm Recurrence, Local, Proportional Hazards Models, Prospective Studies, Survival Analysis, Treatment Outcome, Brain Neoplasms secondary, Brain Neoplasms therapy, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms therapy, Melanoma secondary, Melanoma therapy
Abstract: Background: Prior literature has suggested synergy between immune checkpoint therapy (ICT) and radiotherapy (RT) for the treatment of brain metastases (BrM), but to the authors' knowledge the optimal timing of therapy to maximize this synergy is unclear., Methods: A total of 199 patients with melanoma and non-small cell lung cancer with BrM received ICT and RT between 2007 and 2016 at the study institution. To reduce selection biases, individual metastases were included only if they were treated with RT within 90 days of ICT. Concurrent treatment was defined as RT delivered on the same day as or in between doses of an ICT course; all other treatment was considered to be nonconcurrent. Multivariable Cox proportional hazards models were used to assess time to response and local disease recurrence on a per-metastasis basis, using a sandwich estimator to account for intrapatient correlation., Results: The final cohort included 110 patients with 340 BrM, with 102 BrM treated concurrently and 238 BrM treated nonconcurrently. Response rates were higher with the use of concurrent treatment (70% vs 47%; P < .001), with correspondingly lower rates of progressive disease (5% vs 26%; P < .001). On multivariable analysis, concurrent treatment was found to be associated with improved time to response (hazard ratio, 1.76; 95% CI, 1.18-2.63 [P = .006]) and decreased local recurrence (hazard ratio, 0.42; 95% CI, 0.23-0.78 [P = .006]). This effect appeared to be greater for melanoma than for non-small cell lung cancer, although interaction tests were not statistically significant. Only 1 of 103 metastases which had a complete response later developed disease progression., Conclusions: Concurrent RT and ICT may improve response rates and decrease local recurrence of brain metastases compared with treatment that was nonconcurrent but delivered within 90 days. Further study of this combination in prospective, randomized trials is warranted., (© 2020 American Cancer Society.)
Published: 2020
Full Text: View/download PDF

50. [Relationship between matrix Gla protein and clinical features of ulcerative colitis].

Author: Dong XY, Wu MX, Bai XY, Zhang HM, Yang H, and Qian JM
Subjects: Calcium-Binding Proteins genetics, Extracellular Matrix Proteins genetics, Humans, Intestinal Mucosa, Matrix Gla Protein, Colitis, Ulcerative
Abstract: Objective: To analyze the relationship between matrix Gla protein(MGP) and clinical characteristics of patients with ulcerative colitis (UC). Methods: Fifty-one UC patients who were admitted to the gastroenterology department of Peking union medical college hospital from July 1, 2015 to May 31, 2017 were included. Twenty-seven healthy subjects in the same period were included as normal controls. The expression of MGP mRNA in the colonic mucosa was detected by real-time fluorescence quantitative PCR. Clinical data of the patients were collected during a 2-year follow-up. The public data set containing MGP gene expression profile of UC patients was downloaded from the GEO database, and was divided into four groups according to the microscopic Mayo score. The differential expression of MGP in each group was analyzed. Results: All the fifty-one UC patients were followed up. The expression of MGP mRNA in the colonic mucosa of UC patients treated with hormone and immunosuppressive agents or biological agents or surgery was higher than that of patients treated with mesalazine. MGP mRNA expression was positively correlated with C-reactive protein level. It was also higher in the colonic mucosa of UC patients with clostridium difficilis or cytomegalovirus infection than that of patients without opportunistic infection. The difference of MGP mRNA expression between groups in GEO public data set was statistically significant( P< 0.01), showing an up-regulation trend with the aggravation of inflammation. The expression level of MGP was moderately correlated with the microscopic Mayo score. The relationship between MGP mRNA expression and lifestyle, lesion range, erythrocyte sedimentation rate, parenteral manifestations and recurrence frequency of UC patients was not obvious. Conclusions: MGP is associated with colonic inflammation and its abnormal expression can help to predict the disease activity of patients with UC.
Published: 2020
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

224 results on '"Qian, Jm"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources